NOBLE JARRETT ACCESS DB # 156213

FOR OFFICIAL USE ONLY PLEASE PRINT CLEARLY

Scientific and Technical Information Center

SEARCH REQUEST FORM

Requester's Full Name: MARCELA M GORDERO GARCIA Examiner #: 80381 Date: 6/13/05

Art Unit: 1654 Phone Number: 2-2939 Serial Number: 10/723,144

Location (Bldg/Room#): REM 3C18 (Mailbox #): 3C18 Results Format Preferred (circle): PAPER DISK

3C35 MG

****

To ensure an efficient and quality search, please attach a copy of the cover sheet, claims, and abstract or fill out the following:

Title of Invention: PEPTIDES WHICH INHIBIT ANGIOGENESIS, CELL MIGRATION...

Inventors (please provide full names): SEE ATTACHED BIB. D. S.

Earliest Priority Date: 11/25/02

Search Topic:

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known.

For Sequence Searches Only ***Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.***

PLEASE SRCH SPECIES 15. IF ONLY APPLICANT'S OWN WORK FOUND PLEASE SRCH BROADLY. PLEASE ALSO SRCH INVENTOR'S.

THANKS,

Marcela M Gordero Garcia

****

STAFF USE ONLY

Searcher: Noble

Searcher Phone #:

Searcher Location:

Date Searcher Picked Up:

Date Completed: 6/15/05

Searcher Prep & Review Time: 15

Online Time: 23

Type of Search

NA Sequence (#)

AA Sequence (#)

Structure (#) 3

Bibliographic ✓

Litigation

Fulltext

Other

Vendors and cost where applicable

STN ✓ Dialog

Questel/Orbit Lexis/Nexis

Westlaw WWW/Internet

In-house sequence systems

Commercial Oligomer Score/Length

Interference SPDI Encode/Transl

Other (specify)

STIC Search Report
Biotech-Chem Library

STIC Database Tracking Number: 166213

TO: Marcela Cordero Garcia **Location: rem/3C35/3C18** **Art Unit: 1654** **Wednesday, June 15, 2005** **Case Serial Number: 10/723144**	**From: Noble Jarrell** **Location: Biotech-Chem Library** **Rem 1B71** **Phone: 272-2556** **Noble.jarrell@uspto.gov**

Search Notes

Figure 3



13



14



15

N = 9
O = 9
S = 1



16



17



18

CLAIMS

What is claimed is:

1. A compound of structural Formula (I):



or a pharmaceutically available salt, solvate, hydrate or N-oxide thereof wherein:

a, b, x, y and z are 0 or 1;

A is a cyclic amino acid;

B is a basic amino acid;

C is a small amino acid;

R^1 is alkyl, substituted alkyl, acyl, substituted acyl, alkylsulfonyl, substituted alkylsulfonyl, arylalkyl, substituted arylalkyl, arylsulfonyl, substituted arylsulfonyl, heteroalkyl, substituted heteroalkyl, heteroarylsulfonyl, substituted heteroarylsulfonyl, heteroarylalkyl, substituted heteroarylalkyl, oxycarbonyl or substituted oxycarbonyl;

R^2 is alkyl, $-(CH_2)_mS(O)_nR^5$, $-(CH_2)_mS(O)_n-S(O)_oR^5$ or $-(CMe)_mS(O)_nR^5$

m is 1, 2, 3 or 4;

n and o are independently 0, 1 or 2;

R^3 is $-CH_2CONH_2$ or $-CH_2CH_2CONH_2$;

R^4 is alkyl, $-NR^6R^7$ or $-OR^8$;

R^5 is alkyl, substituted alkyl, acyl, substituted acyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, oxycarbonyl or substituted oxycarbonyl;

R^6 and R^7 are independently hydrogen or alkyl; and

R^8 is alkyl, substituted alkyl, aryl substituted aryl, arylalkyl, substituted arylalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl;

with the provisos that:

R^5 is not methyl when m is 1;

a is 1 unless A is proline, B is histidine, C is serine and b is 0 when a is 0; and

R^2 is $-(CH2)_mS(O)_nR^5$ or $-(CH_2)_mS(O)_n-S(O)_oR^5$ unless b, x, y and z are 1.

2. The compound of Claim 1, wherein A is proline, B is histidine, C is serine and R^3 is $-CH_2CONH_2$.

3. The compound of Claim 1 or Claim 2, wherein R^1 is acyl, substituted acyl, arylalkyl, substituted arylalkyl, oxycarbonyl and substituted oxycarbonyl.

4. The compound of Claim 1 or Claim 2, wherein R^1 is acyl, substituted acyl, oxycarbonyl and substituted oxycarbonyl.

5. The compound of Claim 1 or Claim 2, wherein R^2 is $-(CH2)_mS(O)_nR^5$ or $-(CH_2)_mS(O)_n-S(O)_oR^5$ and m is 1 or 2.

6. The compound of Claim 1 or Claim 2, wherein R^4 is NR^7R^8 and R^7 and R^8 are hydrogen.

```
=> d his

     (FILE 'HOME' ENTERED AT 11:25:08 ON 15 JUN 2005)

     FILE 'HCAPLUS' ENTERED AT 11:26:57 ON 15 JUN 2005
L1            3 US20040162239/PN OR (US2002-429174# OR US2003-475539#)/AP,PRN

     FILE 'REGISTRY' ENTERED AT 11:27:07 ON 15 JUN 2005

     FILE 'HCAPLUS' ENTERED AT 11:27:08 ON 15 JUN 2005
L2              TRA L1 1- RN :      209 TERMS

     FILE 'REGISTRY' ENTERED AT 11:27:09 ON 15 JUN 2005
L3           209 SEA L2

     FILE 'WPIX' ENTERED AT 11:27:13 ON 15 JUN 2005
L4            3 US20040162239/PN OR (US2002-429174# OR US2003-475539#)/AP,PRN

=> b hcap
FILE 'HCAPLUS' ENTERED AT 11:27:35 ON 15 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 15 Jun 2005  VOL 142 ISS 25
FILE LAST UPDATED: 14 Jun 2005  (20050614/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> d all l1 tot

L1   ANSWER 1 OF 3  HCAPLUS  COPYRIGHT 2005 ACS on STN
AN   2004:610128  HCAPLUS
DN   141:157478
ED   Entered STN:  30 Jul 2004
TI   Peptides which target tumor and endothelial cells, compositions and uses
     thereof
IN   Allan, Amy L.; Yoon, Won Hyung; Gladstone, Patricia L.; Ternansky, Robert
     J.; Parry, Graham; Donate, Fernando; Mazar, Andrew
PA   Attenuon, Llc, USA
SO   PCT Int. Appl., 117 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
IC   ICM  C07K
CC   34-3 (Amino Acids, Peptides, and Proteins)
     Section cross-reference(s): 1, 63
FAN.CNT 2
     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     ---------------     ----   --------    --------------------    --------
PI   WO 2004063213        A2    20040729    WO 2003-US37895         20031125 <--
     WO 2004063213        A3    20050303
```

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	US 2004162239	A1	20040819	US 2003-723144	20031125 <--
	US 2005020810	A1	20050127	US 2003-722843	20031125 <--
PRAI	US 2002-429174P	P	20021125 <--		
	US 2003-475539P	P	20030602 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004063213	ICM	C07K
US 2004162239	NCL	514/012.000; 514/013.000; 514/014.000; 514/015.000; 514/016.000; 514/017.000; 514/018.000; 530/324.000; 530/325.000; 530/326.000 <--
US 2005020810	NCL	530/324.000; 530/325.000; 530/326.000; 530/327.000; 530/328.000; 530/329.000 <--

OS MARPAT 141:157478

AB The invention relates generally to peptide analogs of Ac-PHSCN-NH2 which target tumor and endothelial cells and have antitumor, antiangiogenic and antimetastatic activity and to methods for their synthesis and use in pharmaceutical compns. for treating, preventing and detecting diseases characterized by tumor growth, metastasis and angiogenesis. The peptide analogs may serve, inter alia, as carriers of radioactivity, PET-active compds., toxins, fluorescent mols. and PEG mols. Peptides R1[(NHCHR2CO)0-1(X1)0-100]m-X2-X3-X4-X5-X6-[(X7)0-1(NHCHR3CO)0-1]nNR4R5 [R1 is (un)substituted acyl, alkyl, cycloalkyl or imino, or acyl chelate; R2 is substituted alkyl; R4, R5 are (un)substituted alkyl; X1, X7 are NH(CH:CH)1-6CO, NH(CH2)1-6CO, NHCHMeCO; X2-X6 are α-amino acids which are defined; m, n are 0 or 1, with the proviso that R1 is not acetyl when R4 and R5 are H and m and n are 0] are claimed. Thus, Ac-Pro-His-Ser-Cys(Ac)-Asn-OH was prepared by the solid-phase method and coupled to doxorubicin hydrochloride to afford the conjugate.

ST peptide prolylhistidylserylcysteinylaspartamide analog prepn antitumor

IT Angiogenesis
Angiogenesis inhibitors
Antitumor agents
Neoplasm
(preparation of peptides which target tumor and endothelial cells)

IT Peptides, preparation
RL: DGN (Diagnostic use); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of peptides which target tumor and endothelial cells)

IT Polyoxyalkylenes, reactions
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of peptides which target tumor and endothelial cells)

IT 729594-60-9P
RL: DGN (Diagnostic use); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of peptides which target tumor and endothelial cells)

IT 7440-74-6DP, Indium, complexes with DPTA peptide conjugate
262438-43-7DP, analogs 729594-61-0P 729594-62-1P 729594-63-2P
729594-64-3P 729594-65-4P 729594-66-5P 729594-67-6P 729594-68-7P
729594-69-8P 729594-70-1P 729594-71-2P 729594-72-3P 729594-73-4P
729594-74-5P 729594-75-6P 729594-76-7P 729594-77-8P 729594-78-9P
729594-79-0P 729594-80-3P 729594-81-4P 729594-82-5P 729594-83-6P
729594-84-7P 729594-85-8P 729594-86-9P 729594-87-0P 729594-88-1P
729594-89-2P 729594-90-5P 729594-91-6P 729594-92-7P 729594-93-8P

729594-94-9P 729594-95-0P 729594-96-1P 729594-97-2P 729594-98-3P
729594-99-4P 729595-00-0P 729595-01-1P 729595-02-2P 729595-03-3DP,
polyethylene glycol derivative 729595-04-4P 729595-05-5P 729595-06-6P
729595-07-7P 729595-08-8P 729595-09-9P 729595-14-6P 730960-54-0P
731003-01-3DP, Indium complexes 731003-01-3P 731003-02-4P
RL: DGN (Diagnostic use); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of peptides which target tumor and endothelial cells)

IT 456-22-4, 4 Fluorobenzoic acid 501-97-3 553-12-8 3301-79-9, 6 Carboxyfluorescein 13811-11-5 25316-40-9, Doxorubicin hydrochloride 34071-95-9 66134-67-6 76823-03-5, 5 Carboxyfluorescein 106966-68-1 137076-54-1, 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, tris 1 1 dimethylethyl ester 517913-89-2 622405-78-1 729595-15-7 729595-16-8D, resin-bound 729595-17-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of peptides which target tumor and endothelial cells)

IT 729595-10-2DP, resin-bound 729595-11-3DP, resin-bound 729595-12-4DP, resin-bound 729595-13-5DP, resin-bound
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of peptides which target tumor and endothelial cells)

L1 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:467702 HCAPLUS
DN 141:33798
ED Entered STN: 10 Jun 2004
TI Peptides which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, their preparation, and compositions and therapeutic uses thereof
IN Allan, Amy L.; Donate, Fernando; Hopkins, Stephanie A.; Gladstone, Patricia L.; Mazar, Andrew; O'Hare, Sean M.; Parry, Graham; Plunkett, Marian L.; Ternansky, Robert J.; Yoon, Won Hyung
PA Attenuon, LLC, USA
SO PCT Int. Appl., 88 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K
CC 1-8 (Pharmacology)
Section cross-reference(s): 34, 63

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2004047771	A2	20040610	WO 2003-US38175	20031125	<--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW					
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
	US 2004162239	A1	20040819	US 2003-723144	20031125	<--
	US 2005020810	A1	20050127	US 2003-722843	20031125	<--
PRAI	US 2002-429174P	P	20021125	<--		
	US 2003-475539P	P	20030602	<--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004047771	ICM	A61K
US 2004162239	NCL	514/012.000; 514/013.000; 514/014.000; 514/015.000; 514/016.000; 514/017.000; 514/018.000; 530/324.000; 530/325.000; 530/326.000 <--

US 2005020810 NCL 530/324.000; 530/325.000; 530/326.000; 530/327.000; 530/328.000; 530/329.000 <--

OS MARPAT 141:33798

AB The invention discloses peptides which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, as well as methods of making the peptides, pharmaceutical compns. containing the peptides, and methods of using the peptides and pharmaceutical compns. to treat diseases associated with aberrant vascularization, e.g. cancer.

ST peptide cell invasion migration proliferation inhibition; antitumor aberrant vascularization disease peptide prepn

IT Sarcoma
(cartilage chondrosarcoma; peptide inhibitors of angiogenesis, cell migration, cell invasion and cell proliferation, preparation, and compns. and therapeutic uses)

IT Cartilage, neoplasm
(chondrosarcoma; peptide inhibitors of angiogenesis, cell migration, cell invasion and cell proliferation, preparation, and compns. and therapeutic uses)

IT Intestine, neoplasm
(colon; peptide inhibitors of angiogenesis, cell migration, cell invasion and cell proliferation, preparation, and compns. and therapeutic uses)

IT Blood vessel
(endothelium; peptide inhibitors of angiogenesis, cell migration, cell invasion and cell proliferation, preparation, and compns. and therapeutic uses)

IT Blood vessel, neoplasm
Sarcoma
(hemangiosarcoma; peptide inhibitors of angiogenesis, cell migration, cell invasion and cell proliferation, preparation, and compns. and therapeutic uses)

IT Angiogenesis
Angiogenesis inhibitors
Antitumor agents
Brain, neoplasm
Drug delivery systems
Kidney, neoplasm
Mammary gland, neoplasm
Neoplasm
Prostate gland, neoplasm
(peptide inhibitors of angiogenesis, cell migration, cell invasion and cell proliferation, preparation, and compns. and therapeutic uses)

IT Endothelium
(vascular; peptide inhibitors of angiogenesis, cell migration, cell invasion and cell proliferation, preparation, and compns. and therapeutic uses)

IT 701201-26-5D, biotinylated
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peptide inhibitors of angiogenesis, cell migration, cell invasion and cell proliferation, preparation, and compns. and therapeutic uses)

IT 701200-82-0P 701201-01-6P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(peptide inhibitors of angiogenesis, cell migration, cell invasion and cell proliferation, preparation, and compns. and therapeutic uses)

IT 81658-55-1P 701200-81-9P 701200-83-1P 701200-84-2P 701200-85-3P
701200-86-4P 701200-87-5P 701200-88-6P 701200-89-7P 701200-90-0P
701200-91-1P 701200-92-2P 701200-93-3P 701200-94-4P 701200-95-5P
701200-96-6P 701200-97-7P 701200-98-8P 701200-99-9P 701201-00-5P
701201-02-7P 701201-03-8P 701201-04-9P 701201-05-0P 701201-06-1P
701201-07-2P 701201-08-3P 701201-09-4P 701201-10-7P 701201-11-8P
701201-12-9P 701201-13-0P 701201-14-1P 701201-15-2P 701201-16-3P
701201-17-4P 701201-18-5P 701201-19-6P 701201-20-9P 701201-21-0P
701201-22-1P 701201-23-2P 701201-24-3P 701201-25-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(peptide inhibitors of angiogenesis, cell migration, cell invasion and cell proliferation, preparation, and compns. and therapeutic uses)

IT 701201-28-7
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peptide inhibitors of angiogenesis, cell migration, cell invasion and cell proliferation, preparation, and compns. and therapeutic uses)

IT 98-88-4, Benzoyl chloride 100-39-0, Benzyl bromide 106-95-6, Allyl bromide, reactions 930-69-8 1212-08-4, S-Phenyl benzenethiosulfonate 2719-27-9, Cyclohexanoyl chloride 2937-50-0, Allyl chloroformate 2949-92-0, S-Methyl methanethiosulfonate 3282-30-2, Pivaloyl chloride 5271-67-0, 2-Thiophenecarbonyl chloride 6482-24-2, 2-Bromoethyl methylether 7031-27-8, (Phenylthio)acetyl chloride 10400-19-8, Nicotinoyl chloride 25644-88-6, S-Benzyl-L-cysteine sulfone 82911-69-1 262438-43-7 475150-36-8 701201-27-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(peptide inhibitors of angiogenesis, cell migration, cell invasion and cell proliferation, preparation, and compns. and therapeutic uses)

L1 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:849621 HCAPLUS
DN 137:353056
ED Entered STN: 08 Nov 2002
TI Preparation of benzenesulfonylpiperazines as matrix metalloproteinase inhibitors.
IN Chung, Yong-Jun; Lee, Keyong-Ho; Kim, Youn-Chul; Park, Ho-Jin
PA Kolon Ind. Inc., S. Korea
SO PCT Int. Appl., 71 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07D403-12
CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002088115	A1	20021107	WO 2002-KR759	20020424
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	KR 2002083084	A	20021101	KR 2001-22767	20010426
	KR 2003047127	A	20030618	KR 2001-77522	20011207
	KR 2003075322	A	20030926	KR 2002-14481	20020318
	EP 1389204	A1	20040218	EP 2002-720668	20020424
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004533435	T2	20041104	JP 2002-585415	20020424
	US 2004138206	A1	20040715	US 2003-475539	20031211 <--
PRAI	KR 2001-22767	A	20010426		
	KR 2001-77522	A	20011207		
	KR 2002-14481	A	20020318		
	WO 2002-KR759	W	20020424		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2002088115	ICM	C07D403-12

WO 2002088115	ECLA	C07C311/19; C07C311/29; C07D241/04; C07D241/08; C07D243/08; C07D245/02; C07D403/12+241B+207
JP 2004533435	FTERM	4C063/AA01; 4C063/BB03; 4C063/BB08; 4C063/CC34; 4C063/DD04; 4C063/DD12; 4C063/EE01; 4C086/AA01; 4C086/AA02; 4C086/AA03; 4C086/AA04; 4C086/BC49; 4C086/BC73; 4C086/GA07; 4C086/GA08; 4C086/GA09; 4C086/GA12; 4C086/MA01; 4C086/MA04; 4C086/NA14; 4C086/ZA33; 4C086/ZA44; 4C086/ZA45; 4C086/ZA67; 4C086/ZA68; 4C086/ZA89; 4C086/ZA96; 4C086/ZA97; 4C086/ZB11; 4C086/ZB15; 4C086/ZB26; 4C086/ZC06; 4C086/ZC35; 4C086/ZC55; 4H006/AA01; 4H006/AA02; 4H006/AB84
US 2004138206	NCL	514/218.000; 514/254.010; 514/255.020; 514/183.000; 540/575.000; 540/474.000; 544/372.000; 544/383.000
	ECLA	C07C311/19; C07C311/29; C07D241/04; C07D241/08; C07D243/08; C07D245/02; C07D403/12+241B+207 <--

OS MARPAT 137:353056

GI



I

AB Title compds. [I; n = 0-3; A = CO2H, CONHOH, CH2SH, CH2OH; B = H, alkyl, NO2, aryl, heteroaryl, pyrrolyl, halo, alkoxy, aryloxy, alkylamino, alkylthio, CONHR, NHCOR, NHCO2R, NHCONHR, etc.; R = H, alkyl, aryl, heteroaryl, tetragonal to octagonal cyclic compound, alkyl substituted by a tetragonal to octagonal (hetero)cyclic compound; Z = H, O, S, provided that when Z = O, S it takes a double bond; Y = H, alkyl, aryl, heteroaryl, alkyl substituted by a tetragonal to octagonal cyclic compound, alkyl substituted by a tetragonal to octagonal heterocyclyl, CONHR, NHCOR, NHCO2R, NHCONHR, alkyl having a double or triple bond], were prepared Thus, Me 1-(4-methoxybenzenesulfonyl)-5-oxopiperazine-2-carboxylate (preparation given) was stirred 5 h with aqueous NH2OH to give 45% 1-(4-methoxybenzenesulfonyl)-5-oxopiperazine-2-hydroxamic acid. This inhibited MMP-2 with IC50 = 0.004 μM. I are angiogenesis controlling materials that can inhibit overexpression of matrix metalloproteinase that decomps. protein constituents in extracellular matrix and basement membranes of connective tissues.

ST benzenesulfonylpiperazine prepn matrix metalloproteinase inhibitor; cancer angiogenesis inhibitor prepn benzenesulfonylpiperazine; hydroxamate benzenesulfonylpiperazine prepn anticancer; piperazinehydroxamate arylsulfonyl prepn mmp inhibitor

IT Antitumor agents
Human
(preparation of benzenesulfonylpiperazines as matrix metalloproteinase inhibitors)

IT Hydroxamic acids
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzenesulfonylpiperazines as matrix metalloproteinase inhibitors)

IT Angiogenesis
Neoplasm

(treatment; preparation of benzenesulfonylpiperazines as matrix metalloproteinase inhibitors)
IT 9001-12-1, Matrix metalloproteinase-1 146480-35-5, Matrix metalloproteinase-2 146480-36-6, Matrix metalloproteinase-9 161384-17-4, Matrix metalloproteinase-14 175449-82-8, Matrix metalloproteinase-13
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; preparation of benzenesulfonylpiperazines as matrix metalloproteinase inhibitors)
IT 184349-80-2P 474410-18-9P 474410-20-3P 474410-22-5P 474410-24-7P 474410-25-8P 474410-27-0P 474410-28-1P 474410-30-5P 474410-31-6P 474410-33-8P 474410-34-9P 474410-35-0P 474410-36-1P 474410-37-2P 474410-38-3P 474410-39-4P 474410-40-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzenesulfonylpiperazines as matrix metalloproteinase inhibitors)
IT 74-89-5, Methylamine, reactions 98-68-0, 4-Methoxybenzenesulfonyl chloride 100-46-9, Benzylamine, reactions 105-36-2, Ethyl bromoacetate 109-73-9, n-Butylamine, reactions 111-26-2, Hexylamine 111-86-4, Octylamine 112-90-3, Oleylamine 507-09-5, Thiolacetic acid, reactions 696-59-3, 2,5-Dimethoxytetrahydrofuran 765-30-0, Cyclopropylamine 2016-57-1, Decylamine 2038-03-1, N-(2-Aminoethyl)morpholine 2706-56-1, 2-(2-Aminoethyl)pyridine 3731-51-9, 2-Aminomethylpyridine 5619-04-5, DL-Serine methyl ester hydrochloride 5874-57-7 13610-11-2 27578-60-5, 1-(2-Aminoethyl)piperidine 202752-04-3 474410-63-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of benzenesulfonylpiperazines as matrix metalloproteinase inhibitors)
IT 85622-74-8P 184350-19-4P 474410-41-8P 474410-42-9P 474410-43-0P 474410-44-1P 474410-45-2P 474410-46-3P 474410-47-4P 474410-48-5P 474410-49-6P 474410-50-9P 474410-51-0P 474410-52-1P 474410-53-2P 474410-54-3P 474410-55-4P 474410-56-5P 474410-57-6P 474410-58-7P 474410-59-8P 474410-60-1P 474410-61-2P 474410-62-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of benzenesulfonylpiperazines as matrix metalloproteinase inhibitors)
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Agouron Pharmaceuticals Inc; US 5753653 1996 HCAPLUS
(2) Anon; J MED CHEM 2000, V43(3), P369
(3) Fujisawa Pharmaceutical Co Ltd; WO 9827069 A 1998 HCAPLUS
(4) Nippon Soda Co Ltd; WO 0102371 A 2001 HCAPLUS
(5) Pfizer Inc; WO 9633172 A 1996 HCAPLUS

=> b wpix

FILE 'WPIX' ENTERED AT 11:27:45 ON 15 JUN 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE LAST UPDATED: 13 JUN 2005 <20050613/UP>
MOST RECENT DERWENT UPDATE: 200537 <200537/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE, PLEASE VISIT:
http://www.stn-international.de/training_center/patents/stn_guide.pdf <<<

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE http://thomsonderwent.com/coverage/latestupdates/ <<<

>>> FOR INFORMATION ON ALL DERWENT WORLD PATENTS INDEX USER GUIDES, PLEASE VISIT:

http://thomsonderwent.com/support/userguides/ <<<

>>> NEW! FAST-ALERTING ACCESS TO NEWLY-PUBLISHED PATENT
DOCUMENTATION NOW AVAILABLE IN DERWENT WORLD PATENTS INDEX
FIRST VIEW - FILE WPIFV.
FOR FURTHER DETAILS: http://www.thomsonderwent.com/dwpifv <<<

>>> THE CPI AND EPI MANUAL CODES HAVE BEEN REVISED FROM UPDATE 200501.
PLEASE CHECK:
http://thomsonderwent.com/support/dwpiref/reftools/classification/code-revision/
FOR DETAILS. <<<

=> d iall l4 tot

L4 ANSWER 1 OF 3 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN
ACCESSION NUMBER: 2004-561873 [54] WPIX
CROSS REFERENCE: 2004-450190 [42]
DOC. NO. CPI: C2004-205382
TITLE: New peptide derivatives having anti-tumor activity useful for the treatment, prevention or detection of cancer.
DERWENT CLASS: B03 B04
INVENTOR(S): ALLAN, A L; DONATE, F; GLADSTONE, P L; MAZAR, A; PARRY, G; TERNANSKY, R J; YOON, W H
PATENT ASSIGNEE(S): (ATTE-N) ATTENUON LLC; (ALLA-I) ALLAN A L; (DONA-I) DONATE F; (GLAD-I) GLADSTONE P L; (MAZA-I) MAZAR A; (PARR-I) PARRY G; (TERN-I) TERNANSKY R J; (YOON-I) YOON W H
COUNTRY COUNT: 107
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 2004063213	A2	20040729	(200454)*	EN	117	C07K000-00
RW: AT BE BG BW CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW						
W: AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW						
AU 2003298726	A1	20040810	(200479)			C07K000-00
US 2005020810	A1	20050127	(200509)			C07K007-08

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE	
WO 2004063213	A2	WO 2003-US37895	20031125	
AU 2003298726	A1	AU 2003-298726	20031125	
US 2005020810	A1 Provisional	US 2002-429174P	20021125	<--
	Provisional	US 2003-475539P	20030602	<--
		US 2003-722843	20031125	

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2003298726	A1 Based on	WO 2004063213

PRIORITY APPLN. INFO: US 2003-475539P 20030602; US 2002-429174P 20021125; US 2003-722843 20031125
INT. PATENT CLASSIF.:
MAIN: C07K000-00; C07K007-08
SECONDARY: C07K007-06

BASIC ABSTRACT:
WO2004063213 A UPAB: 20050207
NOVELTY - Peptide derivatives (I) and their salts, solvates, hydrates or N-oxides are new.
DETAILED DESCRIPTION - Peptide derivatives of formula (I) and their salts, solvates, hydrates or N-oxides are new.
j, k = 0-1;
p, q = 0-100;
r, s = 0-1;
R1 = (substituted) acyl, acyl chelate, (substituted) alkyl, (substituted) cycloalkyl or (substituted) imino;
R2 = 1-6C alkyl with at least H replaced by a substituents of NR6R7, -OR8, -CO2R9, -S(O)2R10, -P(OR11)OR12 or (substituted) aryl;
R6-R12 = H or R1;
X1 = NH(C=C)gCO-, NH(CH2)hCO- or NHCH(CH3)CO-;
g, h = 1-6;
X2 = cyclic derivative of formula (i-iii);
X3 = imidazole derivative of formula (iv);
X4 = alcohol derivative of formula (v-vi);
l = 1-4;
X5 = sulfonyl derivative of formula (vii);
R13 = H, (substituted) alkyl, (substituted) acyl, (substituted) arylalkyl, (substituted) aryl or -S(O)nR14;
n = 1-5;
R14 = (substituted) alkyl, (substituted) acyl, (substituted) arylalkyl or (substituted) aryl;
x, y = 0-2;
X6 = amide derivative formula (viii);
m = 1-4;
X7 = NH(C=C)dCO-, -NH(CH2)eCO or -NHCH(CH3)CO-;
d, e = 1-6;
R3 = 1-6C alkyl with at least H replace by a substituent of -NR15R16, -OR17, -CO2R18, -S(O)nR19, -P(OR20)OR21 or (substituted) aryl;
R4, R5 = H or (substituted alkyl); and
R15-R21 = H, (substituted) acyl, acyl chelate, (substituted) alkyl, (substituted) cycloalkyl or (substituted) imino.
Provided that R1 is not acetyl when R4 and R5 are H and r and s 0.
ACTIVITY - Cytostatic; Antiangiogenic.
Tests details are described but no results given.
MECHANISM OF ACTION - None given
USE - (I) are useful for the treament, prevention or detection of cancer (claimed), tumor growth, metastasis and angiogenesis.
Dwg.0/0

FILE SEGMENT: CPI
FIELD AVAILABILITY: AB; GI; DCN
MANUAL CODES: CPI: B02-D; B04-C01B; B04-C01C; B04-C01D; B04-C01E; B04-C01F; B04-C01G; B04-N04A; B14-H01

L4 ANSWER 2 OF 3 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN
ACCESSION NUMBER: 2004-450190 [42] WPIX
CROSS REFERENCE: 2004-561873 [54]
DOC. NO. CPI: C2004-168702
TITLE: Novel peptides useful as e.g. angiogenesis inhibitors for treating or preventing cancer, e.g. breast cancer, renal cancer, brain cancer, colon cancer.
DERWENT CLASS: B03
INVENTOR(S): ALLAN, A L; DONATE, F; GLADSTONE, P L; HOPKINS, S A; MAZAR, A; O'HARE, S M; PARRY, G; PLUNKETT, M; TERNANSKY, R J; YOON, W H; PLUNKETT, M L
PATENT ASSIGNEE(S): (ALLA-I) ALLAN A L; (DONA-I) DONATE F; (GLAD-I) GLADSTONE P L; (HOPK-I) HOPKINS S A; (MAZA-I) MAZAR A; (OHAR-I) O'HARE S M; (PARR-I) PARRY G; (PLUN-I) PLUNKETT M; (TERN-I) TERNANSKY R J; (YOON-I) YOON W H; (ATTE-N) ATTENUON LLC
COUNTRY COUNT: 106
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 2004047771	A2	20040610	(200442)*	EN	88	A61K000-00
RW: AT BE BG BW CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW						
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW						
US 2004162239	A1	20040819	(200455)			A61K038-08<--
AU 2003297609	A1	20040618	(200471)			A61K000-00

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE	
WO 2004047771	A2	WO 2003-US38175	20031125	
US 2004162239	A1 Provisional	US 2002-429174P	20021125	<--
	Provisional	US 2003-475539P	20030602	<--
		US 2003-723144	20031125	
AU 2003297609	A1	AU 2003-297609	20031125	

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2003297609	A1 Based on	WO 2004047771

PRIORITY APPLN. INFO: **US 2003-475539P 20030602; US 2002-429174P 20021125;** US 2003-723144 20031125

INT. PATENT CLASSIF.:
MAIN: A61K000-00; A61K038-08
SECONDARY: A61K038-10; C07K007-06; C07K007-08

BASIC ABSTRACT:

WO2004047771 A UPAB: 20041104

NOVELTY - Peptides are new.

DETAILED DESCRIPTION - Peptides of formula R1-Ax-By-C'z-(N-CH(R2)-C(O))a-(N-CH(R3)-C(O))b-R4 (I), their salt, solvates, hydrates or N-oxides are new.

a, b and x - z = 0 or 1;

A = cyclic amino acid;

B = basic amino acid;

C' = small amino acid;

R1 = (hetero)alkyl, acyl, alkylsulfonyl, (hetero)arylalkyl, (hetero)arylsulfonyl or oxycarbonyl (all optionally substituted);

R2 = alkyl, -(CH2)mS(O)nR5, -(CH2)mS(O)n-S(O)oR5 or -(CMe)mS(O)nR5;

m = 1-4;

n and o = 0-2;

R3 = -CH2CONH2 or -CH2CH2CONH2;

R4 = alkyl, -NR6R7 or -OR8;

R5 = (hetero)alkyl, acyl, (hetero)aryl, (hetero)arylalkyl or oxycarbonyl (all optionally substituted);

R6, R7 = H or alkyl;

R8 = (hetero)alkyl, (hetero)aryl or (hetero)arylalkyl(all optionally substituted).

Provided that:

(1) when m is 1, R5 is other than methyl;

(2) a is 1 unless A is proline, B is histidine, C is serine;

(3) when a is 0, b is 0; and

(4) R2 is -(CH2)mS(O)nR5 or -(CH2)mS(O)n-S(O)oR5 unless b, x, y and z are 1.

An INDEPENDENT CLAIM is also included for treatment or prevention of

cancer involving administering (I) optionally with an anti-cancer agent.

ACTIVITY - Cytostatic; Antiangiogenic; Antiarthritic; Antidiabetic; Antiarteriosclerotic; Ophthalmological; Vulnerary; Antirheumatic; Dermatological; Antipsoriatic; Antiparasitic; Osteopathic; Vasotropic; Tranquilizer; Thrombolytic; Gynecological; Antiinflammatory; Respiratory-Gen.; Antiulcer; Antisickling.

MECHANISM OF ACTION - Angiogenesis inhibitor; Cell migration, cell invasion and cell proliferation inhibitor; Tumor growth inhibitor.

Acetyl-Pro-His-Ser-Cys(S-tert-Bu)-Asn-NH2 (A) was tested in vivo for its ability to inhibit FGF-2 mediated angiogenesis in a Matrigel Plug (RTM) model according to Passaniti et al., 1992, Lab Invest. 67:519-528.

(A) showed % inhibition of 88.2 plus or minus 42.9.

USE - (I) Are used for treating or preventing cancer e.g. breast cancer, renal cancer, brain cancer, colon cancer, prostrate cancer, chondrosarcoma or angiosarcoma (claimed); for treating diseases associated with aberrant vascularization including arthritis, diabetes, arteriosclerosis, arteriovenous malformation, corneal graft neovascularization, delayed wound healing, diabetic retinopathy, age related macular degeneration, granulation burn, hemophilic joint, rheumatoid arthritis, hypertrophic scar, neovascular glaucoma, nonunion fracture, Osier Weber Syndrome, psoriasis, retrolental fibroplasia, pterygium, scleroderma, trachoma, vascular adhesion, ocular neovascularization, parasitic disease, hypertrophy following surgery, inhibition of hair growth, macular degeneration, osteoarthritis, benign hyperplasia, atherosclerosis, myocardial angiogenesis, post-balloon angioplasty vascular restenosis, neointima formation following vascular trauma, vascular graft restenosis, coronary collateral formation, deep venous thrombosis, ischemic limb angiogenesis; telangiectasia, pyogenic granuloma, corneal disease, rubeosis, neovascular glaucoma, diabetic and other retinopathy, retrolental fibroplasias, diabetic neovascularization, endometriosis, fibrosis associated with a chronic inflammatory condition, traumatic spinal cord injury including ischemia, scarring or fibrosis, lung fibrosis, chemotherapy-induced fibrosis; wound healing with scarring and fibrosis, peptic ulcers, a bone fracture, keloids, or a disorder of vasculogenesis, hematopoiesis, ovulation, menstruation, pregnancy or placentation associated with pathogenic cell invasion or with angiogenesis, retinopathy of prematurity, sickle cell retinopathy or retinal vein occlusion; for treating uterine disease; to detect or image disease or conditions associated with undesired cell migration, invasion or proliferation.

ADVANTAGE - The compounds (I) are potent inhibitors of angiogenesis, cell migration, cell invasion and cell proliferation.

Dwg.0/5

FILE SEGMENT: CPI
FIELD AVAILABILITY: AB; DCN
MANUAL CODES: CPI: B04-C01A; B06-H; B07-H; B10-A04; B10-A08; B10-A10; B10-A12C; B10-B02; B10-D03; B14-B02; B14-C03; B14-C09; B14-D01B; B14-D01C; B14-E08; B14-F02; B14-F03; B14-F04; B14-F07; B14-H01; B14-K01; B14-L06; B14-N01; B14-N03; B14-N14; B14-N16; B14-N17; B14-P02; B14-R02; B14-S04

L4 ANSWER 3 OF 3 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN
ACCESSION NUMBER: 2003-103447 [09] WPIX
DOC. NO. CPI: C2003-026138
TITLE: New sulfonamide derivatives useful in the treatment of e.g. cancer.
DERWENT CLASS: B03
INVENTOR(S): CHUNG, Y; KIM, Y; LEE, K; PARK, H; JUNG, Y J; KIM, Y C; LEE, G H; PARK, H J; CHUNG, Y J
PATENT ASSIGNEE(S): (KOLO-N) KOLON IND INC; (CHUN-I) CHUNG Y; (KIMY-I) KIM Y; (LEEK-I) LEE K; (PARK-I) PARK H
COUNTRY COUNT: 101
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC

```
     ------------------------------------------------------------
     WO 2002088115   A1 20021107 (200309)* EN    71 C07D403-12
        RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ
            NL OA PT SD SE SL SZ TR TZ UG ZM ZW
         W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK
            DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KZ
            LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO
            RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW
     KR 2002083084   A  20021101 (200319)           C07D403-00
     KR 2003047127   A  20030618 (200370)           C07D241-04
     KR 2003075322   A  20030926 (200409)           C07D403-12
     EP 1389204      A1 20040218 (200413)  EN       C07D403-12
         R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
            RO SE SI TR
     AU 2002251588   A1 20021111 (200433)           C07D403-12
     US 2004138206   A1 20040715 (200447)           A61K031-551
     KR 432928       B  20040528 (200463)           C07D403-00
     JP 2004533435   W  20041104 (200472)       120 C07D241-08

APPLICATION DETAILS:

     PATENT NO       KIND                  APPLICATION          DATE
     ------------------------------------------------------------------
     WO 2002088115   A1                    WO 2002-KR759        20020424
     KR 2002083084   A                     KR 2001-22767        20010426
     KR 2003047127   A                     KR 2001-77522        20011207
     KR 2003075322   A                     KR 2002-14481        20020318
     EP 1389204      A1                    EP 2002-720668       20020424
                                           WO 2002-KR759        20020424
     AU 2002251588   A1                    AU 2002-251588       20020424
     US 2004138206   A1                    WO 2002-KR759        20020424
                                           US 2003-475539       20031211   <--
     KR 432928       B                     KR 2001-22767        20010426
     JP 2004533435   W                     JP 2002-585415       20020424
                                           WO 2002-KR759        20020424

FILING DETAILS:

     PATENT NO       KIND                    PATENT NO
     ------------------------------------------------
     EP 1389204      A1 Based on             WO 2002088115
     AU 2002251588   A1 Based on             WO 2002088115
     KR 432928       B  Previous Publ.       KR 2002083084
     JP 2004533435   W  Based on             WO 2002088115

PRIORITY APPLN. INFO: KR 2002-14481        20020318; KR
                      2001-22767        20010426; KR
                      2001-77522        20011207
INT. PATENT CLASSIF.:
           MAIN:      A61K031-551; C07D241-04; C07D241-08; C07D403-00;
                      C07D403-12
       SECONDARY:     A61K031-495; A61K031-496; A61K031-5377; A61P001-02;
                      A61P001-04; A61P003-10; A61P005-18; A61P009-10;
                      A61P009-14; A61P017-00; A61P017-02; A61P017-10;
                      A61P019-00; A61P019-02; A61P019-10; A61P027-02;
                      A61P029-00; A61P031-18; A61P035-00; A61P035-04;
                      A61P043-00; C07C303-40; C07C311-19; C07D401-06
BASIC ABSTRACT:
     WO 200288115 A UPAB: 20030206
     NOVELTY - New sulfonamide derivatives of formula (I), their optical
     isomers, salts or solvates.
          DETAILED DESCRIPTION - Sulfonamide derivatives of formula (I), their
     optical isomers, salts or solvates are new.
     n  = 0 -3;
          A  = CO2H, CONHOH, CH2SH or CH2OH;
          B  = H, 1-8C lower alkyl, nitro, aryl, heteroaryl, pyrrole, halo,
```

1-8C O-lower alkyl, O-aryl, N-lower alkyl, S-lower alkyl, phenyl (substituted by X), amide compound of formula CONHR or NHCOR, carbamate compound of formula NHCOOR or urea compound of formula NHCONHR;

X = H, 1-8C lower alkyl, 9-20C higher alkyl, 9-20C higher alkyl comprising a double bond, (hetero)aryl, halo, O-lower alkyl, O-aryl, O-heteroaryl, N-aryl, N-heteroaryl, S-aryl, S-heteroaryl, 1-20C alkyl-amine derivative, 1-20C alkyl-carboxylic acid derivative, amine or nitro;

R = H, 1-8C lower alkyl, (hetero)aryl, tetragonal to octagonal (hetero)cyclic compound or 1-8C lower alkyl (substituted by tetragonal to octagonal (hetero)cyclic compound);

Z = H, O or S;

Y = H, 1-18C alkyl, (hetero)aryl, 1-8C lower alkyl (substituted by a tetragonal to octagonal (hetero)cyclic compound), amide compound of formula CONHR or NHCOR, carbamate compound of formula NHCOOR, urea compound of formula NHCONHR, 1-8C lower alkyl having a double or a triple bond, 9-20C higher alkyl having a double or a triple bond.

Provided that when Z is O or S the C(ring atom)-Z bond is a double bond.

INDEPENDENT CLAIMS are also included for:

(1) Preparation of (I);

(2) New 4-phenylsulfonyl-piperazine intermediates (II);

(3) Preparation of (II) comprising reaction of a substituted phenylsulfamide of formula (III) with methanesulfonyl chloride, toluenesulfonyl chloride or triflic anhydride in the presence of a base, and reaction of the product with primary amine;

(4) New substituted phenylsulfamide of formula (III); and

(5) Preparation of (III) comprising reaction of the compound of formula (IV) with ethyl bromoacetate and halogen in presence of an inorganic base and N,N-dimethyl formamide or acetonitrile solvent.

W and X = H, methyl, ethyl, t-butyl or 1-8C lower alkyl group comprising a benzyl group.

ACTIVITY - Cytostatic; Antiarteriosclerotic; Ophthalmological; Antidiabetic; Antiarthritic; Antirheumatic; Antiinflammatory; Antiulcer; Osteopathic; Antiseborrheic; Dermatological; Anti-HIV; Antipsoriatic; Vulnerary.

MECHANISM OF ACTION - Matrix metalloproteinase (MMP) inhibitor.

The MMP inhibitor activities were measured by fluorescence assay as described by Knight, C. G., Willenbrock, F., Murphy, G. A., FEBS Lett. 1992, 296, 263-266 . For 1-(4'-bromo-biphenyl-4-sulfonyl)-4-octyl-5-oxo-piperazine-2-hydroxamate. The results indicated an IC50 (mu M) valve of 0.016, 0.002, 0.0013 and 0.007 for MMP-1, MMP-2, MMP-9 and MMP-13 respectively.

USE - In the treatment of cancer metastasis, solid cancer and angiogenesis (claimed). Also useful in the treatment of cardiovascular disease (e.g. hemangioma, angiofibroma), angiostenosis, edematous sclerosis, eye diseases caused by angiogenesis, corneal transplantation, angiogenic glaucoma, diabetic retinopathy, angiogenic corneal disease, age-related macular degeneration, pterygium, retinal degeneration, retreolental fibroplasias, granular conjunctivitis, skin diseases caused by angiogenesis (e.g. chronic inflammatory diseases e.g. arthritis, psoriasis, telangiectasis, granuloma pyogenicum, sebborhoeic dermatitis), periodontal disease, tumors, rheumatoid arthritis, inflammation, hyperparathyroidism, diabetes, corneal ulcers, osteoporosis, stomach ulcers, wounds, wrinkles, acne, AIDS, burns, arteriosclerosis, bone fractures.

ADVANTAGE - The compound is a potent proteinase inhibitor.

Dwg.0/0

FILE SEGMENT: CPI
FIELD AVAILABILITY: AB; GI; DCN
MANUAL CODES: CPI: B07-D03; B07-D11; B10-A08; B14-C03; B14-C09; B14-D07C; B14-E08; B14-F01; B14-F02F2; B14-F07; B14-G01B; B14-H01; B14-N01; B14-N03; B14-N06B; B14-N11; B14-N17; B14-S04; N02-F01

=> b home

FILE 'HOME' ENTERED AT 11:27:51 ON 15 JUN 2005

=>

```
=> b reg
FILE 'REGISTRY' ENTERED AT 11:40:07 ON 15 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   14 JUN 2005  HIGHEST RN 852282-01-0
DICTIONARY FILE UPDATES:  14 JUN 2005  HIGHEST RN 852282-01-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

*************************************************************************
*                                                                       *
* The CA roles and document type information have been removed from     *
* the IDE default display format and the ED field has been added,       *
* effective March 20, 2005.  A new display format, IDERL, is now        *
* available and contains the CA role and document type information.     *
*                                                                       *
*************************************************************************

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> d sqide l11

L11  ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2005 ACS on STN
RN   701201-02-7  REGISTRY
CN   L-Aspartamide, 1-acetyl-L-prolyl-L-histidyl-L-seryl-S-benzoyl-L-cysteinyl-
     (9CI)  (CA INDEX NAME)
FS   PROTEIN SEQUENCE; STEREOSEARCH
SQL  5
NTE  modified
-------------------------------------------------------------------
 type            ------ location ------         description
-------------------------------------------------------------------
terminal mod.    Pro-1           -         N-acetyl
terminal mod.    Asn-5           -         C-terminal amide
modification     Cys-4           -         benzoyl<Bz>
-------------------------------------------------------------------

SEQ      1 PHSCN

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**
MF   C30 H39 N9 O9 S
SR   CA
LC   STN Files:   CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA  CAplus document type:  Patent
RL.P   Roles from patents:  BIOL (Biological study); PREP (Preparation); USES
       (Uses)

Absolute stereochemistry.
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> => d que sta l47
L15 SCR 1994 AND 2005 AND 1838
L16 SCR 2039 OR 2041 OR 2050 OR 2049 OR 2048 OR 2053 OR 2052 OR 2043 OR 2054
L17 STR



VAR G1=16/12
VAR G2=16/15
VAR G3=17/19
VAR G4=AK/27/25
NODE ATTRIBUTES:
CONNECT IS M3 RC AT 2
CONNECT IS M3 RC AT 3
CONNECT IS M1 RC AT 16
CONNECT IS M1 RC AT 18
CONNECT IS M1 RC AT 27
DEFAULT MLEVEL IS ATOM
GGCAT IS UNS AT 15
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 27

STEREO ATTRIBUTES: NONE

L21 40532 SEA FILE=REGISTRY CSS FUL L17 AND L15 NOT L16
L45 STR





VAR G1=16/12
VAR G2=16/15
VAR G3=17/19
VAR G4=N/28/31
NODE ATTRIBUTES:
CONNECT IS M3 RC AT 2
CONNECT IS M3 RC AT 3
CONNECT IS M1 RC AT 16
CONNECT IS M1 RC AT 18
DEFAULT MLEVEL IS ATOM
GGCAT IS UNS AT 15
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 29

STEREO ATTRIBUTES: NONE
L47 1152 SEA FILE=REGISTRY SUB=L21 CSS FUL L45

100.0% PROCESSED 40401 ITERATIONS 1152 ANSWERS
SEARCH TIME: 00.00.06

=> d his full

(FILE 'HOME' ENTERED AT 11:25:08 ON 15 JUN 2005)

FILE 'HCAPLUS' ENTERED AT 11:26:57 ON 15 JUN 2005
L1 3 SEA ABB=ON PLU=ON US20040162239/PN OR (US2002-429174# OR US2003-475539#)/AP,PRN

FILE 'REGISTRY' ENTERED AT 11:27:07 ON 15 JUN 2005

FILE 'HCAPLUS' ENTERED AT 11:27:08 ON 15 JUN 2005
L2 TRA L1 1- RN : 209 TERMS

FILE 'REGISTRY' ENTERED AT 11:27:09 ON 15 JUN 2005
L3 209 SEA ABB=ON PLU=ON L2

FILE 'WPIX' ENTERED AT 11:27:13 ON 15 JUN 2005
L4 3 SEA ABB=ON PLU=ON US20040162239/PN OR (US2002-429174# OR US2003-475539#)/AP,PRN

FILE 'REGISTRY' ENTERED AT 11:35:57 ON 15 JUN 2005

```
L5          80 SEA ABB=ON  PLU=ON  L3 AND NR=3
L6          51 SEA ABB=ON  PLU=ON  L5 AND 46.150.18/RID AND NCNC2/ES AND
               NC4/ES
L7           8 SEA ABB=ON  PLU=ON  L6 AND O=9
L8           8 SEA ABB=ON  PLU=ON  L7 AND N=9
L9           7 SEA ABB=ON  PLU=ON  L8 AND S=1
L10          2 SEA ABB=ON  PLU=ON  C30H39N9O9S
               SEL RN 1
L11          1 SEA ABB=ON  PLU=ON  701201-02-7/BI AND L10

    FILE 'HCAPLUS' ENTERED AT 11:40:20 ON 15 JUN 2005
L12          1 SEA ABB=ON  PLU=ON  L11

    FILE 'REGISTRY' ENTERED AT 12:00:51 ON 15 JUN 2005
L13            STR
L14          0 SEA CSS SAM L13
L15            SCR 1994 AND 2005 AND 1838
L16            SCR 2039 OR 2041 OR 2050 OR 2049 OR 2048 OR 2053 OR 2052 OR 204
L17            STR L13
L18         50 SEA CSS SAM L17
L19         50 SEA SSS SAM L17 AND L15 NOT L16
L20         50 SEA CSS SAM L17 AND L15 NOT L16
L21      40532 SEA CSS FUL L17 AND L15 NOT L16

    FILE 'HCAPLUS' ENTERED AT 12:22:55 ON 15 JUN 2005
L22      30460 SEA ABB=ON  PLU=ON  L21
               E TERNANSKY R/AU
L23         58 SEA ABB=ON  PLU=ON  ("TERNANSKY R J"/AU OR "TERNANSKY ROBERT"/A
               U OR "TERNANSKY ROBERT J"/AU OR "TERNANSKY ROBERT JOHN"/AU OR
               "TERNANSKY ROBERTJ"/AU)
               E HOPKINS S/AU
L24         40 SEA ABB=ON  PLU=ON  ("HOPKINS S"/AU OR "HOPKINS S A"/AU)
               E HOPKINS STEPHANIE/AU
L25          8 SEA ABB=ON  PLU=ON  ("HOPKINS STEPHANIE"/AU OR "HOPKINS
               STEPHANIE A"/AU OR "HOPKINS STEPHANIE ANN"/AU)
               E YOON WO/AU
               E YOON W/AU
L26         13 SEA ABB=ON  PLU=ON  ("YOON W"/AU OR "YOON W H"/AU)
               E YOON WON/AU
L27         10 SEA ABB=ON  PLU=ON  "YOON WON HYUNG"/AU
               E ALLAN A/AU
L28         35 SEA ABB=ON  PLU=ON  ("ALLAN A"/AU OR "ALLAN A L"/AU)
               E ALLAN AMY/AU
L29          6 SEA ABB=ON  PLU=ON  "ALLAN AMY L"/AU
               E GLADSTONE P/AU
L30         27 SEA ABB=ON  PLU=ON  ("GLADSTONE P"/AU OR "GLADSTONE PATRICIA
               L"/AU OR "GLADSTONE PATRICIA LOUISE"/AU OR "GLADSTONE PATRICIAL
               "/AU)
               E O HARE S/AU
L31         12 SEA ABB=ON  PLU=ON  ("O HARE S"/AU OR "O HARE S M"/AU OR "O
               HARE SEAN"/AU OR "O HARE SEAN M"/AU OR "O HARE SEAN MATTHEW"/AU
               )
               E OHARE S/AU
               E DONATE F.AU
               E DONATE F/AU
L32         25 SEA ABB=ON  PLU=ON  ("DONATE F"/AU OR "DONATE F A"/AU OR
               "DONATE FERNANDO"/AU)
               E MAZAR A/AU
L33         71 SEA ABB=ON  PLU=ON  ("MAZAR A"/AU OR "MAZAR A P"/AU OR "MAZAR
               ANDREW"/AU OR "MAZAR ANDREW P"/AU OR "MAZAR ANDREW PAUL"/AU)
               E PARRY G/AU
L34        180 SEA ABB=ON  PLU=ON  ("PARRY G"/AU OR "PARRY G A"/AU OR "PARRY
               G C"/AU OR "PARRY G C N"/AU OR "PARRY G D R"/AU OR "PARRY G
               J"/AU OR "PARRY G J G"/AU OR "PARRY G P"/AU OR "PARRY G R"/AU
               OR "PARRY G S"/AU OR "PARRY G V"/AU OR "PARRY G W"/AU)
               E PARRY GRAHAM/AU
```

```
L35          39 SEA ABB=ON  PLU=ON  ("PARRY GRAHAM"/AU OR "PARRY GRAHAM C"/AU
                OR "PARRY GRAHAM C N"/AU)
                E PLUNKETT M/AU
L36          23 SEA ABB=ON  PLU=ON  ("PLUNKETT M"/AU OR "PLUNKETT M A"/AU OR
                "PLUNKETT M L"/AU OR "PLUNKETT MARIAN"/AU OR "PLUNKETT MARIAN
                L"/AU)
L37          30 SEA ABB=ON  PLU=ON  (ATTENTION OR ATTENUON)/CS,PA
L38             QUE ABB=ON  PLU=ON  PY<=2002 OR AY<=2002 OR PRY<=2002 OR
                PD<20021125 OR AD<20021125 OR PRD<20021125
L39           1 SEA ABB=ON  PLU=ON  L22 AND (L23 OR L24 OR L25 OR L26 OR L27
                OR L28 OR L29 OR L30 OR L31 OR L32 OR L33 OR L34 OR L35 OR L36
                OR L37)
L40       30459 SEA ABB=ON  PLU=ON  L22 NOT L39
L41       27945 SEA ABB=ON  PLU=ON  L40 AND L38
L42        7098 SEA ABB=ON  PLU=ON  L41 AND P/DT
L43        1727 SEA ABB=ON  PLU=ON  L42 AND US/PC.B
                SEL HIT RN L43 1-30

     FILE 'REGISTRY' ENTERED AT 12:31:10 ON 15 JUN 2005
L44         108 SEA ABB=ON  PLU=ON  (300575-30-8/BI OR 300575-31-9/BI OR
                373389-49-2/BI OR 112218-36-7/BI OR 117074-54-1/BI OR 124584-08
                -3/BI OR 126779-14-4/BI OR 152436-94-7/BI OR 152437-87-1/BI OR
                152437-89-3/BI OR 152437-90-6/BI OR 152437-91-7/BI OR 152437-94
                -0/BI OR 161377-96-4/BI OR 161378-01-4/BI OR 161378-03-6/BI OR
                176501-75-0/BI OR 197582-96-0/BI OR 197583-02-1/BI OR 204765-53
                -7/BI OR 260388-07-6/BI OR 261164-71-0/BI OR 261164-72-1/BI OR
                261164-73-2/BI OR 273407-57-1/BI OR 299157-44-1/BI OR 299157-45
                -2/BI OR 299157-46-3/BI OR 332841-89-1/BI OR 332841-93-7/BI OR
                339269-20-4/BI OR 339269-28-2/BI OR 339984-46-2/BI OR 339984-47
                -3/BI OR 476315-83-0/BI OR 581800-85-3/BI OR 599208-44-3/BI OR
                599209-35-5/BI OR 599209-38-8/BI OR 599209-48-0/BI OR 599209-50
                -4/BI OR 599209-54-8/BI OR 599209-71-9/BI OR 599210-30-7/BI OR
                599210-35-2/BI OR 599210-57-8/BI OR 600133-96-8/BI OR 600133-97
                -9/BI OR 602284-37-7/BI OR 618436-51-4/BI OR 618436-52-5/BI OR
                618436-55-8/BI OR 636114-55-1/BI OR 636115-24-7/BI OR 636115-26
                -9/BI OR 663931-64-4/BI OR 665776-85-2/BI OR 665778-89-2/BI OR
                665779-29-3/BI OR 665779-33-9/BI OR 680987-80-8/BI OR 690235-91
                -7/BI OR 690235-92-8/BI OR 690235-95-1/BI OR 690235-96-2/BI OR
                690235-97-3/BI OR 690235-98-4/BI OR 735280-89-4/BI OR 735281-99
                -9/BI OR 735282-20-9/BI OR 735282-43-6/BI OR 746619-67-0/BI OR
                756881-36-4/BI OR 756881-37-5/BI OR 756881-38-6/BI OR 756881-39
                -7/BI OR 756881-40-0/BI OR 756883-09-7/BI OR 756883-10-0/BI OR
                756883-11-1/BI OR 756883-12-2/BI OR 756883-13-3/BI OR 835626-05
                -6/BI OR 835626-06-7/BI OR 835626-08-9/BI OR 848646-61-7/BI OR
                848646-62-8/BI OR 849629-94-3/BI OR 850634-05-8/BI OR 850634-07
                -0/BI OR 850795-76-5/BI OR 850894-12-1/BI OR 851530-95-5/BI OR
                851724-39-5/BI OR 851724-56-6/BI OR 851724-57-7/BI OR 851724-66
                -8/BI OR 851724-72-6/BI OR 851724-97-5/BI OR 851724-98-6/BI OR
                851725-00-3/BI OR 851770-48-4/BI OR 851770-49-5/BI OR 852149-36
                -1/BI OR 852149-38-3/BI OR 852149-40-7/BI OR 852149-66-7/BI OR
                852149-67-8/BI)
L45             STR L17
L46          30 SEA SUB=L21 CSS SAM L45
L47        1152 SEA SUB=L21 CSS FUL L45

     FILE 'HCAPLUS' ENTERED AT 12:36:42 ON 15 JUN 2005
L48         405 SEA ABB=ON  PLU=ON  L47

     FILE 'HCAOLD' ENTERED AT 12:36:48 ON 15 JUN 2005
L49           0 SEA ABB=ON  PLU=ON  L47
L50           0 SEA ABB=ON  PLU=ON  L48 AND (L23 OR L24 OR L25 OR L26 OR L27
                OR L28 OR L29 OR L30 OR L31 OR L32 OR L33 OR L34 OR L35 OR L36
                OR L37)
L51         381 SEA ABB=ON  PLU=ON  L48 AND L38
L52          33 SEA ABB=ON  PLU=ON  L51 AND US/PC.B
                SEL HIT RN L52
```

```
     FILE 'REGISTRY' ENTERED AT 12:38:37 ON 15 JUN 2005
L53           63 SEA ABB=ON  PLU=ON  (90332-82-4/BI OR 93449-69-5/BI OR
                 93449-72-0/BI OR 186654-69-3/BI OR 186654-70-6/BI OR 521943-71-
                 5/BI OR 522609-86-5/BI OR 522609-87-6/BI OR 636593-87-8/BI OR
                 636593-88-9/BI OR 636593-89-0/BI OR 636593-90-3/BI OR 71659-01-
                 3/BI OR 93449-70-8/BI OR 102995-54-0/BI OR 102995-57-3/BI OR
                 102995-60-8/BI OR 102995-62-0/BI OR 102995-67-5/BI OR 103022-88
                 -4/BI OR 104054-96-8/BI OR 104054-98-0/BI OR 104075-57-2/BI OR
                 104532-38-9/BI OR 104532-39-0/BI OR 111450-99-8/BI OR 111451-00
                 -4/BI OR 114359-15-8/BI OR 114359-16-9/BI OR 114359-18-1/BI OR
                 114359-25-0/BI OR 119624-04-3/BI OR 119624-06-5/BI OR 119834-02
                 -5/BI OR 119834-04-7/BI OR 130309-30-7/BI OR 130309-31-8/BI OR
                 130309-32-9/BI OR 142689-18-7/BI OR 145230-68-8/BI OR 162071-42
                 -3/BI OR 162071-80-9/BI OR 179555-43-2/BI OR 184686-55-3/BI OR
                 184686-56-4/BI OR 209595-10-8/BI OR 209595-18-6/BI OR 209595-31
                 -3/BI OR 212955-65-2/BI OR 217433-25-5/BI OR 226714-12-1/BI OR
                 226714-20-1/BI OR 282096-82-6/BI OR 502620-59-9/BI OR 521292-36
                 -4/BI OR 539853-66-2/BI OR 540737-98-2/BI OR 544448-58-0/BI OR
                 544448-59-1/BI OR 586954-19-0/BI OR 586954-22-5/BI OR 93449-77-
                 5/BI OR 93957-06-3/BI)

=> b hcap
FILE 'HCAPLUS' ENTERED AT 12:41:14 ON 15 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 15 Jun 2005  VOL 142 ISS 25
FILE LAST UPDATED: 14 Jun 2005  (20050614/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> d all fhitstr l39 tot

L39  ANSWER 1 OF 1  HCAPLUS  COPYRIGHT 2005 ACS on STN
AN   2002:142756  HCAPLUS
DN   136:211909
ED   Entered STN:  22 Feb 2002
TI   Human kininogen D5 domain polypeptides, protein and cDNA sequence,
     recombinant production and uses in inhibiting angiogenesis
IN   Mazar, Andrew P.; Juarez, Jose C.
PA   Attenuon, LLC, USA
SO   PCT Int. Appl., 84 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
IC   ICM  C07K014-81
     ICS  C07K019-00; C12N015-62; C12N015-15; C07K016-38; A61K051-08;
          A61K038-57; G01N033-68; C12N005-08; C12N005-10; A61K047-48
CC   3-3 (Biochemical Genetics)
     Section cross-reference(s): 1, 6, 13
```

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002014369	A2	20020221	WO 2001-US23185	20010724
	WO 2002014369	C2	20030403		
	WO 2002014369	A3	20020912		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2001077119	A5	20020225	AU 2001-77119	20010724
	EP 1305342	A2	20030502	EP 2001-954904	20010724
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004515222	T2	20040527	JP 2002-519506	20010724
PRAI	US 2000-220194P	P	20000724		
	WO 2001-US23185	W	20010724		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2002014369	ICM	C07K014-81
	ICS	C07K019-00; C12N015-62; C12N015-15; C07K016-38; A61K051-08; A61K038-57; G01N033-68; C12N005-08; C12N005-10; A61K047-48
WO 2002014369	ECLA	C07K014/81B2
JP 2004515222	FTERM	2G045/AA29; 2G045/BB14; 2G045/BB29; 2G045/BB46; 2G045/BB50; 2G045/CB01; 2G045/DA36; 2G045/FB03; 2G045/FB05; 2G045/FB12; 2G045/GC15; 2G045/GC22; 2G054/AA08; 2G054/BB03; 2G054/CA23; 2G054/CE02; 2G054/EA03; 2G054/GA04; 4B024/AA01; 4B024/AA12; 4B024/CA02; 4B024/DA03; 4B024/EA02; 4B024/EA04; 4B024/FA02; 4B063/QA18; 4B063/QA19; 4B063/QQ08; 4B063/QR48; 4B063/QS03; 4B063/QS15; 4B063/QX01; 4B063/QX02; 4B063/QX07; 4B064/AG27; 4B064/DA05; 4B065/AA93; 4B065/AB06; 4B065/BA02; 4B065/CA44; 4B065/CA46; 4C084/AA02; 4C084/AA07; 4C084/AA12; 4C084/BA01; 4C084/BA08; 4C084/BA16; 4C084/BA17; 4C084/BA18; 4C084/BA19; 4C084/BA23; 4C084/BA44; 4C084/CA18; 4C084/CA53; 4C084/DC01; 4C084/NA14; 4C084/ZA012; 4C084/ZA332; 4C084/ZA362; 4C084/ZA452; 4C084/ZA512; 4C084/ZA542; 4C084/ZA592; 4C084/ZA682; 4C084/ZA812; 4C084/ZA892; 4C084/ZA962; 4C084/ZB212; 4C084/ZB262; 4C084/ZB272; 4C084/ZB312; 4C085/AA14; 4C085/BB22; 4C085/CC32; 4C085/EE01; 4C085/EE05; 4C085/GG01; 4C085/HH03; 4C085/HH11; 4C085/HH13; 4C085/KA27; 4C085/KA29; 4C085/KB07; 4C085/KB09; 4C085/KB18; 4C085/LL18; 4H045/AA10; 4H045/AA11; 4H045/AA30; 4H045/BA10; 4H045/BA15; 4H045/BA17; 4H045/BA41; 4H045/BA60; 4H045/CA40; 4H045/DA76; 4H045/EA23; 4H045/EA27; 4H045/EA28

AB Peptides form the human kininogen D5 domain and fusion peptides thereof having angiogenesis-inhibitory activity. These peptides are used in diagnosis and therapy of diseases associated with endothelial cell migration and proliferation, e.g., the treatment of cancer. The invention further relates to nucleic acid mols. encoding said peptides, antibodies to said peptides and methods for isolating said peptides and cells expressing them. The D5 domain of human kininogen, has one or more of the following properties: (a) inhibits angiogenesis at a IC50 of at least about 1 CLM; (b) binds to a D5 binding site on an endothelial cell with an affinity characterized by a Kd of about 11 M or lower as measured in a direct

binding assay to activated endothelial cells or in a competitive binding assay to purified D5 receptor; (c) activates one or more signaling pathways leading to induction of apoptosis in an endothelial cell; or (d) inhibits a signaling pathway required for maintenance of endothelial cell viability. The invention also relates to host cell, genetic vector and methods for recombinant production of said kininogen D5 domain. The invention also relates to isolating and enriching cells expressing D5 domain binding sites from a cell mixture

ST sequence cDNA kininogen D5 domain human; angiogenesis inhibitor kininogen D5 domain human

IT Protein motifs
(D5 domain; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)

IT Dopamine receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(D5, used in isolation of; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)

IT Antibodies and Immunoglobulins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(IgG1, fusion products; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(MBP (maltose-binding protein), as binding partner; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)

IT Fluorescent substances
(Oregon Green, as label; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)

IT Ligands
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(affinity, binding to; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)

IT Antiarteriosclerotics
(antiatherosclerotics; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)

IT Hyperplasia
(arterial intimal, treatment of; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)

IT Thioredoxins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(as binding partner; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)

IT Eukaryota
(as host; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)

IT Chemiluminescent substances
Chromophores
Color formers
Fluorescent substances
Phosphorescent substances
(as label; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)

IT Allophycocyanins
Phycocyanins
Phycoerythrins
RL: DGN (Diagnostic use); BIOL (Biological study); USES (Uses)
(as label; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)

IT Nervous system, disease
(ataxia telangiectasia, treatment of; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)
IT Hyperplasia
(benign, treatment of; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)
IT Luminescent substances
(bioluminescent, as label; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)
IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(calmodulin-binding, as binding partner; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)
IT Fibrosis
(chemotherapy-induced, associated with chronic inflammation, treatment of; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)
IT Circulation
(coronary, collateral, disorder of, treatment of; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)
IT Menstruation
Ovulation
(disorder of, treatment of; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)
IT Pregnancy
(disorder, treatment of; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)
IT Hematopoiesis
(disorders, treatment of; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)
IT Uterus, disease
(endometriosis, treatment of; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)
IT Blood vessel
(endothelium; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)
IT Lung, disease
(fibrosis, treatment of; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)
IT Anticoagulants
(for deep venous; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)
IT Angiogenesis inhibitors
(for myocardial or ischemic limb; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)
IT Bone, disease
(fracture, treatment of; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)
IT Antitumor agents
(granulosa cell tumor, for pyogenic or neovascular; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)
IT Ovary, neoplasm
(granulosa cell tumor, inhibitors, for pyogenic or neovascular; human

kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)

IT Antibodies and Immunoglobulins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(heavy chain, hinge, CH2 or CH3, fused with kininogen D5 domain; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)

IT Angiogenesis inhibitors
Antiarthritics
Antidiabetic agents
Antitumor agents
Human
Molecular cloning
Plasmid vectors
Protein sequences
Signal transduction, biological
Viral vectors
Wound healing promoters
cDNA sequences
(human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)

IT Kininogens
RL: BPN (Biosynthetic preparation); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)

IT Fusion proteins (chimeric proteins)
RL: BPN (Biosynthetic preparation); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)

IT Antibodies and Immunoglobulins
Radionuclides, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)

IT Antibodies and Immunoglobulins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(humanized; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)

IT Apoptosis
(inducing; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)

IT Cell migration
(inhibition of; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)

IT Cell proliferation
(inhibition, of endothelial cells; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)

IT Drug delivery systems
(injections; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)

IT Spinal cord, disease
(injury, scarring or fibrosis, treatment of; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)

IT Artery, disease
(intima, hyperplasia, treatment of; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)

IT Spinal cord, disease
(ischemia, treatment of; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)

IT Eye, disease
(keratopathy, treatment of; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)
IT Antitumor agents
(leukemia; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)
IT Epitopes
(linear or conformational; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)
IT Antitumor agents
(lymphoma; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)
IT Eye, disease
(macula, degeneration, treatment of; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)
IT Animal cell
(mammalian, as host; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)
IT Antitumor agents
(metastasis; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)
IT Diagnosis
(mol.; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)
IT Antibodies and Immunoglobulins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(monoclonal; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)
IT Angiogenesis
(neovascularization, treatment of; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)
IT Antiulcer agents
(peptic; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)
IT Fibroblast
(proliferation, disorder of, retrolental, treatment of; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)
IT Fibrosis
(pulmonary, treatment of; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)
IT Artery, disease
(restenosis, post-balloon angioplasty or vascular graft, treatment of; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)
IT Eye, disease
(retinopathy, treatment of; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)
IT Eye, disease
(rubeosis, treatment of; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)
IT Injury
(spinal cord, scarring or fibrosis, treatment of; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)
IT Ischemia
(spinal cord, treatment of; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting

angiogenesis)

IT Keloid
(treatment of; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)

IT Endothelium
(vascular; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)

IT Blood vessel, disease
(vasculogenesis, treatment of; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)

IT 402061-21-6P, Kininogen (human D5 doamin)
RL: BPN (Biosynthetic preparation); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)

IT 50812-37-8, Glutathione-S-transferase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(as binding partner; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)

IT 643-79-8, 1,2-Benzenedicarboxaldehyde 2321-07-5, Fluorescein 2321-07-5D, Fluorescein, derivs. 10028-17-8, 3H, biological studies 13558-31-1 13981-27-6, 89Zr, biological studies 14119-09-6, 67Ga, biological studies 14133-76-7, 99Tc, biological studies 14762-75-5, 14C, biological studies 15064-65-0, 201Tl, biological studies 15117-53-0, 35S, biological studies 15715-08-9, 123I, biological studies 15750-15-9, 111In, biological studies 15755-33-6, 72As, biological studies 15757-14-9, 68Ga, biological studies 15758-35-7, 97Ru, biological studies 38183-12-9, Fluorescamine 82354-19-6, Texas red 183185-51-5, Rhodol green 189200-71-3, Rhodamine green
RL: DGN (Diagnostic use); BIOL (Biological study); USES (Uses)
(as label; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)

IT 9001-90-5, Plasmin 9002-04-4, Thrombin 9004-08-4, Cathepsin 9039-53-6, Urokinase 81669-70-7, Metalloproteinase
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(cleavage of linker peptide by; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)

IT 268728-70-7
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(epitope H5-10 sequence; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)

IT 268728-71-8
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(epitope H5-13 sequence; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)

IT 268728-72-9
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(epitope H5-14 sequence; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)

IT 401895-01-0 401895-02-1
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(epitope sequence; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)

IT 605-65-2, Dansyl chloride
RL: DGN (Diagnostic use); BIOL (Biological study); USES (Uses)
(for labeling; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)
IT 10043-66-0, 131I, biological studies 14158-31-7, 125I, biological studies
RL: DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)
IT 10098-91-6, 90Y, biological studies 14391-96-9, 47Sc, biological studies 14981-64-7, 109Pd, biological studies 15092-94-1, 212Pb, biological studies 15755-39-2, 211At, biological studies 15757-86-5, 67Cu, biological studies 29901-95-9, 217Bi, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)
IT **401895-03-2** 401895-04-3
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(linker sequence; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)
IT 402061-22-7
RL: DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nucleotide sequence; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)
IT 402061-33-0 402061-34-1
RL: PRP (Properties)
(unclaimed nucleotide sequence; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)
IT 402061-32-9 402061-35-2
RL: PRP (Properties)
(unclaimed protein sequence; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)
IT 401895-05-4
RL: PRP (Properties)
(unclaimed sequence; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)
IT **401895-03-2**
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(linker sequence; human kininogen D5 domain polypeptides, protein and cDNA sequence, recombinant production and uses in inhibiting angiogenesis)
RN 401895-03-2 HCAPLUS
CN L-Aspartic acid, L-valyl-L-prolyl-L-arginylglycyl-L-seryl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d all hitrn l52 tot

L52 ANSWER 1 OF 33 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:252189 HCAPLUS
DN 140:286142
ED Entered STN: 26 Mar 2004
TI Hybrid polypeptides comprising Ii-key motif and MHC class I or II-presented epitope of antigen, allergen or tumor antigen as vaccines against infection, allergy and cancer
IN Humphreys, Robert E.; Xu, Minzhen
PA Antigen Express, Inc., USA
SO U.S. Pat. Appl. Publ., 90 pp.
CODEN: USXXCO
DT Patent
LA English
IC ICM A61K048-00
ICS C12Q001-68; C07H021-04; C07K014-74
INCL 514044000; 530350000; 435006000; 435069100; 435320100; 435325000; 536023500
CC 15-2 (Immunochemistry)
Section cross-reference(s): 3, 63
FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2004058881	A1	20040325	US 2002-253286	20020924 <--
WO 2004030616	A2	20040415	WO 2003-US28574	20030912 <--
WO 2004030616	A3	20041007		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2002-245871 A 20020917 <--
US 2002-253286 A 20020924 <--

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2004058881	ICM	A61K048-00
	ICS	C12Q001-68; C07H021-04; C07K014-74
	INCL	514044000; 530350000; 435006000; 435069100; 435320100; 435325000; 536023500
US 2004058881	NCL	514/044.000; 530/350.000; 435/006.000; 435/069.100; 435/320.100; 435/325.000; 536/023.500
	ECLA	C07K014/705B28 <--

WO 2004030616 ECLA C07K014/705B28 <--

AB Disclosed is a nucleic acid mol. comprising a first expressible sequence encoding a protein of interest or polypeptide of interest which contains an MHC Class II-presented epitope. In addition, the nucleic acid mol. comprises a second expressible nucleic acid sequence encoding an antigen presentation-enhancing hybrid polypeptide. The antigen presentation enhancing hybrid polypeptide includes the following elements: i) an N-terminal element consisting essentially of 4-16 residues of the mammalian Ii-Key peptide: LRMKLPKPPKPVSKMR and non-N-terminal deletion modifications thereof that retain antigen presentation enhancing activity; ii) a C-terminal element comprising an MHC Class II-presented epitope in the form of a polypeptide or peptidomimetic structure which binds to the antigenic peptide binding site of an MHC class II mol., the MHC Class II-presented epitope being contained in the protein of interest of step a); and iii) an intervening peptidyl structure linking the N-terminal and C-terminal elements of the hybrid, the peptidyl structure having a length of about 20 amino acids or less. Exemplified proteins are allergen: Ara h 1-3, Fel d 1, Phi p 1, Phl p 5a, Bla q 5, and bee venom phospholipase A2; tumor antigen: CEA, CA-125, PSA, gp100, Pmel17, TRP-2, melanoma tyrosinase, MART-1, and Her-2 neu; pathogenic antigen: anthrax toxin lethal factor, anthrax protective antigen, Variola virus B5R protein, and Ebola virus membrane-associated protein VP24; and autoantigen: myelin basic protein, proteolipid protein, and myelin-oligodendrocyte glycoprotein precursor.

ST chimeric polypeptide Ii key motif MHC II epitope vaccine; allergen tumor antigen protein autoantigen epitope Ii key motif; infection allergy cancer autoimmune disease vaccine MHC I epitope

IT Proteolipid protein
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(1; hybrid polypeptides comprising Ii-key motif and MHC class I or II-presented epitope of antigen, allergen or tumor antigen as vaccines against infection, allergy and cancer)

IT Vaccines
(AIDS; hybrid polypeptides comprising Ii-key motif and MHC class I or II-presented epitope of antigen, allergen or tumor antigen as vaccines against infection, allergy and cancer)

IT Allergens
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Ara h 1; hybrid polypeptides comprising Ii-key motif and MHC class I or II-presented epitope of antigen, allergen or tumor antigen as vaccines against infection, allergy and cancer)

IT Allergens
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Ara h 2; hybrid polypeptides comprising Ii-key motif and MHC class I or II-presented epitope of antigen, allergen or tumor antigen as vaccines against infection, allergy and cancer)

IT Allergens
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Ara h 3 (Arachis hypogaea, 3); hybrid polypeptides comprising Ii-key motif and MHC class I or II-presented epitope of antigen, allergen or tumor antigen as vaccines against infection, allergy and cancer)

IT Proteins
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(B5R; hybrid polypeptides comprising Ii-key motif and MHC class I or II-presented epitope of antigen, allergen or tumor antigen as vaccines against infection, allergy and cancer)

IT Allergens
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Bla g 5; hybrid polypeptides comprising Ii-key motif and MHC class I or II-presented epitope of antigen, allergen or tumor antigen as

vaccines against infection, allergy and cancer)

IT Allergens
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Fel d 1 (Felis domesticus, 1); hybrid polypeptides comprising Ii-key motif and MHC class I or II-presented epitope of antigen, allergen or tumor antigen as vaccines against infection, allergy and cancer)

IT Antigens
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(MAA (melanoma-associated antigen); hybrid polypeptides comprising Ii-key motif and MHC class I or II-presented epitope of antigen, allergen or tumor antigen as vaccines against infection, allergy and cancer)

IT Antigens
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(MART-1; hybrid polypeptides comprising Ii-key motif and MHC class I or II-presented epitope of antigen, allergen or tumor antigen as vaccines against infection, allergy and cancer)

IT Histocompatibility antigens
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(MHC (major histocompatibility complex), class I, epitope; hybrid polypeptides comprising Ii-key motif and MHC class I or II-presented epitope of antigen, allergen or tumor antigen as vaccines against infection, allergy and cancer)

IT Histocompatibility antigens
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(MHC (major histocompatibility complex), class II, epitope; hybrid polypeptides comprising Ii-key motif and MHC class I or II-presented epitope of antigen, allergen or tumor antigen as vaccines against infection, allergy and cancer)

IT Glycoproteins
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(MOG (myelin oligodendrocyte glycoprotein); hybrid polypeptides comprising Ii-key motif and MHC class I or II-presented epitope of antigen, allergen or tumor antigen as vaccines against infection, allergy and cancer)

IT Allergens
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Phl p 1 (Phleum pratense, 1); hybrid polypeptides comprising Ii-key motif and MHC class I or II-presented epitope of antigen, allergen or tumor antigen as vaccines against infection, allergy and cancer)

IT Allergens
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Phl p 5a; hybrid polypeptides comprising Ii-key motif and MHC class I or II-presented epitope of antigen, allergen or tumor antigen as vaccines against infection, allergy and cancer)

IT Proteins
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(SILV; hybrid polypeptides comprising Ii-key motif and MHC class I or II-presented epitope of antigen, allergen or tumor antigen as vaccines against infection, allergy and cancer)

IT Proteins
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(TRP-2 (tyrosinase-related protein 2); hybrid polypeptides comprising Ii-key motif and MHC class I or II-presented epitope of antigen, allergen or tumor antigen as vaccines against infection, allergy and cancer)

IT Proteins

RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(VP24 membrane-associated; hybrid polypeptides comprising Ii-key motif and MHC class I or II-presented epitope of antigen, allergen or tumor antigen as vaccines against infection, allergy and cancer)

IT Toxins
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anthrax lethal factor; hybrid polypeptides comprising Ii-key motif and MHC class I or II-presented epitope of antigen, allergen or tumor antigen as vaccines against infection, allergy and cancer)

IT Toxins
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anthrax protective antigen; hybrid polypeptides comprising Ii-key motif and MHC class I or II-presented epitope of antigen, allergen or tumor antigen as vaccines against infection, allergy and cancer)

IT Infection
(anthrax; hybrid polypeptides comprising Ii-key motif and MHC class I or II-presented epitope of antigen, allergen or tumor antigen as vaccines against infection, allergy and cancer)

IT Peptides, biological studies
Proteins
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antigen presentation-enhancing; hybrid polypeptides comprising Ii-key motif and MHC class I or II-presented epitope of antigen, allergen or tumor antigen as vaccines against infection, allergy and cancer)

IT Human immunodeficiency virus
Influenza virus
(antigen; hybrid polypeptides comprising Ii-key motif and MHC class I or II-presented epitope of antigen, allergen or tumor antigen as vaccines against infection, allergy and cancer)

IT Antigens
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(autoantigens; hybrid polypeptides comprising Ii-key motif and MHC class I or II-presented epitope of antigen, allergen or tumor antigen as vaccines against infection, allergy and cancer)

IT Venoms
(bee; hybrid polypeptides comprising Ii-key motif and MHC class I or II-presented epitope of antigen, allergen or tumor antigen as vaccines against infection, allergy and cancer)

IT Skin
(dander; hybrid polypeptides comprising Ii-key motif and MHC class I or II-presented epitope of antigen, allergen or tumor antigen as vaccines against infection, allergy and cancer)

IT Envelope proteins
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(gp160env; hybrid polypeptides comprising Ii-key motif and MHC class I or II-presented epitope of antigen, allergen or tumor antigen as vaccines against infection, allergy and cancer)

IT T cell (lymphocyte)
(helper cell, epitope; hybrid polypeptides comprising Ii-key motif and MHC class I or II-presented epitope of antigen, allergen or tumor antigen as vaccines against infection, allergy and cancer)

IT Allergy
Animal
Antigen presentation
Arachis hypogaea
Autoimmune disease
Betula
Blattaria
Ebola virus
Epitopes

Felis catus
Human
Human immunodeficiency virus 1
Immunotherapy
Infection
Mammalia
Melanoma
Multiple sclerosis
Pathogen
Peptidomimetics
Phleum pratense
Pollen
Protein motifs
Protein sequences
Vaccines
Vaccinia virus
Variola virus
(hybrid polypeptides comprising Ii-key motif and MHC class I or II-presented epitope of antigen, allergen or tumor antigen as vaccines against infection, allergy and cancer)

IT RNA
mRNA
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(hybrid polypeptides comprising Ii-key motif and MHC class I or II-presented epitope of antigen, allergen or tumor antigen as vaccines against infection, allergy and cancer)

IT Allergens
Antigens
CA 125 (carbohydrate antigen)
Carcinoembryonic antigen
Fusion proteins (chimeric proteins)
Myelin basic protein
Prostate-specific antigen
neu (receptor)
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hybrid polypeptides comprising Ii-key motif and MHC class I or II-presented epitope of antigen, allergen or tumor antigen as vaccines against infection, allergy and cancer)

IT Gene, animal
Gene, microbial
Nucleic acids
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hybrid polypeptides comprising Ii-key motif and MHC class I or II-presented epitope of antigen, allergen or tumor antigen as vaccines against infection, allergy and cancer)

IT Vaccines
(influenza; hybrid polypeptides comprising Ii-key motif and MHC class I or II-presented epitope of antigen, allergen or tumor antigen as vaccines against infection, allergy and cancer)

IT Invariant chain (class II antigen)
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(key motif; hybrid polypeptides comprising Ii-key motif and MHC class I or II-presented epitope of antigen, allergen or tumor antigen as vaccines against infection, allergy and cancer)

IT Proteins
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(membrane, VP24; hybrid polypeptides comprising Ii-key motif and MHC class I or II-presented epitope of antigen, allergen or tumor antigen as vaccines against infection, allergy and cancer)

IT Proteins
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(precursor, MOG glycoprotein; hybrid polypeptides comprising Ii-key motif and MHC class I or II-presented epitope of antigen, allergen or tumor antigen as vaccines against infection, allergy and cancer)

IT Mutagenesis
(site-directed, deletion; hybrid polypeptides comprising Ii-key motif and MHC class I or II-presented epitope of antigen, allergen or tumor antigen as vaccines against infection, allergy and cancer)

IT Antigens
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tumor-associated; hybrid polypeptides comprising Ii-key motif and MHC class I or II-presented epitope of antigen, allergen or tumor antigen as vaccines against infection, allergy and cancer)

IT Vaccines
(tumor; hybrid polypeptides comprising Ii-key motif and MHC class I or II-presented epitope of antigen, allergen or tumor antigen as vaccines against infection, allergy and cancer)

IT Anti-AIDS agents
Antitumor agents
(vaccines; hybrid polypeptides comprising Ii-key motif and MHC class I or II-presented epitope of antigen, allergen or tumor antigen as vaccines against infection, allergy and cancer)

IT Infection
(variola, vaccine; hybrid polypeptides comprising Ii-key motif and MHC class I or II-presented epitope of antigen, allergen or tumor antigen as vaccines against infection, allergy and cancer)

IT Apoidea
(venom; hybrid polypeptides comprising Ii-key motif and MHC class I or II-presented epitope of antigen, allergen or tumor antigen as vaccines against infection, allergy and cancer)

IT Infection
(viral; hybrid polypeptides comprising Ii-key motif and MHC class I or II-presented epitope of antigen, allergen or tumor antigen as vaccines against infection, allergy and cancer)

IT 9068-38-6, Reverse transcriptase
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(HIV-1; hybrid polypeptides comprising Ii-key motif and MHC class I or II-presented epitope of antigen, allergen or tumor antigen as vaccines against infection, allergy and cancer)

IT 676170-85-7, Allergen Ara h1 (Peanut) 676176-26-4, Allergen Ara h2 (Peanut) 676176-27-5, Allergen Ara h3 (Peanut) 676176-28-6, Allergen Ara Fel d1 (cat chain-1) 676176-29-7, Allergen Ara Fel d1 (cat chain-2) 676176-30-0, Allergen Phl P5 (Phleum pratense) 676176-31-1, Allergen Phl P5a (Betula) 676176-32-2, Phospholipase A2 (Bee) 676176-33-3, Allergen Bla g5 (Cofkroach) 676176-34-4, Antigen CEA (human) 676176-35-5, Antigen CA-125 (human ovarian cancer) 676176-36-6, Antigen gp100/pmel (human melanoma) 676176-37-7, Protein TRP-2 (human) 676176-38-8, Protein TRP-2 (human) 676176-39-9, Oxygenase, monophenol mono- (human) 676176-40-2, Antigen, MART-1 (human) 676176-41-3, Protein Her-2/neu (human) 676176-42-4 676176-43-5 676176-44-6, Protein B5R (Variola virus) 676176-45-7, Protein VP24 (Ebola virus) 676176-46-8, Myelin basic protein (synthetic)
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid seqeucne; hybrid polypeptides comprising Ii-key motif and MHC class I or II-presented epitope of antigen, allergen or tumor antigen as vaccines against infection, allergy and cancer)

IT 9001-84-7D, Phospholipase A2, chimeric epitope derivs. 9002-10-2D, Tyrosinase, chimeric epitope derivs. 50812-37-8D, Glutathione-S-transferase, chimeric derivs. 122043-82-7D, chimeric derivs. 148951-36-4D, chimeric derivs. 151812-50-9D, chimeric derivs. 154330-44-6D, chimeric derivs. 154330-45-7D, chimeric derivs. 154427-26-6D, chimeric derivs. 154427-28-8D, chimeric derivs. 155029-62-2D, chimeric derivs. 156250-91-8D, chimeric derivs. 156250-92-9D, chimeric derivs. 156250-94-1D, chimeric derivs.

156250-95-2D, chimeric derivs. 156251-11-5D, chimeric derivs.
156761-76-1D, chimeric derivs. 158988-46-6D, chimeric derivs.
160212-35-1D, chimeric derivs. 160213-56-9D, chimeric derivs.
160214-15-3D, chimeric derivs. 160214-17-5D, chimeric derivs.
160214-64-2D, chimeric derivs. 160214-67-5D, chimeric derivs.
160215-66-7D, chimeric derivs. 160217-30-1D, chimeric derivs.
160217-32-3D, chimeric derivs. 160217-37-8D, chimeric derivs.
160217-44-7D, chimeric derivs. 160217-91-4D, chimeric derivs.
160790-21-6D, chimeric derivs. 162558-08-9D, chimeric derivs.
162558-10-3D, chimeric derivs. 168635-85-6D, chimeric derivs.
168635-91-4D, chimeric derivs. 168650-46-2D, chimeric derivs.
172286-82-7D, chimeric derivs. 172958-16-6D, chimeric derivs.
173554-73-9D, chimeric derivs. 174366-65-5D, chimeric derivs.
174366-69-9D, chimeric derivs. 176049-76-6D, chimeric derivs.
176049-79-9D, chimeric derivs. 176049-83-5D, chimeric derivs.
176049-84-6D, chimeric derivs. 177333-26-5D, chimeric derivs.
184297-65-2D, chimeric derivs. 185812-53-7D, chimeric derivs.
187987-68-4D, chimeric derivs. 187987-69-5D, chimeric derivs.
188191-55-1D, chimeric derivs. 188349-69-1D, chimeric derivs.
188606-70-4D, chimeric derivs. 188606-73-7D, chimeric derivs.
188606-81-7D, chimeric derivs. 191857-04-2D, chimeric derivs.
191857-06-4D, chimeric derivs. 191857-08-6D, chimeric derivs.
191857-10-0D, chimeric derivs. 191857-14-4D, chimeric derivs.
191857-30-4D, chimeric derivs. 191857-31-5D, chimeric derivs.
191857-35-9D, chimeric derivs. 191857-36-0D, chimeric derivs.
191857-37-1D, chimeric derivs. 194493-58-8D, chimeric derivs.
194730-57-9D, chimeric derivs. 194730-60-4D, chimeric derivs.
194730-62-6D, chimeric derivs. 194730-64-8D, chimeric derivs.
195523-86-5D, chimeric derivs. 196514-67-7D, chimeric derivs.
197169-94-1D, chimeric derivs. 197170-00-6D, chimeric derivs.
197170-01-7D, chimeric derivs. 197170-23-3D, chimeric derivs.
197170-34-6D, chimeric derivs. 197170-36-8D, chimeric derivs.
197171-78-1D, chimeric derivs. 198887-47-7D, chimeric derivs.
198887-49-9D, chimeric derivs. 198887-71-7D, chimeric derivs.
199184-83-3D, chimeric derivs. 205747-96-2D, chimeric derivs.
211049-24-0D, chimeric derivs. 219312-69-3D, chimeric derivs.
219562-84-2D, chimeric derivs. 220063-48-9D, chimeric derivs.
220111-12-6D, chimeric derivs. 220430-15-9D, chimeric derivs.
220431-68-5D, chimeric derivs. 220431-71-0D, chimeric derivs.
221652-71-7D, chimeric derivs. 221652-72-8D, chimeric derivs.
222412-18-2D, chimeric derivs. 222850-06-8D, chimeric derivs.
229020-52-4D, chimeric derivs. 229020-55-7D, chimeric derivs.
229020-56-8D, chimeric derivs. 229020-58-0D, chimeric derivs.
229020-59-1D, chimeric derivs. 245490-19-1D, chimeric derivs.
259743-35-6D, chimeric derivs. 260984-76-7D, chimeric derivs.
260984-83-6D, chimeric derivs. 260987-83-5D, chimeric derivs.
267000-54-4D, chimeric derivs. 267000-55-5D, chimeric derivs.
267000-56-6D, chimeric derivs. 267000-61-3D, chimeric derivs.
267000-63-5D, chimeric derivs. 267000-91-9D, chimeric derivs.
267000-96-4D, chimeric derivs. 267000-97-5D, chimeric derivs.
268209-83-2D, chimeric derivs. 268209-84-3D, chimeric derivs.
291507-29-4D, chimeric derivs. 291507-31-8D, chimeric derivs.
291507-33-0D, chimeric derivs. 291507-35-2D, chimeric derivs.
291507-37-4D, chimeric derivs. 310453-65-7D, chimeric derivs.
310453-71-5D, chimeric derivs. 318236-09-8 331663-61-7 344570-52-1D, chimeric derivs. 344955-59-5D, chimeric derivs. 345347-02-6D, chimeric derivs. 345348-53-0D, chimeric derivs. 361366-26-9D, chimeric derivs.
370878-07-2D, chimeric derivs. 370878-08-3D, chimeric derivs.
371162-39-9D, chimeric derivs. 383401-04-5D, chimeric derivs.
384823-96-5D, chimeric derivs. 384823-97-6D, chimeric derivs.
399508-89-5D, chimeric derivs. 403667-29-8D, chimeric derivs.
438492-02-5D, chimeric derivs. 471926-95-1D, chimeric derivs.
471927-52-3D, chimeric derivs. 471927-56-7D, chimeric derivs.
480654-08-8, GenBank AAB00386 494213-66-0D, chimeric derivs.
528557-74-6D, chimeric derivs. 528557-80-4D, chimeric derivs.
632297-75-7D, chimeric derivs. 636590-94-8 636590-95-9 636590-96-0

636590-97-1 636590-98-2 636590-99-3 636591-00-9 636591-01-0
636591-02-1 636591-03-2 636591-04-3 636591-05-4 636591-06-5
636591-07-6 636591-08-7 636591-09-8 636591-10-1 636591-11-2
636591-13-4 636591-14-5 636591-15-6 636591-16-7 636591-17-8
636591-18-9 636591-19-0 636591-20-3 636591-21-4 636591-22-5
636591-23-6 636591-24-7 636591-25-8 636591-26-9 636591-27-0
636591-28-1 636591-30-5 636591-31-6 636591-32-7 636591-33-8
636591-34-9 636591-35-0 636591-36-1 636591-37-2 636591-38-3
636591-39-4 636591-40-7 636591-41-8 636591-42-9 636591-43-0
636591-44-1 636591-45-2 636591-46-3 636591-47-4 636591-48-5
636591-49-6 636591-50-9 636591-51-0 636591-52-1 636591-53-2
636591-54-3 636591-55-4 636591-56-5 636591-57-6 636591-58-7
636591-59-8 636591-60-1 636591-61-2 636591-62-3 636591-63-4
636591-64-5 636591-65-6 636591-66-7 636591-67-8 636591-68-9
636591-69-0 636591-70-3 636591-71-4 636591-72-5 636591-73-6
636591-74-7 636591-75-8 636591-76-9 636591-77-0 636591-78-1
636591-79-2 636591-80-5 636591-81-6 636591-82-7 636591-83-8
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hybrid polypeptides comprising Ii-key motif and MHC class I or II-presented epitope of antigen, allergen or tumor antigen as vaccines against infection, allergy and cancer)

IT 636591-84-9 636591-85-0 636591-86-1 636591-87-2 636591-88-3
636591-89-4 636591-90-7 636591-91-8 636591-92-9 636591-93-0
636591-94-1 636591-95-2 636591-96-3 636591-97-4 636591-98-5
636591-99-6 636592-00-2 636592-01-3 636592-02-4 636592-03-5
636592-04-6 636592-05-7 636592-06-8 636592-07-9 636592-08-0
636592-09-1 636592-10-4 636592-11-5 636592-12-6 636592-13-7
636592-14-8 636592-15-9 636592-16-0 636592-17-1 636592-18-2
636592-19-3 636592-20-6 636592-21-7 636592-22-8 636592-23-9
636592-24-0 636592-25-1 636592-26-2 636592-27-3 636592-29-5
636592-30-8 636592-31-9 636592-32-0 636592-33-1 636592-34-2
636592-35-3 636592-36-4 636592-37-5 636592-38-6 636592-39-7
636592-40-0 636592-41-1 636592-42-2 636592-43-3 636592-44-4
636592-45-5 636592-46-6 636592-47-7 636592-48-8 636592-49-9
636592-50-2 636592-51-3 636592-52-4 636592-53-5 636592-54-6
636592-55-7 636592-56-8 636592-57-9 636592-58-0 636592-59-1
636592-60-4 636592-62-6 636592-63-7 636592-64-8 636592-65-9
636592-66-0 636592-67-1 636592-68-2 636592-69-3 636592-71-7
636592-73-9 636592-75-1 636592-76-2 636592-78-4 636592-79-5
636592-80-8 636592-81-9 636592-84-2 636592-87-5 636592-90-0
636592-93-3 636592-96-6 636592-99-9 636593-02-7 636593-05-0
636593-08-3 636593-12-9 636593-15-2 636593-18-5 636593-20-9
636593-22-1 636593-24-3 636593-26-5 636593-28-7 636593-30-1
636593-32-3 636593-36-7 636593-38-9 636593-40-3 636593-44-7
636593-45-8 636593-46-9 636593-48-1 636593-49-2 636593-50-5
636593-51-6 636593-52-7 636593-53-8 636593-54-9 636593-55-0
636593-57-2 636593-58-3 636593-59-4 636593-61-8 636593-62-9
636593-63-0 636593-65-2 636593-66-3 636593-67-4 636593-68-5
636593-69-6 636593-70-9 636593-71-0 636593-72-1 636593-73-2
636593-74-3 636593-75-4 636593-76-5 636593-77-6 636593-78-7
636593-79-8 636593-80-1 636593-81-2 636593-82-3 636593-83-4
636593-84-5 636593-85-6 636593-86-7 **636593-87-8**
636593-88-9 636593-89-0 636593-90-3
636593-91-4 636593-92-5 672908-48-4D, chimeric derivs. 672908-74-6D, chimeric derivs. 672909-01-2D, chimeric derivs. 673447-76-2
673447-77-3 673447-78-4 673447-79-5 673447-80-8 673447-81-9
673447-82-0 673447-83-1 673447-84-2 673447-93-3 673447-94-4
673447-95-5 673447-96-6 673447-97-7 673447-98-8 673447-99-9
673448-00-5 673448-01-6 673448-02-7 673448-03-8 673448-04-9
673448-05-0 673448-06-1 673448-07-2 673448-08-3 673448-09-4
673448-10-7 673448-11-8 673448-12-9 673448-13-0 673448-14-1
673448-15-2 673448-16-3 673448-17-4 673448-18-5 673448-19-6
673448-20-9 673448-21-0 673448-22-1 673448-23-2 673448-24-3
673448-25-4 673448-26-5 673448-27-6 673448-28-7 676118-97-1
676118-98-2 676118-99-3 676119-00-9 676119-01-0 676119-02-1

676119-03-2 676119-04-3 676119-55-4D, chimeric derivs. 676119-56-5D, chimeric derivs. 676119-57-6D, chimeric derivs. 676119-58-7D, chimeric derivs. 676119-59-8D, chimeric derivs. 676119-60-1D, chimeric derivs. 676119-61-2D, chimeric derivs. 676119-62-3D, chimeric derivs. 676119-63-4D, chimeric derivs. 676119-64-5D, chimeric derivs. 676119-65-6D, chimeric derivs. 676119-66-7D, chimeric derivs. 676119-67-8D, chimeric derivs. 676119-68-9D, chimeric derivs. 676119-69-0D, chimeric derivs. 676119-70-3D, chimeric derivs. 676119-71-4D, chimeric derivs. 676119-72-5D, chimeric derivs. 676119-73-6D, chimeric derivs. 676119-74-7D, chimeric derivs.
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hybrid polypeptides comprising Ii-key motif and MHC class I or II-presented epitope of antigen, allergen or tumor antigen as vaccines against infection, allergy and cancer)

IT 676119-75-8D, chimeric derivs. 676119-76-9D, chimeric derivs. 676119-77-0D, chimeric derivs. 676119-78-1D, chimeric derivs. 676119-79-2D, chimeric derivs. 676119-80-5D, chimeric derivs. 676119-81-6D, chimeric derivs. 676119-82-7D, chimeric derivs. 676119-83-8D, chimeric derivs. 676119-84-9D, chimeric derivs. 676119-85-0D, chimeric derivs. 676119-86-1D, chimeric derivs. 676140-82-2D, chimeric derivs. 676140-83-3D, chimeric derivs. 676140-84-4D, chimeric derivs. 676140-85-5D, chimeric derivs. 676140-86-6D, chimeric derivs. 676140-87-7D, chimeric derivs. 676140-88-8D, chimeric derivs. 676140-89-9D, chimeric derivs. 676140-90-2D, chimeric derivs. 676140-91-3D, chimeric derivs. 676140-92-4D, chimeric derivs. 676140-93-5D, chimeric derivs. 676140-94-6D, chimeric derivs. 676140-95-7D, chimeric derivs. 676140-96-8D, chimeric derivs. 676140-97-9D, chimeric derivs. 676140-98-0D, chimeric derivs. 676140-99-1D, chimeric derivs. 676141-00-7D, chimeric derivs. 676141-01-8D, chimeric derivs. 676141-02-9D, chimeric derivs. 676141-03-0D, chimeric derivs. 676141-04-1D, chimeric derivs. 676141-05-2D, chimeric derivs. 676141-06-3D, chimeric derivs. 676141-07-4D, chimeric derivs. 676141-08-5D, chimeric derivs. 676141-09-6D, chimeric derivs. 676141-10-9D, chimeric derivs. 676141-11-0D, chimeric derivs. 676141-12-1D, chimeric derivs. 676141-13-2D, chimeric derivs. 676141-14-3D, chimeric derivs. 676141-15-4D, chimeric derivs. 676141-16-5D, chimeric derivs. 676141-17-6D, chimeric derivs. 676141-18-7D, chimeric derivs. 676141-19-8D, chimeric derivs. 676141-20-1D, chimeric derivs. 676141-21-2D, chimeric derivs. 676141-22-3D, chimeric derivs. 676141-23-4D, chimeric derivs. 676141-24-5D, chimeric derivs. 676141-25-6D, chimeric derivs. 676141-26-7D, chimeric derivs. 676141-27-8D, chimeric derivs. 676141-28-9D, chimeric derivs. 676141-29-0D, chimeric derivs. 676141-30-3D, chimeric derivs. 676141-31-4D, chimeric derivs. 676141-32-5D, chimeric derivs. 676141-33-6D, chimeric derivs. 676141-34-7D, chimeric derivs. 676141-35-8D, chimeric derivs. 676141-36-9D, chimeric derivs. 676141-37-0D, chimeric derivs. 676141-38-1D, chimeric derivs. 676141-39-2D, chimeric derivs. 676141-40-5D, chimeric derivs. 676141-41-6D, chimeric derivs. 676141-42-7D, chimeric derivs. 676141-43-8D, chimeric derivs. 676141-44-9D, chimeric derivs. 676141-45-0D, chimeric derivs. 676141-46-1D, chimeric derivs. 676141-47-2D, chimeric derivs. 676141-48-3D, chimeric derivs. 676141-49-4D, chimeric derivs. 676141-50-7D, chimeric derivs. 676141-51-8D, chimeric derivs. 676141-52-9D, chimeric derivs. 676141-53-0D, chimeric derivs. 676141-54-1D, chimeric derivs. 676141-55-2D, chimeric derivs. 676141-56-3D, chimeric derivs. 676141-57-4D, chimeric derivs. 676141-58-5D, chimeric derivs. 676141-59-6D, chimeric derivs. 676141-60-9D, chimeric derivs. 676141-61-0D, chimeric derivs. 676141-62-1D, chimeric derivs. 676141-63-2D, chimeric derivs. 676141-64-3D, chimeric derivs. 676141-65-4D, chimeric derivs. 676141-66-5D, chimeric derivs. 676141-67-6D, chimeric derivs. 676141-68-7D, chimeric derivs. 676141-69-8D, chimeric derivs. 676141-70-1D, chimeric derivs. 676141-71-2D, chimeric derivs.

676141-72-3D, chimeric derivs. 676141-73-4D, chimeric derivs.
676141-74-5D, chimeric derivs. 676141-75-6D, chimeric derivs.
676141-76-7D, chimeric derivs. 676141-77-8D, chimeric derivs.
676141-78-9D, chimeric derivs. 676141-79-0D, chimeric derivs.
676141-80-3D, chimeric derivs. 676141-81-4D, chimeric derivs.
676141-82-5D, chimeric derivs. 676141-83-6D, chimeric derivs.
676141-84-7D, chimeric derivs. 676141-85-8D, chimeric derivs.
676141-86-9D, chimeric derivs. 676141-87-0D, chimeric derivs.
676141-88-1D, chimeric derivs. 676141-89-2D, chimeric derivs.
676141-90-5D, chimeric derivs. 676141-91-6D, chimeric derivs.
676141-92-7D, chimeric derivs. 676141-93-8D, chimeric derivs.
676141-94-9D, chimeric derivs. 676141-95-0D, chimeric derivs.
676141-96-1D, chimeric derivs. 676141-97-2D, chimeric derivs.
676141-98-3D, chimeric derivs. 676141-99-4D, chimeric derivs.
676142-00-0D, chimeric derivs. 676142-01-1D, chimeric derivs.
676142-02-2D, chimeric derivs. 676142-03-3D, chimeric derivs.
676142-04-4D, chimeric derivs. 676142-05-5D, chimeric derivs.
676142-06-6D, chimeric derivs. 676142-07-7D, chimeric derivs.
676142-08-8D, chimeric derivs. 676142-09-9D, chimeric derivs.
676142-10-2D, chimeric derivs. 676142-11-3D, chimeric derivs.
676142-13-5D, chimeric derivs. 676142-14-6D, chimeric derivs.
676142-15-7D, chimeric derivs. 676142-16-8D, chimeric derivs.
676142-17-9D, chimeric derivs. 676142-18-0D, chimeric derivs.
676142-19-1D, chimeric derivs. 676142-20-4D, chimeric derivs.
676142-21-5D, chimeric derivs. 676142-22-6D, chimeric derivs.
676142-23-7D, chimeric derivs. 676142-24-8D, chimeric derivs.
676142-25-9D, chimeric derivs. 676142-26-0D, chimeric derivs.
676142-27-1D, chimeric derivs. 676142-28-2D, chimeric derivs.
676142-29-3D, chimeric derivs. 676142-30-6D, chimeric derivs.
676142-31-7D, chimeric derivs. 676142-32-8D, chimeric derivs.
676142-33-9D, chimeric derivs. 676142-34-0D, chimeric derivs.
676142-35-1D, chimeric derivs. 676142-36-2D, chimeric derivs.
676142-37-3D, chimeric derivs. 676142-38-4D, chimeric derivs.
676142-39-5D, chimeric derivs. 676142-40-8D, chimeric derivs.
676142-41-9D, chimeric derivs. 676142-42-0D, chimeric derivs.
676142-43-1D, chimeric derivs. 676142-44-2D, chimeric derivs.
676142-45-3D, chimeric derivs. 676142-46-4D, chimeric derivs.
676142-47-5D, chimeric derivs. 676142-48-6D, chimeric derivs.
676142-49-7D, chimeric derivs. 676142-50-0D, chimeric derivs.
676142-51-1D, chimeric derivs. 676142-52-2D, chimeric derivs.
676142-53-3D, chimeric derivs. 676142-54-4D, chimeric derivs.
676142-55-5D, chimeric derivs. 676142-56-6D, chimeric derivs.
676142-57-7D, chimeric derivs. 676142-58-8D, chimeric derivs.
676142-59-9D, chimeric derivs. 676142-60-2D, chimeric derivs.
676142-61-3D, chimeric derivs. 676142-62-4D, chimeric derivs.
676142-63-5D, chimeric derivs. 676142-64-6D, chimeric derivs.
676142-65-7D, chimeric derivs. 676142-66-8D, chimeric derivs.
676142-67-9D, chimeric derivs. 676142-68-0D, chimeric derivs.
676142-69-1D, chimeric derivs. 676142-70-4D, chimeric derivs.
676142-71-5D, chimeric derivs. 676142-72-6D, chimeric derivs.
676142-73-7D, chimeric derivs. 676142-74-8D, chimeric derivs.
676142-75-9D, chimeric derivs. 676142-76-0D, chimeric derivs.
676142-77-1D, chimeric derivs. 676142-78-2D, chimeric derivs.
676142-79-3D, chimeric derivs. 676142-80-6D, chimeric derivs.
676142-81-7D, chimeric derivs. 676142-82-8D, chimeric derivs.
676142-83-9D, chimeric derivs. 676142-84-0D, chimeric derivs.
676142-85-1D, chimeric derivs. 676142-86-2D, chimeric derivs.
676142-87-3D, chimeric derivs. 676142-88-4D, chimeric derivs.
676142-89-5D, chimeric derivs. 676142-90-8D, chimeric derivs.
676142-91-9D, chimeric derivs. 676142-92-0D, chimeric derivs.
676142-93-1D, chimeric derivs. 676142-94-2D, chimeric derivs.
676142-95-3D, chimeric derivs. 676142-96-4D, chimeric derivs.
676142-97-5D, chimeric derivs. 676142-98-6D, chimeric derivs.
676142-99-7D, chimeric derivs. 676143-00-3D, chimeric derivs.
676143-01-4D, chimeric derivs. 676143-02-5D, chimeric derivs.
676143-03-6D, chimeric derivs. 676143-04-7D, chimeric derivs.

Search done by Noble Jarrell

676143-05-8D, chimeric derivs.
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hybrid polypeptides comprising Ii-key motif and MHC class I or II-presented epitope of antigen, allergen or tumor antigen as vaccines against infection, allergy and cancer)

IT 676143-06-9D, chimeric derivs. 676143-07-0D, chimeric derivs.
676143-09-2D, chimeric derivs. 676143-10-5D, chimeric derivs.
676143-11-6D, chimeric derivs. 676143-12-7D, chimeric derivs.
676143-13-8D, chimeric derivs. 676143-14-9D, chimeric derivs.
676143-15-0D, chimeric derivs. 676143-16-1D, chimeric derivs.
676143-17-2D, chimeric derivs. 676143-18-3D, chimeric derivs.
676143-19-4D, chimeric derivs. 676143-20-7D, chimeric derivs.
676143-21-8D, chimeric derivs. 676143-22-9D, chimeric derivs.
676143-23-0D, chimeric derivs. 676143-24-1D, chimeric derivs.
676143-25-2D, chimeric derivs. 676143-26-3D, chimeric derivs.
676143-27-4D, chimeric derivs. 676143-28-5D, chimeric derivs.
676143-29-6D, chimeric derivs. 676143-30-9D, chimeric derivs.
676143-31-0D, chimeric derivs. 676143-32-1D, chimeric derivs.
676143-33-2D, chimeric derivs. 676143-34-3D, chimeric derivs.
676143-35-4D, chimeric derivs. 676143-37-6D, chimeric derivs.
676143-38-7D, chimeric derivs. 676143-39-8D, chimeric derivs.
676143-40-1D, chimeric derivs. 676143-41-2D, chimeric derivs.
676143-42-3D, chimeric derivs. 676143-43-4D, chimeric derivs.
676143-44-5D, chimeric derivs. 676143-45-6D, chimeric derivs.
676143-46-7D, chimeric derivs. 676143-47-8D, chimeric derivs.
676143-48-9D, chimeric derivs. 676143-49-0D, chimeric derivs.
676143-50-3D, chimeric derivs. 676143-51-4D, chimeric derivs.
676143-52-5D, chimeric derivs. 676143-53-6D, chimeric derivs.
676143-54-7D, chimeric derivs. 676143-55-8D, chimeric derivs.
676143-56-9D, chimeric derivs. 676143-57-0D, chimeric derivs.
676143-58-1D, chimeric derivs. 676143-59-2D, chimeric derivs.
676143-60-5D, chimeric derivs. 676143-61-6D, chimeric derivs.
676143-62-7D, chimeric derivs. 676143-63-8D, chimeric derivs.
676143-64-9D, chimeric derivs. 676143-65-0D, chimeric derivs.
676143-66-1D, chimeric derivs. 676143-67-2D, chimeric derivs.
676143-68-3D, chimeric derivs. 676143-69-4D, chimeric derivs.
676143-70-7D, chimeric derivs. 676143-71-8D, chimeric derivs.
676143-72-9D, chimeric derivs. 676143-73-0D, chimeric derivs.
676143-74-1D, chimeric derivs. 676143-75-2D, chimeric derivs.
676143-76-3D, chimeric derivs. 676143-77-4D, chimeric derivs.
676143-78-5D, chimeric derivs. 676143-79-6D, chimeric derivs.
676143-80-9D, chimeric derivs. 676143-81-0D, chimeric derivs.
676143-82-1D, chimeric derivs. 676143-83-2D, chimeric derivs.
676143-84-3D, chimeric derivs. 676143-85-4D, chimeric derivs.
676143-86-5D, chimeric derivs. 676143-87-6D, chimeric derivs.
676143-88-7D, chimeric derivs. 676143-89-8D, chimeric derivs.
676143-90-1D, chimeric derivs. 676143-91-2D, chimeric derivs.
676143-92-3D, chimeric derivs. 676143-93-4D, chimeric derivs.
676143-94-5D, chimeric derivs. 676143-95-6D, chimeric derivs.
676170-86-8D, chimeric derivs. 676170-87-9D, chimeric derivs.
676170-88-0D, chimeric derivs. 676170-89-1D, chimeric derivs.
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hybrid polypeptides comprising Ii-key motif and MHC class I or II-presented epitope of antigen, allergen or tumor antigen as vaccines against infection, allergy and cancer)

IT 660-88-8, δ-Aminovaleric acid
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(spacer; hybrid polypeptides comprising Ii-key motif and MHC class I or II-presented epitope of antigen, allergen or tumor antigen as vaccines against infection, allergy and cancer)

IT 92915-79-2 161177-45-3 162025-12-9 201289-87-4 201289-88-5
331663-58-2 639461-73-7 639461-74-8 639461-75-9 676143-96-7
676143-97-8 676143-98-9 676143-99-0 676186-29-1
RL: PRP (Properties)

(unclaimed sequence; hybrid polypeptides comprising Ii-key motif and MHC class I or II-presented epitope of antigen, allergen or tumor antigen as vaccines against infection, allergy and cancer)

IT 636593-87-8 636593-88-9 636593-89-0
636593-90-3
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hybrid polypeptides comprising Ii-key motif and MHC class I or II-presented epitope of antigen, allergen or tumor antigen as vaccines against infection, allergy and cancer)

L52 ANSWER 2 OF 33 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:1007595 HCAPLUS
DN 140:75934
ED Entered STN: 28 Dec 2003
TI Ii-key/antigenic epitope hybrid peptide vaccines for epitope-specific therapy
IN Humphreys, Robert; Xu, Minzhen
PA Antigen Express, Inc., USA
SO U.S. Pat. Appl. Publ., 87 pp., Cont.-in-part of U.S. Pat. Appl. 2003 91,582.
CODEN: USXXCO
DT Patent
LA English
IC ICM A61K039-00
ICS C07H021-04; C12P021-02; C12N005-06; C07K014-74
INCL 424192100; 435069300; 435320100; 435325000; 530350000; 536023500
CC 15-2 (Immunochemistry)
Section cross-reference(s): 3, 63
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 2003235594	A1	20031225	US 2002-245871	20020917	<--
	US 6432409	B1	20020813	US 1999-396813	19990914	<--
	US 2003091582	A1	20030515	US 2002-197000	20020717	<--
	WO 2004030616	A2	20040415	WO 2003-US28574	20030912	<--
	WO 2004030616	A3	20041007			

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI	US 1999-396813	A3	19990914	<--
	US 2002-197000	A2	20020717	<--
	US 2002-245871	A	20020917	<--
	US 2002-253286	A	20020924	<--

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES	
US 2003235594	ICM	A61K039-00	
	ICS	C07H021-04; C12P021-02; C12N005-06; C07K014-74	
	INCL	424192100; 435069300; 435320100; 435325000; 530350000; 536023500	
US 2003235594	NCL	424/192.100; 435/069.300; 435/320.100; 435/325.000; 530/350.000; 536/023.500	
	ECLA	C07K014/705B28; C07K019/00; G01N033/50D2F2	<--
US 6432409	NCL	424/192.100; 424/184.100; 424/185.100; 530/328.000	
	ECLA	C07K014/705B28; C07K019/00; G01N033/50D2F2	<--
US 2003091582	NCL	424/185.100; 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500	
	ECLA	C07K014/705B28; C07K019/00; G01N033/50D2F2	<--

WO 2004030616 ECLA C07K014/705B28 <--

AB Disclosed is an antigen presentation enhancing hybrid polypeptide which includes three elements. The first element is an N-terminal element consisting essentially of 4-16 residues of the mammalian Ii-Key peptide LRMKLPKPPKPVSKMR and non-N-terminal deletion modifications thereof that retain antigen presentation enhancing activity. The second element is a chemical structure covalently linking the N-terminal element described above to the MHC Class II-presented epitope described below. The chemical structure is a covalently joined group of atoms which when arranged in a linear fashion forms a flexible chain which extends up to the length of 20 amino acids likewise arranged in a linear fashion, the chemical structure being selected from the group consisting of: (i) immunol. neutral chemical structures, (ii) a MHC Class I epitope or a portion thereof, and/or (iii) an antibody-recognized determinant or a portion thereof. Finally, the enhancing antigen presentation enhancing hybrid polypeptide includes a C-terminal element comprising an antigenic epitope in the form of a polypeptide or peptidomimetic structure which binds to the antigenic peptide binding site of an MHC class II mol. The hybrid polypeptides are useful as vaccines for epitope-specific therapy of e.g. cancer, infection, autoimmune disease, allergy and transplant. The hybrid peptides may also useful for enhancing MHC class II-presented antigenic peptide to donor T lymphocytes for reinfusion therapy.

ST Ii peptide antigen epitope chimeric protein vaccine T lymphocyte

IT Vaccines
(AIDS; Ii-key/antigenic epitope hybrid peptide vaccines for epitope-specific therapy)

IT Allergens
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Ara h 1; Ii-key/antigenic epitope hybrid peptide vaccines for epitope-specific therapy)

IT Allergens
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Ara h 2; Ii-key/antigenic epitope hybrid peptide vaccines for epitope-specific therapy)

IT Allergens
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Ara h 3; Ii-key/antigenic epitope hybrid peptide vaccines for epitope-specific therapy)

IT Allergens
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Ara h 4; Ii-key/antigenic epitope hybrid peptide vaccines for epitope-specific therapy)

IT Proteins
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(B5R; Ii-key/antigenic epitope hybrid peptide vaccines for epitope-specific therapy)

IT Allergens
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Bla q 5; Ii-key/antigenic epitope hybrid peptide vaccines for epitope-specific therapy)

IT Allergens
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Fel d f; Ii-key/antigenic epitope hybrid peptide vaccines for epitope-specific therapy)

IT Allergy
Antitumor agents
Arachis hypogaea
Autoimmune disease
Blattaria

Ebola virus
Epitopes
Food allergy
Human
Human immunodeficiency virus
Infection
Mammalia
Melanoma
Mutagenesis
Ovary, neoplasm
Pathogen
Peptidomimetics
Pollen
Prostate gland, neoplasm
Protein motifs
Protein sequences
T cell (lymphocyte)
Transplant and Transplantation
Vaccines
Variola virus
(Ii-key/antigenic epitope hybrid peptide vaccines for epitope-specific therapy)

IT CA 125 (carbohydrate antigen)
Carcinoembryonic antigen
Myelin basic protein
Prostate-specific antigen
Proteolipid protein
neu (receptor)
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Ii-key/antigenic epitope hybrid peptide vaccines for epitope-specific therapy)

IT Antigens
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(MAA (melanoma-associated antigen), Pmel 17; Ii-key/antigenic epitope hybrid peptide vaccines for epitope-specific therapy)

IT Antigens
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(MART-1; Ii-key/antigenic epitope hybrid peptide vaccines for epitope-specific therapy)

IT Histocompatibility antigens
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(MHC (major histocompatibility complex), class I; Ii-key/antigenic epitope hybrid peptide vaccines for epitope-specific therapy)

IT Histocompatibility antigens
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(MHC (major histocompatibility complex), class II; Ii-key/antigenic epitope hybrid peptide vaccines for epitope-specific therapy)

IT Glycoproteins
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(MOG (myelin oligodendrocyte glycoprotein); Ii-key/antigenic epitope hybrid peptide vaccines for epitope-specific therapy)

IT Allergens
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Phl p 1 (Phleum pratense, 1); Ii-key/antigenic epitope hybrid peptide vaccines for epitope-specific therapy)

IT Allergens
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Phl p 5a and 5b; Ii-key/antigenic epitope hybrid peptide vaccines for

epitope-specific therapy)
IT Proteins
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(SILV; Ii-key/antigenic epitope hybrid peptide vaccines for epitope-specific therapy)
IT Proteins
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(TRP-2 (tyrosinase-related protein 2); Ii-key/antigenic epitope hybrid peptide vaccines for epitope-specific therapy)
IT Betula
(allergy; Ii-key/antigenic epitope hybrid peptide vaccines for epitope-specific therapy)
IT Toxins
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anthrax lethal factor; Ii-key/antigenic epitope hybrid peptide vaccines for epitope-specific therapy)
IT Toxins
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anthrax protective antigen; Ii-key/antigenic epitope hybrid peptide vaccines for epitope-specific therapy)
IT Toxins
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anthrax; Ii-key/antigenic epitope hybrid peptide vaccines for epitope-specific therapy)
IT Venoms
(bee; Ii-key/antigenic epitope hybrid peptide vaccines for epitope-specific therapy)
IT Immunity
(cell-mediated; Ii-key/antigenic epitope hybrid peptide vaccines for epitope-specific therapy)
IT Antigens
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(chimeric; Ii-key/antigenic epitope hybrid peptide vaccines for epitope-specific therapy)
IT T cell (lymphocyte)
(cytotoxic; Ii-key/antigenic epitope hybrid peptide vaccines for epitope-specific therapy)
IT Skin
(dander, allergen; Ii-key/antigenic epitope hybrid peptide vaccines for epitope-specific therapy)
IT Nut (seed)
(edible; Ii-key/antigenic epitope hybrid peptide vaccines for epitope-specific therapy)
IT Antigen presentation
(enhancer; Ii-key/antigenic epitope hybrid peptide vaccines for epitope-specific therapy)
IT Immunotherapy
(epitope-specific; Ii-key/antigenic epitope hybrid peptide vaccines for epitope-specific therapy)
IT Peptides, biological studies
RL: BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(fusion peptides; Ii-key/antigenic epitope hybrid peptide vaccines for epitope-specific therapy)
IT Envelope proteins
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(gp160env; Ii-key/antigenic epitope hybrid peptide vaccines for epitope-specific therapy)

IT T cell (lymphocyte)
(helper cell/inducer, TH1; Ii-key/antigenic epitope hybrid peptide vaccines for epitope-specific therapy)
IT T cell (lymphocyte)
(helper cell/inducer, TH2; Ii-key/antigenic epitope hybrid peptide vaccines for epitope-specific therapy)
IT T cell (lymphocyte)
(helper cell; Ii-key/antigenic epitope hybrid peptide vaccines for epitope-specific therapy)
IT Drug delivery systems
(infusions; Ii-key/antigenic epitope hybrid peptide vaccines for epitope-specific therapy)
IT Invariant chain (class II antigen)
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(key peptide; Ii-key/antigenic epitope hybrid peptide vaccines for epitope-specific therapy)
IT Proteins
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(membrane, VP24; Ii-key/antigenic epitope hybrid peptide vaccines for epitope-specific therapy)
IT Antibodies and Immunoglobulins
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(recognized epitope; Ii-key/antigenic epitope hybrid peptide vaccines for epitope-specific therapy)
IT Cytokines
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(release pattern; Ii-key/antigenic epitope hybrid peptide vaccines for epitope-specific therapy)
IT Mutagenesis
(site-directed, deletion; Ii-key/antigenic epitope hybrid peptide vaccines for epitope-specific therapy)
IT Mutagenesis
(site-directed, substitution; Ii-key/antigenic epitope hybrid peptide vaccines for epitope-specific therapy)
IT Vaccines
(tumor; Ii-key/antigenic epitope hybrid peptide vaccines for epitope-specific therapy)
IT Anti-AIDS agents
Antitumor agents
(vaccines; Ii-key/antigenic epitope hybrid peptide vaccines for epitope-specific therapy)
IT Infection
(variola, vaccine; Ii-key/antigenic epitope hybrid peptide vaccines for epitope-specific therapy)
IT Apoidea
(venom; Ii-key/antigenic epitope hybrid peptide vaccines for epitope-specific therapy)
IT Infection
(viral; Ii-key/antigenic epitope hybrid peptide vaccines for epitope-specific therapy)
IT 318236-09-8 331663-61-7 636590-94-8 636590-95-9 636590-96-0
636590-97-1 636590-98-2 636590-99-3 636591-00-9 636591-01-0
636591-02-1 636591-03-2 636591-04-3 636591-05-4 636591-06-5
636591-07-6 636591-08-7 636591-09-8 636591-10-1 636591-11-2
636591-12-3 636591-13-4 636591-14-5 636591-15-6 636591-16-7
636591-17-8 636591-18-9 636591-19-0 636591-20-3 636591-21-4
636591-22-5 636591-23-6 636591-24-7 636591-25-8 636591-26-9
636591-27-0 636591-28-1 636591-29-2 636591-30-5 636591-31-6
636591-32-7 636591-33-8 636591-34-9 636591-35-0 636591-36-1
636591-37-2 636591-38-3 636591-39-4 636591-40-7 636591-41-8
636591-42-9 636591-43-0 636591-44-1 636591-45-2 636591-46-3
636591-47-4 636591-48-5 636591-49-6 636591-50-9 636591-51-0
636591-52-1 636591-53-2 636591-54-3 636591-55-4 636591-56-5

636591-57-6 636591-58-7 636591-59-8 636591-60-1 636591-61-2
636591-62-3 636591-63-4 636591-64-5 636591-65-6 636591-66-7
636591-67-8 636591-68-9 636591-69-0 636591-70-3 636591-71-4
636591-72-5 636591-73-6 636591-74-7 636591-75-8 636591-76-9
636591-77-0 636591-78-1 636591-79-2 636591-80-5 636591-81-6
636591-82-7 636591-83-8 636591-84-9 636591-85-0 636591-86-1
636591-87-2 636591-88-3 636591-89-4 636591-90-7 636591-91-8
636591-92-9 636591-93-0 636591-94-1 636591-95-2 636591-96-3
636591-97-4 636591-98-5 636591-99-6 636592-00-2 636592-01-3
636592-02-4 636592-03-5 636592-04-6 636592-05-7 636592-06-8
636592-07-9 636592-08-0 636592-09-1 636592-10-4 636592-11-5
636592-12-6 636592-13-7 636592-14-8 636592-15-9 636592-16-0
636592-17-1 636592-18-2 636592-19-3 636592-20-6 636592-21-7
636592-22-8 636592-23-9 636592-24-0 636592-25-1 636592-26-2
636592-27-3 636592-28-4 636592-29-5 636592-30-8 636592-31-9
636592-32-0 636592-33-1 636592-34-2 636592-35-3 636592-36-4
636592-37-5 636592-38-6 636592-39-7 636592-40-0 636592-41-1
636592-42-2 636592-43-3 636592-44-4 636592-45-5 636592-46-6
636592-47-7 636592-48-8 636592-49-9 636592-50-2 636592-51-3
636592-52-4 636592-53-5 636592-54-6 636592-55-7 636592-56-8
636592-57-9 636592-58-0 636592-59-1 636592-60-4 636592-62-6
636592-63-7 636592-64-8 636592-65-9 636592-66-0 636592-67-1
636592-68-2 636592-69-3 636592-70-6 636592-71-7 636592-73-9
636592-75-1 636592-76-2 636592-77-3 636592-78-4 636592-79-5
636592-80-8 636592-81-9 636592-84-2 636592-87-5 636592-90-0
636592-93-3 636592-96-6 636592-99-9 636593-02-7 636593-05-0
636593-08-3 636593-12-9 636593-15-2 636593-18-5 636593-20-9
636593-22-1 636593-24-3 636593-26-5 636593-28-7 636593-30-1
636593-32-3 636593-34-5 636593-36-7 636593-38-9 636593-40-3
636593-42-5 636593-44-7 636593-45-8 636593-46-9 636593-47-0
636593-48-1 636593-49-2 636593-50-5 636593-51-6 636593-52-7
636593-53-8 636593-54-9 636593-55-0 636593-57-2 636593-58-3
636593-59-4 636593-60-7 636593-61-8 636593-62-9 636593-63-0
636593-64-1 636593-65-2 636593-66-3 636593-67-4 636593-68-5
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Ii-key/antigenic epitope hybrid peptide vaccines for epitope-specific therapy)

IT 636593-69-6 636593-70-9 636593-71-0 636593-72-1 636593-73-2
636593-74-3 636593-75-4 636593-76-5 636593-77-6 636593-78-7
636593-79-8 636593-80-1 636593-81-2 636593-82-3 636593-83-4
636593-84-5 636593-85-6 636593-86-7 **636593-87-8**
636593-88-9 636593-89-0 636593-90-3
636593-91-4 636593-92-5 637767-90-9 637767-91-0 637768-04-8
637768-25-3 637768-26-4 637768-27-5 637768-30-0 637768-44-6
637768-45-7
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Ii-key/antigenic epitope hybrid peptide vaccines for epitope-specific therapy)

IT 660-88-8, 5-Aminovaleric acid 9001-84-7, Phospholipase A2 9002-10-2, Tyrosinase 9007-43-6, Cytochrome C, biological studies 50812-37-8, Glutathione-S-transferase 58438-03-2, β-2-Naphthyl-L-alanine 74163-81-8 128502-56-7 201289-87-4
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Ii-key/antigenic epitope hybrid peptide vaccines for epitope-specific therapy)

IT 51-35-4, L-Hydroxyproline 70-26-8, L-Ornithine 156-86-5, L-Homoarginine 300-39-0 372-75-8, L-Citrulline 943-73-7 949-99-5, p-Nitro-L-phenylalanine 1132-68-9, p-Fluoro-L-phenylalanine 3060-46-6, N-Methyl-L-leucine 3685-51-6 14173-39-8, p-Chloro-L-phenylalanine 38739-13-8, 3-Bromo-L-tyrosine 55516-54-6, β-1-Naphthyl-L-alanine
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(modification; Ii-key/antigenic epitope hybrid peptide vaccines for

epitope-specific therapy)
IT 162025-12-9 201289-88-5 331663-58-2 639461-73-7 639461-74-8
639461-75-9 639544-57-3 639544-58-4 639544-59-5 639544-60-8
639544-61-9 639546-01-3 639546-02-4 639546-03-5 639546-04-6
639546-05-7 639546-06-8 639546-07-9 639546-08-0 639546-09-1
639546-10-4 639546-11-5 639546-12-6 639546-13-7 639546-14-8
639546-15-9 639546-16-0 639546-17-1 639546-18-2
RL: PRP (Properties)
(unclaimed sequence; ii-key/antigenic epitope hybrid peptide vaccines for epitope-specific therapy)
IT **636593-87-8 636593-88-9 636593-89-0**
636593-90-3
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Ii-key/antigenic epitope hybrid peptide vaccines for epitope-specific therapy)

L52 ANSWER 3 OF 33 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:678488 HCAPLUS
DN 139:214718
ED Entered STN: 29 Aug 2003
TI Chiral peptide nucleic acids with a N-aminoethyl-D-proline backbone
IN Lowe, Gordon
PA Isis Innovation Ltd., UK
SO U.S. Pat. Appl. Publ., 14 pp.
CODEN: USXXCO
DT Patent
LA English
IC ICM A61K038-16
ICS A61K031-52; C07K014-00
INCL 514012000; 514013000; 514014000; 514015000; 514016000; 514017000; 514018000; 514263200; 544277000; 544266000
CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 6, 33
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2003162699	A1	20030828	US 2001-22585	20011030 <--
US 6716961	B2	20040406		
PRAI US 2001-22585		20011030 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2003162699	ICM	A61K038-16
	ICS	A61K031-52; C07K014-00
	INCL	514012000; 514013000; 514014000; 514015000; 514016000; 514017000; 514018000; 514263200; 544277000; 544266000
US 2003162699	NCL	530/300.000; 435/006.000; 530/322.000; 536/022.100; 536/023.100; 536/024.300; 544/269.000; 544/277.000; 544/319.000
	ECLA	C07K014/00B1 <--

OS MARPAT 139:214718
GI



I

AB Chiral peptide nucleic acids are provided which hybridize strongly with complementary nucleic acids and have potential as antigene and antisense agents and as tools in mol. biol. The compds. have formula I [n is 1-200; B is an (un)protected base; X is OH or OR2, where R2 is a protecting, activating, or lipophilic group, an amino acid, amino amide, or nucleoside; Y is H or a protecting, lipophilic, or aminoacyl group or a nucleoside; R, R1 are H, alkyl, aryl, or aralkyl or may form a cycloalkyl ring]. Thus, H-[(Ψ-CH2)Gly-D-Pro(T)]10-Lys-NH2 was prepared and complexed with oligonucleotides [Tm = 53° for complex with poly(rA)].

ST proline aminoethyl backbone peptide nucleic acid prepn; oligonucleotide hybridization aminoethylproline peptide nucleic acid prepn

IT Nucleic acid hybridization
(preparation of chiral peptide nucleic acids with N-aminoethyl-D-proline backbone and hybridization with oligonucleotides)

IT Oligonucleotides
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of chiral peptide nucleic acids with N-aminoethyl-D-proline backbone and hybridization with oligonucleotides)

IT Peptide nucleic acids
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of chiral peptide nucleic acids with N-aminoethyl-D-proline backbone and hybridization with oligonucleotides)

IT **586954-19-0P**
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of chiral peptide nucleic acids with N-aminoethyl-D-proline backbone and hybridization with oligonucleotides)

IT 206760-16-9
RL: PRP (Properties)
(preparation of chiral peptide nucleic acids with N-aminoethyl-D-proline backbone and hybridization with oligonucleotides)

IT 586954-21-4P 586954-37-2P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation of chiral peptide nucleic acids with N-aminoethyl-D-proline backbone and hybridization with oligonucleotides)

IT 98-74-8, 4 Nitrobenzenesulfonyl chloride 141-43-5, Ethanolamine, reactions 189163-50-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of chiral peptide nucleic acids with N-aminoethyl-D-proline backbone and hybridization with oligonucleotides)

IT 18226-05-6P 43090-97-7P 318515-52-5P 318515-53-6P 318515-54-7P 318515-55-8P 318515-56-9P 586954-18-9P **586954-22-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of chiral peptide nucleic acids with N-aminoethyl-D-proline backbone and hybridization with oligonucleotides)

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Anon; EP 0095584 1983 HCAPLUS
(2) Anon; EP 0646596 1995 HCAPLUS
(3) Anon; CA 2131760 1995 HCAPLUS
(4) L oebberding; US 5623049 A 1997 HCAPLUS
(5) Lowe; US 6403763 B1 2002 HCAPLUS
(6) Thottathil; US 4501901 A 1985 HCAPLUS

IT **586954-19-0P**
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of chiral peptide nucleic acids with N-aminoethyl-D-proline backbone and hybridization with oligonucleotides)

IT **586954-22-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of chiral peptide nucleic acids with N-aminoethyl-D-proline backbone and hybridization with oligonucleotides)

L52 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:473242 HCAPLUS
DN 139:30802
ED Entered STN: 20 Jun 2003
TI Preparation of hexa-, hepta-, and octapeptides having antiangiogenic activity
IN Haviv, Fortuna; Bradley, Michael F.
PA USA
SO U.S. Pat. Appl. Publ., 20 pp.
CODEN: USXXCO
DT Patent
LA English
IC ICM A61K038-08
ICS C07K007-06
INCL 514016000; 530328000
CC 1-6 (Pharmacology)
Section cross-reference(s): 34
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2003114386	A1	20030619	US 2002-283553	20021030 <--
PRAI US 2001-335035P	P	20011031 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2003114386	ICM	A61K038-08
	ICS	C07K007-06
	INCL	514016000; 530328000
US 2003114386	NCL	514/016.000; 530/328.000
	ECLA	C07K007/06B <--

OS MARPAT 139:30802
AB Hexa-, hepta-, and octapeptides, which are useful for treating conditions that arise from or are exacerbated by angiogenesis, are described. Also disclosed are pharmaceutical compns. comprising these compds., methods of treatment using these compds., and methods of inhibiting angiogenesis.
ST hexapeptide heptapeptide octapeptide prepn antiangiogenic activity; cancer treatment antiangiogenic peptide
IT Peptides, biological studies
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(heptapeptides; preparation of hexa-, hepta-, and octapeptides having antiangiogenic activity)
IT Peptides, biological studies
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(hexapeptides; preparation of hexa-, hepta-, and octapeptides having antiangiogenic activity)
IT Peptides, biological studies
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(octapeptides; preparation of hexa-, hepta-, and octapeptides having antiangiogenic activity)
IT Angiogenesis
Angiogenesis inhibitors
Antitumor agents
Neoplasm
(preparation of hexa-, hepta-, and octapeptides having antiangiogenic activity)
IT 544447-91-8P 544447-93-0P 544447-95-2P 544447-97-4P 544447-99-6P
544448-01-3P 544448-03-5P 544448-05-7P 544448-07-9P 544448-09-1P

544448-11-5P 544448-13-7P 544448-15-9P 544448-17-1P 544448-19-3P
544448-21-7P 544448-23-9P 544448-25-1P 544448-27-3P 544448-29-5P
544448-31-9P 544448-33-1P 544448-35-3P 544448-37-5P 544448-39-7P
544448-41-1P 544448-43-3P 544448-45-5P 544448-47-7P 544448-49-9P
544448-51-3P 544448-53-5P 544448-56-8P **544448-58-0P**
544448-60-4P 544448-62-6P 544448-64-8P 544448-66-0P 544448-68-2P
544448-70-6P 544448-72-8P 544448-73-9P 544448-75-1P 544448-77-3P
544448-79-5P 544448-81-9P 544448-83-1P 544448-85-3P 544448-87-5P
544448-89-7P 544448-91-1P 544448-93-3P 544448-95-5P 544448-97-7P
544448-99-9P 544449-01-6P 544449-03-8P 544449-05-0P 544449-07-2P
544449-13-0P 544449-15-2P 544449-17-4P 544449-20-9P 544449-21-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of hexa-, hepta-, and octapeptides having antiangiogenic activity)

IT 3222-47-7, 6-Methylnicotinic acid 220497-64-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of hexa-, hepta-, and octapeptides having antiangiogenic activity)

IT 544447-92-9P 544447-94-1P 544447-96-3P 544447-98-5P 544448-00-2P
544448-02-4P 544448-04-6P 544448-06-8P 544448-08-0P 544448-10-4P
544448-12-6P 544448-14-8P 544448-16-0P 544448-18-2P 544448-20-6P
544448-22-8P 544448-24-0P 544448-26-2P 544448-28-4P 544448-30-8P
544448-32-0P 544448-34-2P 544448-36-4P 544448-38-6P 544448-40-0P
544448-42-2P 544448-44-4P 544448-46-6P 544448-48-8P 544448-50-2P
544448-52-4P 544448-54-6P 544448-57-9P **544448-59-1P**
544448-61-5P 544448-63-7P 544448-65-9P 544448-67-1P 544448-69-3P
544448-71-7P 544448-74-0P 544448-76-2P 544448-78-4P 544448-80-8P
544448-82-0P 544448-84-2P 544448-86-4P 544448-88-6P 544448-90-0P
544448-92-2P 544448-94-4P 544448-96-6P 544448-98-8P 544449-00-5P
544449-02-7P 544449-04-9P 544449-06-1P 544449-08-3P 544449-10-7P
544449-12-9P 544449-14-1P 544449-16-3P 544449-18-5P 544454-06-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of hexa-, hepta-, and octapeptides having antiangiogenic activity)

IT **544448-58-0P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of hexa-, hepta-, and octapeptides having antiangiogenic activity)

IT **544448-59-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of hexa-, hepta-, and octapeptides having antiangiogenic activity)

L52 ANSWER 5 OF 33 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:455015 HCAPLUS
DN 139:30854
ED Entered STN: 13 Jun 2003
TI Tri-, tetra-, and penta-peptides having antiangiogenic activity
IN Haviv, Fortuna; Bradley, Michael F.
PA USA
SO U.S. Pat. Appl. Publ., 21 pp.
CODEN: USXXCO
DT Patent
LA English
IC ICM A61K038-08
ICS C07K007-06
INCL 514017000; 530329000
CC 1-12 (Pharmacology)
Section cross-reference(s): 34, 63
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI US 2003109456 A1 20030612 US 2002-283813 20021030 <--
PRAI US 2001-335018P P 20011031 <--
CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2003109456	ICM	A61K038-08
	ICS	C07K007-06
	INCL	514017000; 530329000
US 2003109456	NCL	514/017.000; 530/329.000
	ECLA	A61K038/06; A61K038/07; A61K038/08; C07K005/08A1B; C07K005/08A1F; C07K005/08B; C07K005/08H1; C07K005/10A1B; C07K005/10A1F; C07K005/10A1A; C07K005/10B; C07K005/10C; C07K005/10H; C07K007/02 <--

OS MARPAT 139:30854
AB Peptides which are useful for treating conditions that arise from or are exacerbated by angiogenesis, are described. Also disclosed are pharmaceutical compns. comprising these compds., methods of treatment using these compds., and methods of inhibiting angiogenesis. Peptides were prepared by solid phase synthesis. Representative peptides inhibited human endothelial cell migration by at least 50% when tested at 1 nM.
ST antiangiogenic peptide treatment disease cancer; angiogenesis inhibitor peptide
IT Blood vessel
(endothelium, peptide inhibition of cell migration of; peptides having antiangiogenic activity)
IT Disease, animal
(from angiogenesis, treatment of; peptides having antiangiogenic activity)
IT Cell migration
(of endothelial cells, peptide inhibition of; peptides having antiangiogenic activity)
IT Peptides, biological studies
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pentapeptides; peptides having antiangiogenic activity)
IT Solid phase synthesis
(peptide; peptides having antiangiogenic activity)
IT Angiogenesis
Angiogenesis inhibitors
Antitumor agents
Drug delivery systems
Human
Mammalia
(peptides having antiangiogenic activity)
IT Tripeptides
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peptides having antiangiogenic activity)
IT Peptides, biological studies
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tetrapeptides; peptides having antiangiogenic activity)
IT Neoplasm
(treatment of; peptides having antiangiogenic activity)
IT Endothelium
(vascular, peptide inhibition of cell migration of; peptides having antiangiogenic activity)
IT 521291-79-2P 521291-80-5P 521291-81-6P 521291-82-7P 521291-83-8P
521291-85-0P 521291-86-1P 521291-87-2P 521291-88-3P 521291-89-4P
521291-90-7P 521291-91-8P 521291-92-9P 521291-93-0P 521291-94-1P
521291-95-2P 521291-96-3P 521291-97-4P 521291-98-5P 521291-99-6P
521292-00-2P 521292-01-3P 521292-02-4P 521292-03-5P 521292-04-6P
521292-05-7P 521292-06-8P 521292-07-9P 521292-08-0P 521292-09-1P
521292-10-4P 521292-11-5P 521292-12-6P 521292-13-7P 521292-14-8P
521292-15-9P 521292-16-0P 521292-17-1P 521292-18-2P 521292-19-3P
521292-20-6P 521292-21-7P 521292-22-8P 521292-23-9P 521292-24-0P

521292-25-1P 521292-26-2P 521292-27-3P 521292-28-4P 521292-29-5P
521292-30-8P 521292-31-9P 521292-32-0P 521292-33-1P 521292-34-2P
521292-35-3P **521292-36-4P** 521292-37-5P 539853-15-1P
539853-36-6P 539853-38-8P 539853-40-2P 539853-42-4P 539853-44-6P
539853-46-8P 539853-49-1P 539853-51-5P 539853-53-7P 539853-55-9P
539853-57-1P 539853-59-3P 539853-61-7P 539853-63-9P
539853-66-2P 539853-68-4P
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(peptides having antiangiogenic activity)

IT 64-19-7, Acetic acid, reactions 3025-95-4, N-Acetyl-β-alanine 133174-15-9 149117-86-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(peptides having antiangiogenic activity)

IT **521292-36-4P 539853-66-2P**
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(peptides having antiangiogenic activity)

L52 ANSWER 6 OF 33 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:455014 HCAPLUS
DN 139:30853
ED Entered STN: 13 Jun 2003
TI Hepta-, octa- and nonapeptides having antiangiogenic activity
IN Haviv, Fortuna; Bradley, Michael F.
PA USA
SO U.S. Pat. Appl. Publ., 26 pp.
CODEN: USXXCO
DT Patent
LA English
IC ICM A61K038-10
ICS A61K038-08; C07K007-08; C07K007-06
INCL 514016000; 514017000; 530328000; 530329000
CC 1-12 (Pharmacology)
Section cross-reference(s): 34, 63
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2003109455	A1	20030612	US 2002-283550	20021030 <--
PRAI US 2001-335017P	P	20011031 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2003109455	ICM	A61K038-10
	ICS	A61K038-08; C07K007-08; C07K007-06
	INCL	514016000; 514017000; 530328000; 530329000
US 2003109455	NCL	514/016.000; 514/017.000; 530/328.000; 530/329.000
	ECLA	C07K007/06A; C07K014/515 <--

OS MARPAT 139:30853
AB Peptides which are useful for treating conditions that arise from or are exacerbated by angiogenesis, are described. Also disclosed are pharmaceutical compns. comprising these compds., methods of treatment using these compds., and methods of inhibiting angiogenesis. Peptides were prepared by solid phase synthesis. Representative peptides inhibited human endothelial cell migration by at least 50% when tested at 1 nM.
ST antiangiogenic peptide treatment disease cancer; angiogenesis inhibitor peptide
IT Blood vessel
(endothelium, peptide inhibition of cell migration of; peptides having antiangiogenic activity)
IT Disease, animal
(from angiogenesis, treatment of; peptides having antiangiogenic activity)
IT Peptides, biological studies

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(heptapeptides; peptides having antiangiogenic activity)

IT Peptides, biological studies
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nonapeptides; peptides having antiangiogenic activity)

IT Peptides, biological studies
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(octapeptides; peptides having antiangiogenic activity)

IT Cell migration
(of endothelial cells, peptide inhibition of; peptides having antiangiogenic activity)

IT Solid phase synthesis
(peptide; peptides having antiangiogenic activity)

IT Angiogenesis
Angiogenesis inhibitors
Antitumor agents
Drug delivery systems
Human
Mammalia
(peptides having antiangiogenic activity)

IT Neoplasm
(treatment of; peptides having antiangiogenic activity)

IT Endothelium
(vascular, peptide inhibition of cell migration of; peptides having antiangiogenic activity)

IT 445467-72-1P 445467-73-2P 521942-45-0P 521942-46-1P 521942-47-2P
521942-48-3P 521942-50-7P 521942-51-8P 521942-52-9P 521942-53-0P
521942-54-1P 521942-55-2P 521942-56-3P 521942-57-4P 521942-58-5P
521942-59-6P 521942-60-9P 521942-61-0P 521942-62-1P 521942-63-2P
521942-64-3P 521942-65-4P 521942-66-5P 521942-67-6P 521942-68-7P
521942-69-8P 521942-70-1P 521942-71-2P 521942-72-3P 521942-73-4P
521942-74-5P 521942-75-6P 521942-76-7P 521942-77-8P 521942-78-9P
521942-79-0P 521942-80-3P 521942-81-4P 521942-82-5P 521942-84-7P
521942-85-8P 521942-86-9P 521942-87-0P 521942-88-1P 521942-89-2P
521942-90-5P 521942-91-6P 521942-92-7P 521942-93-8P 521942-94-9P
521942-95-0P 521942-96-1P 521942-97-2P 521942-98-3P 521942-99-4P
521943-00-0P 521943-01-1P 521943-02-2P 521943-03-3P 521943-04-4P
521943-05-5P 521943-06-6P 521943-07-7P 521943-08-8P 521943-09-9P
521943-10-2P 521943-11-3P 521943-12-4P 521943-13-5P 521943-14-6P
521943-15-7P 521943-16-8P 521943-17-9P 521943-18-0P 521943-20-4P
521943-21-5P 521943-22-6P 521943-23-7P 521943-24-8P 521943-25-9P
521943-26-0P 521943-27-1P 521943-28-2P 521943-29-3P 521943-30-6P
521943-31-7P 521943-32-8P 521943-33-9P 521943-34-0P 521943-35-1P
521943-36-2P 521943-37-3P 521943-38-4P 521943-39-5P 521943-40-8P
521943-41-9P 521943-42-0P 521943-43-1P 521943-44-2P 521943-45-3P
521943-46-4P 521943-47-5P 521943-48-6P 521943-49-7P 521943-50-0P
521943-51-1P 521943-52-2P 521943-53-3P 521943-54-4P 521943-55-5P
521943-56-6P 521943-57-7P 521943-58-8P 521943-59-9P 521943-60-2P
521943-61-3P 521943-63-5P 521943-64-6P 521943-65-7P 521943-66-8P
521943-67-9P 521943-68-0P 521943-69-1P **521943-71-5P**
521943-72-6P 521943-73-7P 521943-74-8P 521943-75-9P 521943-76-0P
521943-77-1P 521943-78-2P 521943-79-3P 521943-80-6P 521943-82-8P
521943-83-9P 521943-84-0P 521943-86-2P 521943-87-3P 521943-88-4P
521943-90-8P 521943-92-0P 521943-95-3P 521943-99-7P 521944-00-3P
521944-01-4P 521944-02-5P 521944-03-6P 521944-04-7P 540737-52-8P
540737-59-5P 540737-60-8P 540737-61-9P 540737-62-0P 540737-63-1P
540737-64-2P 540737-65-3P 540737-66-4P 540737-68-6P 540737-70-0P
540737-72-2P 540737-73-3P 540737-75-5P 540737-76-6P 540737-77-7P
540737-78-8P 540737-79-9P 540737-80-2P 540737-82-4P 540737-84-6P
540737-85-7P 540737-86-8P 540737-87-9P 540737-88-0P 540737-89-1P
540737-90-4P 540737-91-5P 540737-92-6P 540737-93-7P 540737-94-8P
540737-95-9P 540737-96-0P 540737-97-1P **540737-98-2P**
540737-99-3P 540738-00-9P 540738-01-0P 540738-02-1P 540738-03-2P

540738-04-3P 540738-05-4P 540738-06-5P 540738-08-7P
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(peptides having antiangiogenic activity)
IT 521942-49-4 521943-62-4 521943-81-7
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peptides having antiangiogenic activity)
IT 64-19-7, Acetic acid, reactions 3222-47-7, 6-Methylnicotinic acid 118904-37-3 133174-15-9 173963-93-4 199006-54-7 200616-40-6 252049-05-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(peptides having antiangiogenic activity)
IT **521943-71-5P 540737-98-2P**
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(peptides having antiangiogenic activity)

L52 ANSWER 7 OF 33 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:435296 HCAPLUS
DN 138:385741
ED Entered STN: 06 Jun 2003
TI Preparation of tetra-, penta-, hexa- and heptapeptides having antiangiogenic activity
IN Haviv, Fortuna; Bradley, Michael F.
PA USA
SO U.S. Pat. Appl. Publ., 55 pp.
CODEN: USXXCO
DT Patent
LA English
IC ICM A61K038-10
ICS A61K038-08; C07K007-06; C07K007-08
INCL 514016000; 514017000; 530328000; 530329000
CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1, 63
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2003105023	A1	20030605	US 2002-283549	20021030 <--
PRAI US 2001-335019P	P	20011031 <--		
US 2001-335412P	P	20011031 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2003105023	ICM	A61K038-10
	ICS	A61K038-08; C07K007-06; C07K007-08
	INCL	514016000; 514017000; 530328000; 530329000
US 2003105023	NCL	514/016.000; 514/017.000; 530/328.000; 530/329.000
	ECLA	C07K007/06A; C07K007/06B; C07K007/08A; C07K007/08B <--

OS MARPAT 138:385741
AB The invention describes peptides Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8 [Xaa1 is H or R(CH2)nCO, where n is 0-8 and R is alkoxy, alkyl, amino, aryl, carboxy, cycloalkenyl, cycloalkyl, or heterocyclyl; Xaa2-Xaa7 are amino acid residues, which are defined (Xaa7 may also be absent); Xaa8 is D-alanylamide, azaglycylamide, glycylamide, hydroxy, D-lysyl(Nε-acetyl)amide, NH(CH2)nCHR1R2 [n = 0-8; R1 = H, alkyl, cycloalkenyl, cycloalkyl; R2 = H, alkoxy, alkyl, aryl, cycloalkenyl, cycloalkyl, heterocyclyl, hydroxy (with provisos)], or NHR3, where R3 = H, cycloalkenyl, cycloalkyl, or hydroxy] and Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7 (same Xaa1-Xaa6 (Xaa6 may also be absent), Xaa7 is as defined for Xaa8), which are useful for treating conditions that arise from or are exacerbated by angiogenesis. An example is N-Ac-D-Ile-Thr-Nva-Ile-Arg-Pro-NHEt, which was prepared by the solid-phase method. Compds. of the

invention demonstrate enhanced potency compared to previously described antiangiogenic peptides, i.e., they inhibited human endothelial cell migration by approx. 55-70% at a concentration of 0.01 nM.

ST peptide prepn angiogenesis inhibitor

IT Solid phase synthesis
(peptide; preparation of tetra-, penta-, hexa- and heptapeptides having antiangiogenic activity)

IT Angiogenesis
Angiogenesis inhibitors
Human
(preparation of tetra-, penta-, hexa- and heptapeptides having antiangiogenic activity)

IT Peptides, preparation
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tetra-, penta-, hexa- and heptapeptides having antiangiogenic activity)

IT 522609-34-3P 522609-35-4P 522609-36-5P 522609-37-6P 522609-38-7P
522609-39-8P 522609-40-1P 522609-41-2P 522609-42-3P 522609-43-4P
522609-44-5P 522609-45-6P 522609-46-7P 522609-47-8P 522609-48-9P
522609-49-0P 522609-50-3P 522609-51-4P 522609-52-5P 522609-53-6P
522609-54-7P 522609-55-8P 522609-56-9P 522609-57-0P 522609-58-1P
522609-59-2P 522609-60-5P 522609-61-6P 522609-62-7P 522609-63-8P
522609-64-9P 522609-65-0P 522609-66-1P 522609-67-2P 522609-68-3P
522609-69-4P 522609-70-7P 522609-71-8P 522609-72-9P 522609-73-0P
522609-74-1P 522609-75-2P 522609-76-3P 522609-77-4P 522609-78-5P
522609-79-6P 522609-80-9P 522609-81-0P 522609-82-1P 522609-83-2P
522609-84-3P 522609-85-4P **522609-86-5P** **522609-87-6P**
522609-88-7P 522609-89-8P 522609-90-1P 522609-91-2P 522609-92-3P
522609-93-4P 522609-95-6P 522609-96-7P 522609-97-8P 522609-98-9P
522609-99-0P 522610-00-0P 522610-01-1P 522610-02-2P 522610-03-3P
522610-04-4P 522610-05-5P 522610-06-6P 522610-07-7P 522610-08-8P
522610-09-9P 522610-10-2P 522610-11-3P 522610-12-4P 522610-13-5P
522610-14-6P 522610-15-7P 522610-16-8P 522610-17-9P 522610-18-0P
522610-19-1P 522610-20-4P 522610-21-5P 522610-22-6P 522610-23-7P
522610-24-8P 522610-25-9P 522610-26-0P 522610-27-1P 522610-28-2P
522610-29-3P 522610-30-6P 522610-31-7P 522610-32-8P 522610-33-9P
522610-34-0P 522610-35-1P 522610-36-2P 522610-37-3P 522610-38-4P
522610-39-5P 522610-40-8P 522610-41-9P 522610-42-0P 522610-43-1P
522610-44-2P 522610-45-3P 522610-46-4P 522610-47-5P 522610-48-6P
522610-49-7P 522610-50-0P 522610-51-1P 522610-52-2P 522610-53-3P
522610-54-4P 522610-55-5P 522610-56-6P 522610-57-7P 522610-58-8P
522610-59-9P 522610-60-2P 522610-61-3P 522610-62-4P 522610-63-5P
522610-64-6P 522610-65-7P 522610-66-8P 522610-67-9P 522610-68-0P
522610-69-1P 522610-70-4P 522610-71-5P 522610-72-6P 522610-73-7P
522610-74-8P 522610-75-9P 522610-76-0P 522610-77-1P 522610-78-2P
522610-79-3P 522610-80-6P 522610-81-7P 522610-82-8P 522610-83-9P
522610-84-0P 522610-85-1P 522610-87-3P 522610-88-4P 522610-90-8P
522610-91-9P 522610-92-0P 522610-93-1P 522610-95-3P 522610-96-4P
522610-98-6P 522610-99-7P 522611-00-3P 522611-01-4P 522611-02-5P
522611-03-6P 522611-04-7P 522611-05-8P 522611-06-9P 522611-07-0P
522611-08-1P 522611-09-2P 522611-10-5P 522611-11-6P 522611-12-7P
522611-13-8P 522611-14-9P 522611-15-0P 522611-16-1P 522611-17-2P
522611-19-4P 522611-20-7P 522611-21-8P 522611-22-9P 522611-23-0P
522611-24-1P 522611-25-2P 522611-26-3P 522611-27-4P 522611-28-5P
522611-29-6P 522611-30-9P 522611-31-0P 522611-32-1P 522611-33-2P
522611-34-3P 522611-35-4P 522611-36-5P 522611-37-6P 522611-38-7P
522611-39-8P 522611-40-1P 522611-41-2P 522611-43-4P 522611-44-5P
522611-45-6P 522611-46-7P 522611-47-8P 522611-48-9P 522611-49-0P
522611-50-3P 522611-51-4P 522611-52-5P 522611-54-7P 522611-55-8P
522611-56-9P 522611-57-0P 522611-58-1P 522611-59-2P 522611-60-5P
522611-61-6P 522611-62-7P 522611-63-8P 522611-64-9P 522611-65-0P
522611-66-1P 522611-67-2P 522611-68-3P 522611-69-4P 522611-70-7P
522611-71-8P 522611-72-9P 522611-73-0P 522611-74-1P 522611-75-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tetra-, penta-, hexa- and heptapeptides having antiangiogenic activity)

IT 522611-76-3P 522611-77-4P 522611-78-5P 522611-79-6P 522611-80-9P
522611-81-0P 522611-82-1P 522611-83-2P 522611-84-3P 522611-85-4P
522611-86-5P 522611-87-6P 522611-88-7P 522611-89-8P 522611-90-1P
522611-91-2P 522611-92-3P 522611-93-4P 522611-94-5P 522611-95-6P
522611-96-7P 522611-97-8P 522611-98-9P 522611-99-0P 522612-00-6P
522612-01-7P 522612-02-8P 522612-04-0P 522612-05-1P 522612-06-2P
522612-07-3P 522612-08-4P 522612-09-5P 522612-10-8P 522612-11-9P
522612-20-0P 522612-34-6P 522612-38-0P 522612-53-9P 522612-55-1P
522612-56-2P 522612-57-3P 522612-58-4P 522612-59-5P 522612-60-8P
522612-61-9P 522612-62-0P 522612-63-1P 522612-64-2P 522612-65-3P
522612-66-4P 522612-67-5P 522612-68-6P 522612-69-7P 522612-70-0P
522612-71-1P 522612-72-2P 522612-73-3P 522612-74-4P 522612-75-5P
522612-76-6P 522612-77-7P 522612-78-8P 522612-79-9P 522612-80-2P
522612-81-3P 522612-82-4P 522612-83-5P 522612-84-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tetra-, penta-, hexa- and heptapeptides having antiangiogenic activity)

IT 3222-47-7, 6-Methyl-nicotinic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of tetra-, penta-, hexa- and heptapeptides having antiangiogenic activity)

IT 524091-35-8 524091-36-9 524091-37-0 524091-38-1 524091-39-2
524091-40-5 524091-41-6 524091-42-7 524091-43-8 524091-44-9
524091-45-0 524091-46-1 524091-47-2 524091-48-3 524091-49-4
524091-50-7 524091-51-8 524091-52-9 524091-53-0 524091-54-1
524091-55-2 524091-56-3 524091-57-4 524091-58-5 524091-59-6
524091-60-9 524091-61-0 524091-62-1 524091-63-2 524091-64-3
524091-65-4 524759-44-2
RL: PRP (Properties)
(unclaimed protein sequence; preparation of tetra-, penta-, hexa- and heptapeptides having antiangiogenic activity)

IT **522609-86-5P 522609-87-6P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tetra-, penta-, hexa- and heptapeptides having antiangiogenic activity)

L52 ANSWER 8 OF 33 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:435295 HCAPLUS
DN 138:385740
ED Entered STN: 06 Jun 2003
TI Preparation of tetra-, penta-, hexa- and heptapeptides having antiangiogenic activity
IN Haviv, Fortuna; Bradley, Michael F.
PA USA
SO U.S. Pat. Appl. Publ., 55 pp., Cont.-in-part of U.S. Ser. No. 7.
CODEN: USXXCO
DT Patent
LA English
IC ICM A61K038-00
INCL 514016000; 514017000; 514018000
CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1, 63
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003105022	A1	20030605	US 2002-263811	20021004 <--
	US 2003119745	A1	20030626	US 2001-540	20011031 <--
	US 2003125261	A1	20030703	US 2001-7	20011031 <--

```
     CA 2466152            AA    20030508    CA 2002-2466152        20021030 <--
     WO 2003037266         A2    20030508    WO 2002-US34760        20021030 <--
     WO 2003037266         A3    20031211
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,
             CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     EP 1451209            A2    20040901    EP 2002-789322         20021030 <--
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
     JP 2005512980         T2    20050512    JP 2003-539612         20021030 <--
PRAI US 2001-540           A2    20011031  <--
     US 2001-7             A2    20011031  <--
     US 2002-263811        A     20021004  <--
     WO 2002-US34760       W     20021030  <--
CLASS
 PATENT NO.       CLASS  PATENT FAMILY CLASSIFICATION CODES
 --------------   -----  ----------------------------------------------
 US 2003105022    ICM    A61K038-00
                  INCL   514016000; 514017000; 514018000
 US 2003105022    NCL    514/016.000; 514/017.000; 514/018.000
                  ECLA   C07K005/10A1F; C07K007/06B                        <--
 US 2003119745    NCL    514/016.000; 514/017.000; 530/328.000; 530/329.000
                  ECLA   C07K005/10A1F; C07K007/06B                        <--
 US 2003125261    NCL    514/017.000
                  ECLA   C07K005/10A1F; C07K007/06B                        <--
 WO 2003037266    ECLA   C07K005/10A1F; C07K007/06B                        <--
 JP 2005512980    FTERM  4C084/AA02; 4C084/AA07; 4C084/BA01; 4C084/BA09;
                         4C084/BA17; 4C084/BA23; 4C084/CA59; 4C084/ZA33;
                         4C084/ZA36; 4C084/ZA39; 4C084/ZA44; 4C084/ZA66;
                         4C084/ZA86; 4C084/ZA89; 4C084/ZA96; 4C084/ZB15;
                         4C084/ZB26; 4H045/AA10; 4H045/AA20; 4H045/AA30;
                         4H045/BA01; 4H045/BA13; 4H045/BA14; 4H045/BA15;
                         4H045/EA28; 4H045/FA33; 4H045/GA21               <--
OS   MARPAT 138:385740
AB   The invention describes peptides Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8
     [Xaa1 is H or R(CH2)nCO, where n is 0-8 and R is alkoxy, alkyl, amino,
     aryl, carboxy, cycloalkenyl, cycloalkyl, or heterocyclyl; Xaa2-Xaa7 are
     amino acid residues, which are defined (Xaa7 may also be absent); Xaa8 is
     D-alanylamide, azaglycylamide, glycylamide, hydroxy, D-lysyl(Nε-
     acetyl)amide, NH(CH2)nCHR1R2 [n = 0-8; R1 = H, alkyl, cycloalkenyl,
     cycloalkyl; R2 = H, alkoxy, alkyl, aryl, cycloalkenyl, cycloalkyl,
     heterocyclyl, hydroxy (with provisos)], or NHR3, where R3 = H,
     cycloalkenyl, cycloalkyl, or hydroxy] and Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-
     Xaa7 (same Xaa1-Xaa6 (Xaa6 may also be absent), Xaa7 is as defined for
     Xaa8), which are useful for treating conditions that arise from or are
     exacerbated by angiogenesis.  An example is N-Ac-D-Ile-Thr-Nva-Ile-Arg-Pro-
     NHEt, which was prepared by the solid-phase method.  Compds. of the
     invention demonstrate enhanced potency compared to previously described
     antiangiogenic peptides, i.e., they inhibited human endothelial cell
     migration by approx. 55-70% at a concentration of 0.01 nM.
ST   peptide prepn angiogenesis inhibitor
IT   Solid phase synthesis
        (peptide; preparation of tetra-, penta-, hexa- and heptapeptides having
        antiangiogenic activity)
IT   Angiogenesis
     Angiogenesis inhibitors
     Human
        (preparation of tetra-, penta-, hexa- and heptapeptides having
        antiangiogenic activity)
```

IT Peptides, preparation
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tetra-, penta-, hexa- and heptapeptides having antiangiogenic activity)

IT 522609-34-3P 522609-35-4P 522609-36-5P 522609-37-6P 522609-38-7P
522609-39-8P 522609-40-1P 522609-41-2P 522609-42-3P 522609-43-4P
522609-44-5P 522609-45-6P 522609-46-7P 522609-47-8P 522609-48-9P
522609-49-0P 522609-50-3P 522609-51-4P 522609-52-5P 522609-53-6P
522609-54-7P 522609-55-8P 522609-56-9P 522609-57-0P 522609-58-1P
522609-59-2P 522609-60-5P 522609-61-6P 522609-62-7P 522609-63-8P
522609-64-9P 522609-65-0P 522609-66-1P 522609-67-2P 522609-68-3P
522609-69-4P 522609-70-7P 522609-71-8P 522609-72-9P 522609-73-0P
522609-74-1P 522609-75-2P 522609-76-3P 522609-77-4P 522609-78-5P
522609-79-6P 522609-80-9P 522609-81-0P 522609-82-1P 522609-83-2P
522609-84-3P 522609-85-4P **522609-86-5P 522609-87-6P**
522609-88-7P 522609-89-8P 522609-90-1P 522609-91-2P 522609-92-3P
522609-93-4P 522609-95-6P 522609-96-7P 522609-97-8P 522609-98-9P
522609-99-0P 522610-00-0P 522610-01-1P 522610-02-2P 522610-03-3P
522610-04-4P 522610-05-5P 522610-06-6P 522610-07-7P 522610-08-8P
522610-09-9P 522610-10-2P 522610-11-3P 522610-12-4P 522610-13-5P
522610-14-6P 522610-15-7P 522610-16-8P 522610-17-9P 522610-18-0P
522610-19-1P 522610-20-4P 522610-21-5P 522610-22-6P 522610-23-7P
522610-24-8P 522610-25-9P 522610-26-0P 522610-27-1P 522610-28-2P
522610-29-3P 522610-30-6P 522610-31-7P 522610-32-8P 522610-33-9P
522610-34-0P 522610-35-1P 522610-36-2P 522610-37-3P 522610-38-4P
522610-39-5P 522610-40-8P 522610-41-9P 522610-42-0P 522610-43-1P
522610-44-2P 522610-45-3P 522610-46-4P 522610-47-5P 522610-48-6P
522610-49-7P 522610-50-0P 522610-51-1P 522610-52-2P 522610-53-3P
522610-54-4P 522610-55-5P 522610-56-6P 522610-57-7P 522610-58-8P
522610-59-9P 522610-60-2P 522610-61-3P 522610-62-4P 522610-63-5P
522610-64-6P 522610-65-7P 522610-66-8P 522610-67-9P 522610-68-0P
522610-69-1P 522610-70-4P 522610-71-5P 522610-72-6P 522610-73-7P
522610-74-8P 522610-75-9P 522610-76-0P 522610-77-1P 522610-78-2P
522610-79-3P 522610-80-6P 522610-81-7P 522610-82-8P 522610-83-9P
522610-84-0P 522610-85-1P 522610-87-3P 522610-88-4P 522610-90-8P
522610-91-9P 522610-92-0P 522610-93-1P 522610-95-3P 522610-96-4P
522610-98-6P 522610-99-7P 522611-00-3P 522611-01-4P 522611-02-5P
522611-03-6P 522611-04-7P 522611-05-8P 522611-06-9P 522611-07-0P
522611-08-1P 522611-09-2P 522611-10-5P 522611-11-6P 522611-12-7P
522611-13-8P 522611-14-9P 522611-15-0P 522611-16-1P 522611-17-2P
522611-19-4P 522611-20-7P 522611-21-8P 522611-22-9P 522611-23-0P
522611-24-1P 522611-25-2P 522611-26-3P 522611-27-4P 522611-28-5P
522611-29-6P 522611-30-9P 522611-31-0P 522611-32-1P 522611-33-2P
522611-34-3P 522611-35-4P 522611-36-5P 522611-37-6P 522611-38-7P
522611-39-8P 522611-40-1P 522611-41-2P 522611-43-4P 522611-44-5P
522611-45-6P 522611-46-7P 522611-47-8P 522611-48-9P 522611-49-0P
522611-50-3P 522611-51-4P 522611-52-5P 522611-54-7P 522611-55-8P
522611-56-9P 522611-57-0P 522611-58-1P 522611-59-2P 522611-60-5P
522611-61-6P 522611-62-7P 522611-63-8P 522611-64-9P 522611-65-0P
522611-66-1P 522611-67-2P 522611-68-3P 522611-69-4P 522611-70-7P
522611-71-8P 522611-72-9P 522611-73-0P 522611-74-1P 522611-75-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tetra-, penta-, hexa- and heptapeptides having antiangiogenic activity)

IT 522611-76-3P 522611-77-4P 522611-78-5P 522611-79-6P 522611-80-9P
522611-81-0P 522611-82-1P 522611-83-2P 522611-84-3P 522611-85-4P
522611-86-5P 522611-87-6P 522611-88-7P 522611-89-8P 522611-90-1P
522611-91-2P 522611-92-3P 522611-93-4P 522611-94-5P 522611-95-6P
522611-96-7P 522611-97-8P 522611-98-9P 522611-99-0P 522612-00-6P
522612-01-7P 522612-02-8P 522612-04-0P 522612-05-1P 522612-06-2P
522612-07-3P 522612-08-4P 522612-09-5P 522612-10-8P 522612-11-9P
522612-20-0P 522612-34-6P 522612-38-0P 522612-53-9P 522612-55-1P

522612-56-2P 522612-57-3P 522612-58-4P 522612-59-5P 522612-60-8P
522612-61-9P 522612-62-0P 522612-63-1P 522612-64-2P 522612-65-3P
522612-66-4P 522612-67-5P 522612-68-6P 522612-69-7P 522612-70-0P
522612-71-1P 522612-72-2P 522612-73-3P 522612-74-4P 522612-75-5P
522612-76-6P 522612-77-7P 522612-78-8P 522612-79-9P 522612-80-2P
522612-81-3P 522612-82-4P 522612-83-5P 522612-84-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tetra-, penta-, hexa- and heptapeptides having antiangiogenic activity)

IT 3222-47-7, 6-Methyl-nicotinic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of tetra-, penta-, hexa- and heptapeptides having antiangiogenic activity)

IT 524091-35-8 524091-36-9 524091-37-0 524091-38-1 524091-39-2
524091-40-5 524091-41-6 524091-42-7 524091-43-8 524091-44-9
524091-45-0 524091-46-1 524091-47-2 524091-48-3 524091-49-4
524091-50-7 524091-51-8 524091-52-9 524091-53-0 524091-54-1
524091-55-2 524091-56-3 524091-57-4 524091-58-5 524091-59-6
524091-60-9 524091-61-0 524091-62-1 524091-63-2 524091-64-3
524091-65-4 524759-44-2
RL: PRP (Properties)
(unclaimed protein sequence; preparation of tetra-, penta-, hexa- and heptapeptides having antiangiogenic activity)

IT **522609-86-5P 522609-87-6P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tetra-, penta-, hexa- and heptapeptides having antiangiogenic activity)

L52 ANSWER 9 OF 33 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:396443 HCAPLUS
DN 138:369199
ED Entered STN: 23 May 2003
TI Preparation of hepta-, octa- and nonapeptides having antiangiogenic activity
IN Haviv, Fortuna; Bradley, Michael F.
PA USA
SO U.S. Pat. Appl. Publ., 26 pp., Cont.-in-part of U.S. Ser. No. 681.
CODEN: USXXCO
DT Patent
LA English
IC ICM A61K038-10
ICS C07K007-08; A61K038-08; C07K007-06
INCL 514016000; 514017000; 530328000; 530329000
CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1, 63
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 2003096758	A1	20030522	US 2002-263812	20021004	<--
	US 2003125259	A1	20030703	US 2001-681	20011031	<--
	CA 2466170	AA	20030508	CA 2002-2466170	20021030	<--
	WO 2003037268	A2	20030508	WO 2002-US34811	20021030	<--
	WO 2003037268	A3	20030912			

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,

CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
EP 1451210 A2 20040901 EP 2002-789330 20021030 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
JP 2005512981 T2 20050512 JP 2003-539614 20021030 <--
PRAI US 2001-681 A2 20011031 <--
US 2002-263812 A 20021004 <--
WO 2002-US34811 W 20021030 <--

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2003096758	ICM	A61K038-10
	ICS	C07K007-08; A61K038-08; C07K007-06
	INCL	514016000; 514017000; 530328000; 530329000
US 2003096758	NCL	514/016.000; 514/017.000; 530/328.000; 530/329.000
	ECLA	C07K007/06A <--
US 2003125259	NCL	514/016.000; 514/017.000; 530/328.000; 530/329.000
	ECLA	C07K007/06A <--
WO 2003037268	ECLA	C07K007/06A <--
JP 2005512981	FTERM	4C084/AA02; 4C084/AA07; 4C084/BA01; 4C084/BA09; 4C084/BA17; 4C084/BA23; 4C084/BA31; 4C084/BA32; 4C084/CA59; 4C084/NA14; 4C084/ZA331; 4C084/ZA361; 4C084/ZA441; 4C084/ZA442; 4C084/ZA451; 4C084/ZA511; 4C084/ZA531; 4C084/ZA681; 4C084/ZA811; 4C084/ZA861; 4C084/ZA891; 4C084/ZA961; 4C084/ZB021; 4C084/ZB151; 4C084/ZB261; 4C084/ZB271; 4C084/ZC411; 4C084/ZC412; 4C084/ZC511; 4H045/AA10; 4H045/BA14; 4H045/BA15; 4H045/EA23; 4H045/EA28; 4H045/FA34; 4H045/GA21 <--

OS MARPAT 138:369199

AB The invention describes peptides Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10 [Xaa1is H or R(CH2)nCO, where n is 0-8 and R is alkoxy, alkyl, amino, aryl, carboxy, cycloalkenyl, cycloalkyl, or heterocyclyl; Xaa2-Xaa9 are amino acid residues, which are defined (Xaa9 may also be absent); Xaa10 is D-alanylamide, azaglycylamide, glycylamide, D-lysyl(Nε-acetyl)amide, NH(CH2)nCHR1R2 [n = 0-8; R1 = H, alkyl, cycloalkenyl, cycloalkyl; R2 = H, alkoxy, alkyl, aryl, cycloalkenyl, cycloalkyl, heterocyclyl, hydroxy (with provisos)], or NHR3, where R3 = H, cycloalkenyl, cycloalkyl, or hydroxy], which are useful for treating conditions that arise from or are exacerbated by angiogenesis. An example is N-Ac-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-Pro-NHEt, which was prepared by the solid-phase method. Compds. of the invention inhibit human endothelial cell migration by approx. 50-95% at a concentration of 0.1 nM.

ST peptide prepn angiogenesis inhibitor

IT Solid phase synthesis
(peptide; preparation of hepta-, octa- and nonapeptides having antiangiogenic activity)

IT Angiogenesis
Angiogenesis inhibitors
Human
(preparation of hepta-, octa- and nonapeptides having antiangiogenic activity)

IT Peptides, preparation
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of hepta-, octa- and nonapeptides having antiangiogenic activity)

IT 445467-72-1P 445467-73-2P 521942-45-0P 521942-46-1P 521942-47-2P
521942-48-3P 521942-49-4P 521942-50-7P 521942-51-8P 521942-52-9P
521942-53-0P 521942-54-1P 521942-55-2P 521942-56-3P 521942-57-4P
521942-58-5P 521942-59-6P 521942-60-9P 521942-61-0P 521942-62-1P
521942-63-2P 521942-64-3P 521942-65-4P 521942-66-5P 521942-67-6P
521942-68-7P 521942-69-8P 521942-70-1P 521942-71-2P 521942-72-3P
521942-73-4P 521942-74-5P 521942-75-6P 521942-76-7P 521942-77-8P
521942-78-9P 521942-79-0P 521942-80-3P 521942-81-4P 521942-82-5P
521942-84-7P 521942-85-8P 521942-86-9P 521942-87-0P 521942-88-1P

521942-89-2P 521942-90-5P 521942-92-7P 521942-93-8P 521942-94-9P
521942-95-0P 521942-96-1P 521942-97-2P 521942-98-3P 521942-99-4P
521943-00-0P 521943-01-1P 521943-02-2P 521943-03-3P 521943-04-4P
521943-05-5P 521943-06-6P 521943-07-7P 521943-08-8P 521943-09-9P
521943-10-2P 521943-11-3P 521943-12-4P 521943-13-5P 521943-14-6P
521943-15-7P 521943-16-8P 521943-17-9P 521943-18-0P 521943-20-4P
521943-21-5P 521943-22-6P 521943-23-7P 521943-24-8P 521943-25-9P
521943-26-0P 521943-27-1P 521943-28-2P 521943-29-3P 521943-30-6P
521943-31-7P 521943-32-8P 521943-33-9P 521943-34-0P 521943-35-1P
521943-36-2P 521943-37-3P 521943-38-4P 521943-39-5P 521943-40-8P
521943-41-9P 521943-42-0P 521943-43-1P 521943-44-2P 521943-45-3P
521943-46-4P 521943-47-5P 521943-48-6P 521943-49-7P 521943-50-0P
521943-51-1P 521943-52-2P 521943-53-3P 521943-54-4P 521943-55-5P
521943-56-6P 521943-57-7P 521943-58-8P 521943-59-9P 521943-60-2P
521943-61-3P 521943-62-4P 521943-63-5P 521943-64-6P 521943-65-7P
521943-66-8P 521943-67-9P 521943-68-0P 521943-69-1P 521943-70-4P
521943-71-5P 521943-72-6P 521943-73-7P 521943-74-8P
521943-75-9P 521943-76-0P 521943-77-1P 521943-78-2P 521943-79-3P
521943-80-6P 521943-81-7P 521943-82-8P 521943-83-9P 521943-84-0P
521943-85-1P 521943-86-2P 521943-87-3P 521943-88-4P 521943-90-8P
521943-92-0P 521943-95-3P 521943-99-7P 521944-00-3P 521944-01-4P
521944-02-5P 521944-03-6P 521944-04-7P 521944-05-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of hepta-, octa- and nonapeptides having antiangiogenic activity)

IT 3222-47-7, 6-Methylnicotinic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of hepta-, octa- and nonapeptides having antiangiogenic activity)

IT **521943-71-5P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of hepta-, octa- and nonapeptides having antiangiogenic activity)

L52 ANSWER 10 OF 33 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:242029 HCAPLUS
DN 138:265604
ED Entered STN: 28 Mar 2003
TI Tripeptide amides that block viral infectivity and methods of use thereof
IN Van der Spoel, David; Hetenyi, Csaba; Vegvari, Akos; Hoglund, Stefan; Su, Jin; Sandin-Reneby, Sarah; Goobar-Larsson, Laura; Vahlne, Anders
PA Swed.
SO U.S. Pat. Appl. Publ., 17 pp.
CODEN: USXXCO
DT Patent
LA English
IC ICM C07K016-00
ICS C07K007-00; C07K005-00; A61K038-00; A01N037-18; A61K038-06; C07K017-00
INCL 530331000; 514002000
CC 1-5 (Pharmacology)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2003060599	A1	20030327	US 2001-938806	20010824 <--
US 6593455	B2	20030715		
PRAI US 2001-938806		20010824 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2003060599	ICM	C07K016-00
	ICS	C07K007-00; C07K005-00; A61K038-00; A01N037-18;

A61K038-06; C07K017-00
INCL 530331000; 514002000
US 2003060599 NCL 530/331.000; 530/332.000; 530/334.000; 530/345.000
ECLA C07K005/08 <--

AB The disclosed embodiments relate to the discovery that tripeptide amides, which correspond to viral capsid sequences, can be used to inhibit viral infection, including human immunodeficiency virus (HIV) infection. Also, medicaments comprising tripeptide amides and methods of using said compds. for the prevention and treatment of viral infection, such as HIV infection, are provided.

ST tripeptide amide capsid protein antiviral

IT Peptides, biological studies
Tripeptides
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amides; tripeptide amides that block viral infectivity and uses thereof)

IT Virion structure
(capsid; tripeptide amides that block viral infectivity and uses thereof)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(capsid; tripeptide amides that block viral infectivity and uses thereof)

IT gag proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(p24gag; tripeptide amides that block viral infectivity and uses thereof)

IT Anti-AIDS agents
Antiviral agents
Human
Human T-lymphotropic virus 1
Human immunodeficiency virus 1
Human immunodeficiency virus 2
Mason-Pfizer monkey virus
Mouse mammary tumor virus
Murine leukemia virus
Rous sarcoma virus
Simian immunodeficiency virus
(tripeptide amides that block viral infectivity and uses thereof)

IT Amides, biological studies
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tripeptides; tripeptide amides that block viral infectivity and uses thereof)

IT Infection
(viral; tripeptide amides that block viral infectivity and uses thereof)

IT 502620-75-9
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peptide amides that block viral infectivity and uses thereof)

IT 325690-92-4 502620-57-7 502620-58-8 **502620-59-9**
502620-60-2 502620-61-3 502620-62-4 502620-63-5 502620-64-6
502620-65-7 502620-66-8 502620-67-9 502620-68-0 502620-69-1
502620-70-4 502620-71-5 502620-72-6 502620-73-7 502620-74-8
502620-76-0 502620-77-1 502620-78-2 502620-79-3 502620-80-6
502620-81-7 502620-82-8 502620-83-9 502620-84-0
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tripeptide amides that block viral infectivity and uses thereof)

IT 503080-69-1 503080-70-4 503080-71-5 503080-72-6 503080-73-7

503080-74-8 503080-75-9 503080-76-0
RL: PRP (Properties)
(unclaimed protein sequence; tripeptide amides that block viral infectivity and methods of use thereof)
IT 503080-77-1
RL: PRP (Properties)
(unclaimed sequence; tripeptide amides that block viral infectivity and methods of use thereof)
IT **502620-59-9**
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tripeptide amides that block viral infectivity and uses thereof)

L52 ANSWER 11 OF 33 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:522525 HCAPLUS
DN 137:98942
ED Entered STN: 12 Jul 2002
TI Bone stimulating factor
IN Tam, Cherk Shing
PA Osteopharm Inc., Can.
SO U.S. Pat. Appl. Publ., 23 pp., Cont.-in-part of U.S. Ser. No. 48,058.
CODEN: USXXCO
DT Patent
LA English
IC ICM A61K038-00
ICS C12N015-63; C07K017-00; A61K038-27; A61K038-24; C07K016-00; C07K014-00; C12N005-02; C07K001-00; C12N005-00; C12N015-74; C12N015-70; C12N015-09; C12N015-00; C12P021-06; C07H021-04
INCL 435069100
CC 63-3 (Pharmaceuticals)
Section cross-reference(s): 2, 15
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002090671	A1	20020711	US 1999-229304	19990113 <--
	US 6693081	B2	20040217		
	WO 9712036	A2	19970403	WO 1996-CA653	19960926 <--
	WO 9712036	A3	19970605		
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG				
	CA 2358908	AA	20000720	CA 2000-2358908	20000113 <--
	WO 2000042069	A1	20000720	WO 2000-CA31	20000113 <--
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2000030282	A5	20000801	AU 2000-30282	20000113 <--
	AU 779261	B2	20050113		
	EP 1161450	A1	20011212	EP 2000-900467	20000113 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002538775	T2	20021119	JP 2000-593635	20000113 <--
	BR 2000007816	A	20021231	BR 2000-7816	20000113 <--
	NZ 512637	A	20030829	NZ 2000-512637	20000113 <--
	NO 2001003257	A	20010817	NO 2001-3257	20010629 <--

```
     BG 105682              A     20030430    BG 2001-105682         20010709 <--
     US 2004147450          A1    20040729    US 2003-718526         20031124 <--
PRAI WO 1996-CA653          A1    19960926  <--
     US 1998-48058          A2    19980326  <--
     US 1995-4314P          P     19950926  <--
     US 1999-229304         A     19990113  <--
     WO 2000-CA31           W     20000113  <--
CLASS
 PATENT NO.       CLASS  PATENT FAMILY CLASSIFICATION CODES
 --------------   -----  ----------------------------------------------
 US 2002090671    ICM    A61K038-00
                  ICS    C12N015-63; C07K017-00; A61K038-27; A61K038-24;
                         C07K016-00; C07K014-00; C12N005-02; C07K001-00;
                         C12N005-00; C12N015-74; C12N015-70; C12N015-09;
                         C12N015-00; C12P021-06; C07H021-04
                  INCL   435069100
 US 2002090671    NCL    514/016.000; 530/328.000; 530/345.000; 530/380.000;
                         530/402.000                                      <--
 WO 9712036       ECLA   C07K014/51; C07K014/52                           <--
 WO 2000042069    ECLA   C07K014/51                                       <--
 US 2004147450    NCL    514/014.000; 514/015.000; 514/016.000; 514/017.000;
                         530/327.000; 530/328.000; 530/329.000; 530/330.000
                  ECLA   C07K014/51; C07K014/52                           <--
AB   Polypeptides which increase or promote mammalian bone growth, related
     nucleotide sequences, antibodies, diagnostic kits and treatments are
     disclosed.  Subsequences of the polypeptide Asp Ser Asp Leu Tyr Ala Glu
     Leu Arg Cys Met Cys Ile Lys Thr Thr Ser Gly Ile His Pro Lys Asn Ile Gln
     Ser Leu Glu Val Ile Gly Lys Gly Thr His Cys Asn Gln Val Glu Val Ile Ala
     Thr Leu Lys Asp Gly Arg Lys Ile Cys Leu Asp Pro Asp Ala Pro Arg Ile Lys
     Lys Ile Val Gln Lys Lys Leu Ala Gly Asp Glu Ser Ala Asp have been shown to
     promote growth.  Subsequences include Asp Ser Asp Leu Tyr Ala Glu Leu Arg
     Cys Met Cys Ile Lys Thr Thr Ser Gly Ile His Pro Lys Asn Ile Gln Ser; Ile
     Lys Thr Thr Ser Gly Ile His Pro Lys Asn Ile Glu Ser; Cys Met Cys Ile Lys
     Thr Thr Ser Gly Ile His Pro Lys Asn Ile Gln and TTSGIHPK.
ST   protein bone growth stimulator sequence
IT   Nucleic acid hybridization
        (DNA-DNA; bone-stimulating factor peptide prepns.)
IT   Animal tissue culture
     Bone formation
     Genetic engineering
     Genetic vectors
     Mammalia
     Molecular cloning
     Osteoporosis
     Protein sequences
     Transformation, genetic
        (bone-stimulating factor peptide prepns.)
IT   Fusion proteins (chimeric proteins)
     RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
     (Biological study); USES (Uses)
        (bone-stimulating; bone-stimulating factor peptide prepns.)
IT   Antibodies and Immunoglobulins
     RL: ARG (Analytical reagent use); DGN (Diagnostic use); ANST (Analytical
     study); BIOL (Biological study); USES (Uses)
        (fusion protein-specific; bone-stimulating factor peptide prepns.)
IT   Diagnosis
        (kits for; bone-stimulating factor peptide prepns.)
IT   441121-50-2, 7-81-β-Thromboglobulin (human)
     RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
     (Biological study)
        (amino acid sequence; bone-stimulating factor peptide prepns.)
IT   189064-62-8   189064-63-9 282096-82-6   441043-60-3
     RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
     (Biological study)
        (bone-stimulating factor peptide prepns.)
IT   441410-42-0
```

RL: PRP (Properties)
(unclaimed nucleotide sequence; bone stimulating factor)
IT 441410-33-9 441410-34-0 441410-35-1 441410-36-2 441410-37-3
441410-38-4 441410-39-5 441410-40-8 441410-41-9 441410-43-1
RL: PRP (Properties)
(unclaimed protein sequence; bone stimulating factor)
IT 144207-67-0 189064-68-4 441286-64-2
RL: PRP (Properties)
(unclaimed sequence; bone stimulating factor)
IT 282096-82-6
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(bone-stimulating factor peptide prepns.)

L52 ANSWER 12 OF 33 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:744640 HCAPLUS
DN 135:283543
ED Entered STN: 11 Oct 2001
TI Lamprey LHRH-III and analogs as FSH-releasing peptides for use in enhancing or inhibiting fertility
IN Mccann, Samuel M.; Yu, Wen H.
PA Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, USA
SO U.S., 17 pp.
CODEN: USXXAM
DT Patent
LA English
IC ICM C07K007-23
INCL 530328000
CC 2-5 (Mammalian Hormones)
Section cross-reference(s): 1, 12
FAN.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 6300471	B1	20011009	US 1998-89522	19980603 <--
PRAI US 1997-92112P	P	19970604 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 6300471	ICM	C07K007-23
	INCL	530328000
US 6300471	NCL	530/328.000; 530/399.000
	ECLA	C07K007/23; C07K014/575 <--

AB Lamprey LHRH-III is a potent FSH-releasing factor, and may be used to enhance fertility. Antagonists to lamprey LHRH-III may be used to inhibit fertility.
ST LHRH analogs FSH release infertility treatment fertility inhibition contraceptive
IT Fertility
(disorder; lamprey LHRH-III and analogs as FSH-releasing peptides for use in enhancing or inhibiting fertility)
IT Contraceptives
Fertility
(lamprey LHRH-III and analogs as FSH-releasing peptides for use in enhancing or inhibiting fertility)
IT 33515-09-2, Luteinizing hormone-releasing factor (swine) 86073-88-3, Luteinizing hormone-releasing factor (Oncorhynchus keta) 91097-16-4, Luteinizing hormone-releasing factor II (chicken) 102634-23-1, Luteinizing hormone-releasing factor I (Petromyzon marinus) 147859-97-0, Luteinizing hormone-releasing factor III (Petromyzon marinus) 147859-97-0D, Luteinizing hormone-releasing factor III (Petromyzon marinus), analogs 178414-87-4 217432-91-2 217432-92-3 217432-93-4 217432-94-5 217432-95-6 217432-96-7 217432-97-8 217432-98-9 217432-99-0 217433-00-6 217433-01-7 217433-02-8 217433-03-9 217433-04-0 217433-05-1 217433-06-2 217433-07-3 217433-08-4 217433-09-5 217433-10-8 217433-11-9 217433-12-0 217433-13-1

217433-14-2 217433-15-3 217433-16-4 217433-17-5 217433-18-6
217433-19-7 217433-20-0 217433-21-1 217433-22-2 217433-23-3
217433-24-4 **217433-25-5**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lamprey LHRH-III and analogs as FSH-releasing peptides for use in enhancing or inhibiting fertility)

IT 9002-68-0, FSH 9034-38-2, FSH-releasing hormone
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(lamprey LHRH-III and analogs as FSH-releasing peptides for use in enhancing or inhibiting fertility)

RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Dees, W; Alcohol 1985, V2, P641 MEDLINE
(2) Dhariwal, A; Endocrinology 1965, V76, P290 HCAPLUS
(3) Dhariwal, A; Neuroendocrinology 1967, V2, P294 HCAPLUS
(4) Folkers; US 4721775 1988 HCAPLUS
(5) Igarashi, M; Endocrinology 1964, V74, P446 MEDLINE
(6) Lincoln, D; Endocrinology 1995, P218
(7) Lumpkin, M; Brain Res Bull 1987, V18, P175 HCAPLUS
(8) Lumpkin, M; Endocrinology 1984, V115, P2473 HCAPLUS
(9) McCann; US 09297989 1999
(10) McCann, S; Annals New York Academy of Sciences 1993, V687, P55 HCAPLUS
(11) Mizunuma, H; Life Sci 1983, V33, P2003 HCAPLUS
(12) Samson, W; Peptides 1980, V1, P97 HCAPLUS
(13) Schally, A; Endrocinology 1976, V98, P380 HCAPLUS
(14) Schally, A; Science 1971, V173, P1036 HCAPLUS
(15) Sower, S; Endocrinology 1993, V132, P1125 HCAPLUS
(16) Stopa, E; Peptides 1988, V9, P419 HCAPLUS
(17) Vale; US 4973577 1990 HCAPLUS
(18) Veber; US 3888836 1975 HCAPLUS
(19) Yu, W; Brain Res Bull 1990, V25, P867 HCAPLUS
(20) Yu, W; Proc Natl Acad Sci USA 1997, V94, P9499 HCAPLUS

IT **217433-25-5**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lamprey LHRH-III and analogs as FSH-releasing peptides for use in enhancing or inhibiting fertility)

L52 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2000:271945 HCAPLUS
DN 132:308660
ED Entered STN: 26 Apr 2000
TI Preparation of fluorescent peptides
IN Faure, Marie-Pierre; Vincent, Jean-Pierre; Gaudriault, Georges; Beaudet, Alain; Desjardins, Clarissa
PA Advanced Bioconcept, Inc., Can.
SO U.S., 16 pp., Cont.-in-part of U.S. Ser. No. 504,856, abandoned.
CODEN: USXXAM
DT Patent
LA English
IC ICM C07K007-00
INCL 530350000
CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1

FAN.CNT 9

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 6054557	A	20000425	US 1996-682810	19960710	<--
	US 5693679	A	19971202	US 1995-416007	19950404	<--
	US 5824772	A	19981020	US 1995-475751	19950607	<--
	WO 9801472	A1	19980115	WO 1997-CA481	19970707	<--

RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

```
     EP 920453            A1    19990609    EP 1997-929062          19970707 <--
         R:  CH, DE, FR, GB, LI, SE, FI
     US 6815423           B1    20041109    US 1999-285387          19990402 <--
     US 6821952           B1    20041123    US 1999-285422          19990402 <--
     US 6680367           B1    20040120    US 1999-356139          19990719 <--
     US 6677430           B1    20040113    US 2000-539593          20000331 <--
PRAI US 1995-416007       A2    19950404  <--
     US 1995-475751       A2    19950607  <--
     US 1995-504856       B2    19950720  <--
     US 1996-682810       A     19960710  <--
     WO 1997-CA481        W     19970707  <--
CLASS
 PATENT NO.       CLASS  PATENT FAMILY CLASSIFICATION CODES
 --------------   -----  ----------------------------------------------------
 US 6054557       ICM    C07K007-00
                  INCL   530350000
 US 6054557       NCL    530/350.000; 435/007.100; 530/302.000; 530/324.000
                  ECLA   C07K007/06B; C07K014/575G; C07K014/575L; G01N033/50D6;
                         G01N033/569H; C07K007/14; C07K014/575              <--
 US 5693679       NCL    530/311.000; 435/007.100
                  ECLA   C07K007/14; C07K014/575; C07K014/575G; C07K014/575L <--
 US 5824772       NCL    530/311.000; 435/007.100
                  ECLA   C07K007/14; C07K014/575; C07K014/575G; C07K014/575L <--
 WO 9801472       ECLA   C07K007/06B; C07K014/575                            <--
 US 6815423       NCL    514/015.000; 435/007.100; 530/327.000
                  ECLA   C07K007/06B; C07K007/14; C07K014/575; C07K014/575G;
                         C07K014/575L; G01N033/50D6; G01N033/569H           <--
 US 6821952       NCL    514/012.000; 435/007.100; 530/324.000
                  ECLA   C07K007/06B; C07K007/14; C07K014/575; C07K014/575G;
                         C07K014/575L; G01N033/50D6; G01N033/569H           <--
 US 6680367       NCL    530/350.000; 435/007.100; 530/324.000
                  ECLA   C07K007/06B; C07K014/575L; G01N033/50D6; G01N033/569H;
                         C07K007/14; C07K014/575; C07K014/575G              <--
 US 6677430       NCL    530/324.000; 435/007.100; 530/350.000
                  ECLA   C07K007/06B; C07K007/14; C07K014/575; C07K014/575G;
                         C07K014/575L; G01N033/50D6; G01N033/569H           <--
OS   MARPAT 132:308660
AB   Fluorescent peptides were prepared by attaching galanin or a galanin analog,
     derivative, or fragment to a light-emitting moiety through a CX bond (X = O,
     S, OH, CO, NH, H, alkoxy, NH, alkyl).  Thus, galanin and endothelin were
     attached to fluorescein via the lysyl ε-amino group via reaction
     with fluorescein N-hydroxysuccinimide ester.  The products retained their
     biol. activity and retained a high affinity for their resp. receptors.
ST   fluorescent peptide prepn
IT   Dyes
     Fluorescent substances
        (preparation of fluorescent peptides)
IT   Opioids
     Peptides, preparation
     RL: BAC (Biological activity or effector, except adverse); BSU (Biological
     study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
     BIOL (Biological study); PREP (Preparation); USES (Uses)
        (preparation of fluorescent peptides)
IT   Phycoerythrins
     RL: RCT (Reactant); RACT (Reactant or reagent)
        (preparation of fluorescent peptides)
IT   138039-55-1, Cascade Blue
     RL: RCT (Reactant); RACT (Reactant or reagent)
        (Cascade Blue; preparation of fluorescent peptides)
IT   122752-15-2DP, Deltorphin I, fluorescent derivs. 142689-18-7DP,
     fluorescent derivs.   184250-68-8P   184250-69-9P   187613-11-2P
     187613-15-6P   201998-65-4P   202075-15-8P   202075-16-9P   202075-17-0P
     202075-18-1P   202189-24-0P   202189-25-1P   202189-26-2P   202189-27-3P
     RL: BAC (Biological activity or effector, except adverse); BSU (Biological
     study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
     BIOL (Biological study); PREP (Preparation); USES (Uses)
```

(preparation of fluorescent peptides)
IT 81-88-9 91-64-5, Coumarin 2321-07-5, Fluorescein 10199-89-0
25535-16-4, Propidium iodide 47165-04-8, Dapi 82354-19-6, Texas red
82446-52-4, Lucifer yellow 114547-31-8, Rat galanin 117399-94-7, Human
endothelin 117548-22-8 117557-83-2 138026-71-8, Bodipy
143491-54-7, Ftc 146616-66-2 201998-61-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of fluorescent peptides)
RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Amoscato; Peptide Protein Res 1987, V29, P177 HCAPLUS
(2) Anon; DE 2702699 A1 1977 HCAPLUS
(3) Anon; EP 0240914 A2 1987 HCAPLUS
(4) Anon; EP 0333071 1988 HCAPLUS
(5) Anon; JP 63051400 1988 HCAPLUS
(6) Anon; EP 0331126 A2 1989 HCAPLUS
(7) Anon; EP 0466565 A1 1992 HCAPLUS
(8) Anon; WO 9304194 1993 HCAPLUS
(9) Anon; WO 9318068 1993 HCAPLUS
(10) Anon; EP 0606804 1994 HCAPLUS
(11) Anon; EP 0608987 1994
(12) Anon; WO 9522341 1995 HCAPLUS
(13) Anon; GB 2291708 1996 HCAPLUS
(14) Anon; WO 9631531 1996 HCAPLUS
(15) Anon; WO 9704311 1997 HCAPLUS
(16) Ashworth; Proc Natl Acad Sci USA 1995, V92, P512 HCAPLUS
(17) Bowden; Proc Natl Acad Sci USA 1994, V91, P8964 HCAPLUS
(18) Cardullo; Developmental Biology 1994, V162, P600 HCAPLUS
(19) Carraway; J of Biol Chem 1973, V248, P6854 HCAPLUS
(20) Cauvin; Regulatory Peptides 1991, V35, P161 HCAPLUS
(21) Chard; Laboratory Techniques in Biochemistry and Molecular Biology
(22) Cheng; FEBS Letters 1979, V100, P113 HCAPLUS
(23) Christophe; Biochimica et Biophysica Acta 1993, V1154, P183 HCAPLUS
(24) Keutel; US 4046633 1977 HCAPLUS
IT **142689-18-7DP**, fluorescent derivs.
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of fluorescent peptides)

L52 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1999:816983 HCAPLUS
DN 132:72858
ED Entered STN: 29 Dec 1999
TI Preparation of cobalt Schiff base compounds and their use in the
inhibition of enzymes and zinc finger-containing proteins
IN Meade, Thomas J.; Takeuchi, Toshihiko; Gray, Harry B.; Simon, Melvin;
Louie, Angelique Y.
PA California Institute of Technology, USA
SO U.S., 26 pp., Cont.-in-part of U.S. Ser. No. 358,068.
CODEN: USXXAM
DT Patent
LA English
IC ICM A61K031-295
ICS A61K031-70; A61K038-02; C12N009-99
INCL 514006000
CC 78-7 (Inorganic Chemicals and Reactions)
Section cross-reference(s): 1, 6, 7
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6008190	A	19991228	US 1995-570761	19951212 <--
	CA 2207748	AA	19960620	CA 1995-2207748	19951214 <--
	CA 2240183	AA	19970619	CA 1996-2240183	19961212 <--
	WO 9721431	A1	19970619	WO 1996-US19900	19961212 <--

W: AU, CA, IL, JP

```
        RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
     AU 9713336          A1    19970703    AU 1997-13336          19961212 <--
     AU 720841           B2    20000615
     EP 1021176          A1    20000726    EP 1996-944811         19961212 <--
        R:  AT, BE, CH, DE, DK, FR, GB, IT, LI, NL, SE
     JP 2001503376       T2    20010313    JP 1997-522239         19961212 <--
PRAI US 1994-358068      A2    19941215  <--
     US 1995-570761      A     19951212  <--
     WO 1996-US19900     W     19961212  <--
CLASS
 PATENT NO.       CLASS  PATENT FAMILY CLASSIFICATION CODES
 --------------   -----  ----------------------------------------------
 US 6008190       ICM    A61K031-295
                  ICS    A61K031-70; A61K038-02; C12N009-99
                  INCL   514006000
 US 6008190       NCL    514/006.000; 424/DIG.006; 435/184.000; 514/044.000;
                         514/501.000; 530/345.000; 530/400.000; 536/023.100;
                         556/032.000; 556/138.000; 556/146.000
                  ECLA   C07C251/12; C07C251/16; C07F015/06B; C07H021/00G    <--
 WO 9721431       ECLA   C07F015/06B; C07H021/00G                           <--
OS   MARPAT 132:72858
GI
```



I

AB The invention relates to the preparation of novel cobalt compds., having a general structure (I) wherein Co is either Co(II) or Co(III), and each of the R groups is selected from the group consisting of hydrogen, alkyl, hydrophilic organic acid, alkyl amine, amine, alkyl alc., alc., polypeptide or nucleic acid. The invention further relates to methods of using such compds. to reduce the biol. activity of proteins, particularly enzymes and zinc finger-containing proteins. Thus, [Co(III)(acacen)(NH3)2]Cl (H2acacen = Schiff base from the condensation of two acetylacetones with one ethylenediamine) and several related peptide coupled complexes were prepared and their inhibition of thrombin tested.

ST cobalt Schiff base prepn enzyme inhibitor; zinc finger protein inhibitor cobalt Schiff base; peptide Schiff base cobalt prepn enzyme inhibitor

IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(DNA-binding, zinc finger-containing; preparation of cobalt Schiff base complexes and their inhibition of enzymes and zinc-finger containing proteins)

IT Transcription factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(Sp1; preparation of cobalt Schiff base complexes and their inhibition of enzymes and zinc-finger containing proteins)

IT Schiff bases
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(cobalt complexes; preparation of cobalt Schiff base complexes and their inhibition of enzymes and zinc-finger containing proteins)

IT Enzymes, preparation
Nucleic acids

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(conjugates, with cobalt Schiff base complexes; preparation of cobalt Schiff base complexes and their inhibition of enzymes and zinc-finger containing proteins)

IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(nucleocapsid, retroviral, zinc-finger containing peptide of; preparation of cobalt Schiff base complexes and their inhibition of enzymes and zinc-finger containing proteins)

IT Enzymes, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(preparation of cobalt Schiff base complexes and their inhibition of enzymes and zinc-finger containing proteins)

IT Proteins, specific or class
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(with cobalt Schiff base complexes; preparation of cobalt Schiff base complexes and their inhibition of enzymes and zinc-finger containing proteins)

IT 9001-03-0, Carbonic anhydrase 9002-04-4, Thrombin 9073-78-3, Thermolysin
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(inhibition by cobalt Schiff base complexes)

IT 6310-76-5P 82427-19-8P 179555-40-9P 179555-48-7P 192700-54-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate in preparation of cobalt Schiff base complexes with protein inhibition activity)

IT 179555-42-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and coupling with peptides to give enzyme inhibitors)

IT 15907-18-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of cobalt Schiff base complexes and their inhibition of enzymes and zinc-finger containing proteins)

IT 7440-48-4DP, Cobalt, Schiff base complexes, preparation 179555-45-4P 179555-46-5P 179555-47-6P 192700-63-3P 252990-52-6P 253120-17-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of cobalt Schiff base complexes and their inhibition of enzymes and zinc-finger containing proteins)

IT 192700-58-6P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of cobalt Schiff base complexes and their inhibition of enzymes and zinc-finger containing proteins)

IT **179555-43-2**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); BIOL (Biological study); RACT (Reactant or reagent)
(reactant for preparation of cobalt Schiff base complexes with protein inhibition activity)

IT 107-15-3, 1,2-Ethanediamine, reactions 123-54-6, Acetylacetone, reactions 51568-18-4, 4,6-Dioxoheptanoic acid 57245-94-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant for preparation of cobalt Schiff base complexes with protein inhibition activity)

RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Anon; WO 96/18402 1996 HCAPLUS
(2) Beato, M; Cell 1989, V56, P335 HCAPLUS
(3) Berg, J; Acc Chem Res 1995, V28, P14 HCAPLUS
(4) Berg, J; Annu Rev Biophys Biophys Chem 1990, V19, P405 HCAPLUS
(5) Berg, J; Cell 1989, V57, P1065 HCAPLUS
(6) Berg, J; Current Opinion in Structural Biology 1993, V3, P11 HCAPLUS
(7) Berg, J; Proc Natl Acad Sci USA 1992, V89, P11109 HCAPLUS
(8) Berg, J; Prog Inorg Chem 1989, V37, P143 HCAPLUS
(9) Berg, J; Science 1986, V232, P485 HCAPLUS
(10) Bhattacharya; J Chem Soc Commun 1995, V24, P2489
(11) Dannull; The Embo Journal 1944, V13(7), P1525
(12) Dori; US 4866053 1989 HCAPLUS
(13) Dori; US 4866054 1989 HCAPLUS
(14) Dori; US 5049557 1991 HCAPLUS
(15) Dori; US 5142076 1992 HCAPLUS
(16) El Absy; Revue Roumaine de Chimie 1982, V27(8), P917 HCAPLUS
(17) Evans; Cell 1988, V52, P1 HCAPLUS
(18) Evans, R; Science 1988, V240, P889 HCAPLUS
(19) Freedman; Nature 1988, V334, P543 HCAPLUS
(20) Fujii; 1975 HCAPLUS
(21) Fujii; J Sci Hiroshima Univ Ser A 1974, V38(2-3), P313 HCAPLUS
(22) Grinstaff; US 5880149 1999 HCAPLUS
(23) Hawthorne; US 5324879 1994 HCAPLUS
(24) Kaptein, R; Current Opinion in structural Biology 1993, V3, P50 HCAPLUS
(25) Lonsdale; US 4948506 1990 HCAPLUS
(26) Marcu; Revue Roumaine de Chimie 1989, V34(4), P1029 HCAPLUS
(27) Norman; US 4735634 1988 HCAPLUS
(28) Ranford; J Chem Soc Dalton Trans 1993, P3393 HCAPLUS
(29) Reisenhofer; 1981
(30) Roman; US 4451270 1984 HCAPLUS
(31) Sakaguchi; Proc Natl Acad Sci USA 1993, V90, P5219 HCAPLUS
(32) Scheer; US 5106841 1992 HCAPLUS
(33) Scheer; US 5210096 1993 HCAPLUS
(34) Sievers; US 4514522 1985 HCAPLUS
(35) Spiratos; 1984 HCAPLUS
(36) Ware; J Med Chem 1993, V36, P1839 HCAPLUS
IT **179555-43-2**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); BIOL (Biological study); RACT (Reactant or reagent)
(reactant for preparation of cobalt Schiff base complexes with protein inhibition activity)

L52 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1999:426832 HCAPLUS
DN 131:82975
ED Entered STN: 12 Jul 1999
TI μ-Opioid receptor ligands: agonists and antagonists
IN Dooley, Colette T.; Houghten, Richard A.
PA Torrey Pines Institute for Molecular Studies, USA
SO U.S., 92 pp.
CODEN: USXXAM
DT Patent
LA English
IC ICM C07K005-00
INCL 530330000
CC 1-11 (Pharmacology)
Section cross-reference(s): 2
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5919897	A	19990706	US 1995-488659	19950607 <--
PRAI	US 1995-488659		19950607 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 5919897	ICM	C07K005-00
	INCL	530330000
US 5919897	NCL	530/330.000; 260/998.200; 514/018.000; 514/019.000; 530/331.000; 530/345.000
	ECLA	C07K014/665 <--

OS MARPAT 131:82975

AB Opioid peptides are provided. Disclosed are opioid peptides having the general structures Ac-Phe-Arg-Trp-Trp-Tyr-Xaa-NH2; Ac-Arg-Trp-Ile-Gly-Trp-Xaa-NH2; Trp-Trp-Pro-Lys-His-Xaa-NH2; and shorter versions of the latter, namely, Trp-Trp-Pro-Xaa-NH2; Tyr-Pro-Phe-Gly-Phe-Xaa-NH2; (D)Ile-(D)Met-(D)Ser-(D)Trp-(D)Trp-Glyn -Xaa-NH2; and (D)Ile-(D)Met-(D)Thr-(D)Trp-Gly-Xaa-NH2. Within each genus, Xaa is substituted by a specific amino acid. The invention also relates to an opioid peptide having the general structure Tyr-A1-B2-C3-NH2, wherein A is D-Nve or D-Nle, B is Gly, Phe, or Trp, and C is Trp or Nap. Also included within the invention are opioid peptides of the general structure MexHyN-Tyr-Tyr-Phem-Pron-NH2, which are peptides modified by permethylation, perallylation, perethylation, perbenzylation and/or pernaphthylation and which can be further modified by reduction Compds. of the invention are useful for the study of opiate ligand-receptor interactions and for therapeutic applications.

ST mu opioid receptor agonist antagonist peptide

IT Structure-activity relationship
(opioid receptor-binding; μ-opioid receptor agonist and antagonist peptides)

IT Opioid receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(κ-opioid; μ-opioid receptor agonist and antagonist peptides)

IT Opioid receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(δ-opioid; μ-opioid receptor agonist and antagonist peptides)

IT Opioids
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(μ-; μ-opioid receptor agonist and antagonist peptides)

IT Peptides, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(μ-opioid receptor agonist and antagonist peptides)

IT Opioid antagonists
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(μ-opioid; μ-opioid receptor agonist and antagonist peptides)

IT Opioid receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(μ-opioid; μ-opioid receptor agonist and antagonist peptides)

IT 9012-42-4, Adenyl cyclase
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(μ-opioid receptor agonist and antagonist peptides)

IT 186655-59-4P 186655-60-7P 186655-61-8P 186655-62-9P 186655-63-0P
186655-66-3P 186655-68-5P 186655-70-9P 186655-72-1P 186655-74-3P
186655-76-5P 186655-78-7P 186655-79-8P 186655-80-1P 186655-81-2P
186655-82-3P 186655-83-4P 186655-84-5P 186655-85-6P 186655-86-7P
186655-87-8P 186655-88-9P 186655-89-0P 186655-91-4P 186655-92-5P
186655-94-7P 186655-95-8P 186655-96-9P 186655-97-0P 186655-98-1P
186656-02-0P 186656-03-1P 186656-04-2P 186656-05-3P 186656-06-4P
186656-07-5P 186656-08-6P 186656-09-7P 186656-10-0P 186656-11-1P

186656-12-2P 186656-13-3P 192126-43-5P 192126-44-6P 192126-45-7P
229466-88-0P 229466-89-1P 229466-90-4P 229466-91-5P 229466-92-6P
229466-93-7P 229466-94-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(μ-opioid receptor agonist and antagonist peptides)

IT 20240-32-8D, derivs. 58822-25-6, 1-5-β-Neoendorphin (human)
117756-23-7D, derivs. 152274-67-4 164117-54-8 164117-55-9
164117-56-0 164117-57-1 164117-58-2 164117-59-3 164117-60-6
164117-61-7 164117-62-8 164117-63-9 164117-64-0 164117-65-1
164117-66-2 164117-67-3 164117-68-4 164117-69-5 164117-70-8
164117-71-9 164117-72-0 164117-73-1 164117-74-2 164117-75-3
164117-76-4 164117-77-5 164117-78-6 164117-79-7 164117-80-0
164117-81-1 164117-82-2 164117-83-3 164117-84-4 164117-85-5
164117-86-6 164117-87-7 164117-88-8 164117-89-9 164117-90-2
164117-91-3 164117-92-4 164117-93-5 171807-45-7 171807-46-8
171807-49-1 171807-50-4 186654-16-0 186654-17-1 186654-18-2
186654-19-3 186654-20-6 186654-21-7 186654-22-8 186654-23-9
186654-24-0 186654-25-1 186654-26-2 186654-28-4 186654-30-8
186654-32-0 186654-34-2 186654-36-4 186654-38-6 186654-40-0
186654-42-2 186654-44-4 **186654-69-3 186654-70-6**
186654-71-7 186654-72-8 186654-73-9 186654-74-0 186654-75-1
186654-76-2 186654-77-3 186654-78-4 186654-79-5 186654-80-8
186654-81-9 186654-82-0 186654-83-1 186654-84-2 186654-85-3
186654-86-4 186654-87-5 186654-88-6 186654-89-7 186654-90-0
186654-91-1 186654-92-2 186654-93-3 186654-94-4 186654-95-5
186654-96-6 186654-97-7 186654-98-8 186654-99-9 186655-00-5
186655-01-6 186655-02-7 186655-03-8 186655-04-9 186655-05-0
186655-06-1 186655-07-2 186655-08-3 186655-09-4 186655-10-7
186655-11-8 186655-12-9 186655-13-0 186655-14-1 186655-15-2
186655-16-3 186655-17-4 186655-18-5 186655-19-6 186655-20-9
186655-21-0 186655-22-1 186655-23-2 186655-24-3 186655-25-4
186655-26-5 186655-27-6 186655-28-7 186655-29-8 186655-30-1
186655-31-2 186655-32-3 186655-33-4 186655-34-5 186655-35-6
186655-36-7 186655-37-8 186655-38-9 186655-39-0 186655-40-3
186655-41-4 186655-42-5 186655-43-6 186655-44-7 186655-45-8
186655-46-9 186655-47-0 186655-48-1 186655-49-2 186655-50-5
186655-51-6 186655-52-7 186655-53-8 186655-54-9 186655-55-0
186655-56-1 186655-57-2 186655-58-3 229466-95-9 229466-96-0D, derivs. 229466-97-1D, derivs. 229466-98-2D, derivs. 229466-99-3D, derivs.
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(μ-opioid receptor agonist and antagonist peptides)

RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Anon; STN International Fast Notes
(2) Blondelle; Trends in Analytical Chem 1995, V14(2), P83 HCAPLUS
(3) Charpentier; Biochem Biophys Res Commun 1991, V179(3), P1161 HCAPLUS
(4) Dooley; US 5367053 1994 HCAPLUS
(5) Dooley; Life Science 1993, V52, P1509 HCAPLUS
(6) Dooley; Peptides 94: Proceedings of the 23rd European Peptide Symposium 1995
(7) Dooley; Proc Natl Acad Sci USA 1993, V90, P10811 HCAPLUS
(8) Dooley; Regulatory Peptides 1994, V54, P87 HCAPLUS
(9) Dooley; Science 1994, V266, P2019 HCAPLUS
(10) Erchegyi; Peptides 1992, V13, P623 HCAPLUS
(11) Houghten; US 5480971 1996 HCAPLUS
(12) Houghten; BioMed Chem Lett 1993, V3, P405 HCAPLUS
(13) Hruby; Medicinal Res Rev 1989, V9(3), P343 HCAPLUS
(14) Ostresh; Proc Natl Acad Sci USA 1994, V91, P11138
(15) Schiller; US 5455230 1995 HCAPLUS
(16) Schiller; Biochem and Biophys Res Comm 1978, V85(4), P1332 HCAPLUS

(17) Schiller, P; Progress in Medicinal Chem 1991, V28, P301 HCAPLUS
IT **186654-69-3 186654-70-6**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(μ-opioid receptor agonist and antagonist peptides)

L52 ANSWER 16 OF 33 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1999:384006 HCAPLUS
DN 131:13990
ED Entered STN: 22 Jun 1999
TI Methods and peptides for the treatment of non-IgE-mediated diseases
IN Hahn, Gary S.
PA Dura Pharmaceuticals, Inc., USA
SO U.S., 14 pp., Cont.-in-part of U.S. Ser. No. 942,671.
CODEN: USXXAM
DT Patent
LA English
IC ICM A61K038-00
ICS A61K038-02; C07K005-00; C07K007-00
INCL 514017000
CC 1-7 (Pharmacology)
Section cross-reference(s): 62, 63
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 5912233	A	19990615	US 1995-462304	19950605	<--
	US 5468730	A	19951121	US 1992-942671	19920908	<--
PRAI	US 1992-878867	A1	19920505	<--		
	US 1992-942671	A2	19920908	<--		
	US 1989-382623	A2	19891123	<--		
	US 1989-411489	B2	19891123	<--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES	
US 5912233	ICM	A61K038-00	
	ICS	A61K038-02; C07K005-00; C07K007-00	
	INCL	514017000	
US 5912233	NCL	514/017.000; 530/330.000	
	ECLA	C07K005/08C1; C07K005/10A1A; C07K005/10A1F; C07K005/10C1; C07K005/10H; C07K016/00	<--
US 5468730	NCL	514/017.000; 530/330.000	
	ECLA	C07K005/10A1A; C07K005/10A1F; C07K005/10C1; C07K005/10H; C07K016/00; C07K016/06A	<--

OS MARPAT 131:13990
AB Methods and compns. for the treatment of non-Ige-mediated inflammatory response or disease conditions are described. The methods and compns. use peptides Asp-Ser-Asp-Pro-Arg and Asp-Ser-Asn-Pro-Arg and derivatized forms thereof.
ST inflammation inhibitor peptide
IT Immunoglobulins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(E; peptides for treatment of non-IgE-mediated diseases)
IT Intestine, disease
(colitis; peptides for treatment of non-IgE-mediated diseases)
IT Allergy
(delayed hypersensitivity; peptides for treatment of non-IgE-mediated diseases)
IT Intestine, disease
(inflammatory; peptides for treatment of non-IgE-mediated diseases)
IT Disease, animal
(irritation, non-IgE-mediated; peptides for treatment of non-IgE-mediated diseases)
IT Inflammation
(non-IgE-mediated; peptides for treatment of non-IgE-mediated diseases)
IT Urticaria

(non-allergic; peptides for treatment of non-IgE-mediated diseases)
IT Anti-inflammatory agents
Cosmetics
Drug delivery systems
(peptides for treatment of non-IgE-mediated diseases)
IT Peptides, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peptides for treatment of non-IgE-mediated diseases)
IT Toxoids
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(tetanus, delayed-type hypersensitivity induced by; peptides for treatment of non-IgE-mediated diseases)
IT Drug delivery systems
(topical; peptides for treatment of non-IgE-mediated diseases)
IT 9000-07-1, Carrageenan
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(inflammation induced by; peptides for treatment of non-IgE-mediated diseases)
IT 62087-72-3 62087-72-3D, derivs. 62510-55-8D, derivs. 62510-55-8D, derivs. **226714-12-1 226714-20-1** 226714-26-7
226714-34-7
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peptides for treatment of non-IgE-mediated diseases)
RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Hahn; US 5468730 1995 HCAPLUS
IT **226714-12-1 226714-20-1**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peptides for treatment of non-IgE-mediated diseases)

L52 ANSWER 17 OF 33 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1998:604687 HCAPLUS
DN 129:241779
ED Entered STN: 24 Sep 1998
TI Human procollagen C proteinase and peptide substrates for its determination
IN Brenner, Mitch
PA Fibrogen Inc., USA
SO U.S., 19 pp.
CODEN: USXXAM
DT Patent
LA English
IC ICM A61K038-04
ICS A61K038-00; C07K001-00
INCL 530327000
CC 7-2 (Enzymes)
Section cross-reference(s): 1
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5807981	A	19980915	US 1995-572225	19951213 <--
PRAI US 1995-572225		19951213 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 5807981	ICM	A61K038-04
	ICS	A61K038-00; C07K001-00
	INCL	530327000

US 5807981 NCL 530/327.000; 530/328.000; 530/345.000; 530/409.000; 530/410.000
ECLA C07K014/78 <--

AB Human procollagen C proteinase is characterized and substrate peptides developed. These substrates can be used to identify modulators of enzyme function. Similarly, peptide analogs of substrates that can be used to inhibit the enzyme are also described. These peptides may be used in the treatment of disorders associated with unregulated production of collagen.

ST peptide substrate procollagen C proteinase human

IT Drug screening
(for modulators of procollagen C proteinase; human procollagen C proteinase and peptide substrates for its determination)

IT Protein sequences
(of procollagen C proteinase of human; human procollagen C proteinase and peptide substrates for its determination)

IT Collagens, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(procollagens, type I, procollagen C proteinase assay substrates derived from; human procollagen C proteinase and peptide substrates for its determination)

IT Collagens, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(procollagens, type III, procollagen C proteinase assay substrates derived from; human procollagen C proteinase and peptide substrates for its determination)

IT Peptides, properties
RL: ARU (Analytical role, unclassified); PRP (Properties); ANST (Analytical study)
(substrates for procollagen C proteinase; human procollagen C proteinase and peptide substrates for its determination)

IT Collagens, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(α1 and α2 subunits, procollagen C proteinase assay substrates derived from; human procollagen C proteinase and peptide substrates for its determination)

IT 213184-60-2
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; human procollagen C proteinase and peptide substrates for its determination)

IT 212955-49-2 212955-54-9 212955-61-8 212955-65-2
212955-71-0 212955-74-3 212955-83-4 212955-88-9 212955-94-7
212955-97-0 212956-00-8 212956-04-2 212956-08-6 212956-13-3
RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)
(as substrate for procollagen C proteinase; human procollagen C proteinase and peptide substrates for its determination)

IT 68651-95-6, Procollagen C proteinase
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(human procollagen C proteinase and peptide substrates for its determination)

IT 153216-21-8 212956-20-2
RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)
(peptides containing, as substrate for procollagen C proteinase; human procollagen C proteinase and peptide substrates for its determination)

RE.CNT 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Ala-Kokko; Biochem J 1989, V260, P509 HCAPLUS
(2) Anon; WO PCTUS8701537 1988
(3) Bitter; Methods in Enzymol 1987, V153, P516 HCAPLUS
(4) Bond; Protein Science 1995, V4, P1247 HCAPLUS
(5) Bornstein; The Proteins 1979, P412
(6) Brisson; Nature 1984, V310, P511 HCAPLUS
(7) Broglie; Science 1984, V224, P838 HCAPLUS
(8) Caruthers; Nucleic Acids Res Symp Ser 1980, V7, P215 HCAPLUS

(9) Chow; Nucleic Acids Res 1981, V9, P2807 HCAPLUS
(10) Colberre-Garapin; J Mol Biol 1981, V150, P1
(11) Coruzzi; EMBO J 1984, V3, P1671 HCAPLUS
(12) Crea; Nucleic Acids Res 1980, V9, P2331
(13) Davidson; Eur J Biochem 1979, V100, P551 HCAPLUS
(14) Duskin; Arch Biochem Biophys 1978, V185, P326
(15) Fessler; Annu Rev Biochem 1978, V47, P129 HCAPLUS
(16) Fukagawa; Developmental Biology 1994, V163, P175 HCAPLUS
(17) Goldberg; Cell 1975, V4, P45 HCAPLUS
(18) Gurley; Mol Cell Biol 1986, V6, P559 HCAPLUS
(19) Hartman; Proc Natl Acad Sci USA 1988, V85, P8047 HCAPLUS
(20) Hojima; J Biol Chem 1985, V260, P15996 HCAPLUS
(21) Inouye; Nucleic Acids Res 1985, V13, P3101 HCAPLUS
(22) Kessler; Anal Biochem 1978, V86, P463 HCAPLUS
(23) Kessler; Collagen Relat Res 1986, V6, P249 HCAPLUS
(24) Kessler; Eur J Biochem 1989, V186, P115 HCAPLUS
(25) Kivirikko; Extracellular Matrix Biochemistry 1984, P83
(26) Kuhn; Structure and Function of Collagen Types 1987, P1 HCAPLUS
(27) Leung; J Biol Chem 1979, V254, P224 HCAPLUS
(28) Logan; Proc Natl Acad Sci USA 1984, V81, P3655 HCAPLUS
(29) Lowy; Cell 1980, V22, P817 HCAPLUS
(30) Mackett; J Virol 1984, V49, P857 HCAPLUS
(31) Mackett; Proc Natl Acad Sci USA 1982, V79, P7415 HCAPLUS
(32) Mangel; US 4640893 1987 HCAPLUS
(33) Matteucci; Tetrahedron Letters 1980, V21, P719 HCAPLUS
(34) Miyazono; J Biol Chem 1988, V263, P6407 HCAPLUS
(35) Mulligan; Proc Natl Acad Sci USA 1981, V78, P2072 HCAPLUS
(36) Ngyen; Developmental Biology 1994, V166, P569
(37) Njieha; Biochemistry 1982, V21, P757 HCAPLUS
(38) O'Hare; Proc Natl Acad Sci USA 1981, V78, P1527 HCAPLUS
(39) Panicali; Proc Natl Sci USA 1982, V79, P4927 HCAPLUS
(40) Prockop; N Engl J Med 1984, V311, P376 MEDLINE
(41) Ruther; EMBO J 1983, V2, P1791 MEDLINE
(42) Ryhanen; Arch Biochem Biophys 1982, V215, P230 HCAPLUS
(43) Santerre; Gene 1984, V30, P147 HCAPLUS
(44) Smith; J Viol 1983, V46, P584 HCAPLUS
(45) Szybalska; Proc Natl Acad Sci USA 1962, V48, P2026 MEDLINE
(46) Takahara; J Biol Chem 1994, V269, P26280 HCAPLUS
(47) Takamatsu; EMBO J 1987, V6, P307 HCAPLUS
(48) Titany; Biochemistry 1987, V26, P222
(49) van Heeke; J Biol Chem 1989, V264, P5503 HCAPLUS
(50) Wang; US 4877864 1989 HCAPLUS
(51) Wang; US 5108922 1992 HCAPLUS
(52) Wigler; Cell 1977, V11, P223 HCAPLUS
(53) Wigler; Proc Natl Acad Sci USA 1980, V77, P3567 HCAPLUS
(54) Wozney; Science 1988, V242, P1528 HCAPLUS
(55) Yaron; Analytical Biochemistry 1979, V95, P228 HCAPLUS

IT **212955-65-2**
RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)
(as substrate for procollagen C proteinase; human procollagen C proteinase and peptide substrates for its determination)

L52 ANSWER 18 OF 33 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1998:457248 HCAPLUS
DN 129:104211
ED Entered STN: 23 Jul 1998
TI Platelet factor 4-related anti-inflammatory peptides
IN Counts, David F.; Duff, Ronald G.
PA Curative Health Services, Inc., USA
SO U.S., 55 pp., Cont.-in-part of U. S. Ser. No. 80,371, abandoned.
CODEN: USXXAM
DT Patent
LA English
IC ICM A61K038-07
ICS A61K038-08; A61K038-12; C07K007-06

INCL 514011000
CC 1-7 (Pharmacology)
Section cross-reference(s): 63
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 5776892	A	19980707	US 1994-259550	19940616	<--
	US 5470831	A	19951128	US 1993-37486	19930324	<--
PRAI	US 1990-631823	B1	19901221	<--		
	US 1993-37486	A2	19930324	<--		
	US 1993-80371	B2	19930618	<--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES	
US 5776892	ICM	A61K038-07	
	ICS	A61K038-08; A61K038-12; C07K007-06	
	INCL	514011000	
US 5776892	NCL	514/011.000; 514/015.000; 514/016.000; 514/017.000; 514/018.000; 530/317.000; 530/327.000; 530/328.000; 530/329.000; 530/330.000; 530/345.000	
	ECLA	C07K005/10A1B; C07K014/52; C07K014/52A1	<--
US 5470831	NCL	514/016.000; 514/015.000; 514/017.000; 514/018.000; 530/328.000; 530/329.000; 530/330.000	
	ECLA	C07K005/10A1B; C07K014/52	<--

OS MARPAT 129:104211
AB Peptides, peptide analogs and peptide derivs. related to platelet factor 4 are disclosed which exhibit anti-inflammatory activity, as are pharmaceutical compns. comprising the peptides and methods of inhibiting inflammation using the peptides.
ST platelet factor 4 peptide antiinflammatory
IT Neutrophil
(chemotaxis; platelet factor 4-related anti-inflammatory peptides)
IT Allergy
(delayed hypersensitivity; platelet factor 4-related anti-inflammatory peptides)
IT Structure-activity relationship
(inflammation-inhibiting; platelet factor 4-related anti-inflammatory peptides)
IT Lung, disease
(inflammation; platelet factor 4-related anti-inflammatory peptides)
IT Drug delivery systems
(injections, s.c.; platelet factor 4-related anti-inflammatory peptides)
IT Connective tissue
(mixed connective tissue disease; platelet factor 4-related anti-inflammatory peptides)
IT Chemotaxis
(neutrophil; platelet factor 4-related anti-inflammatory peptides)
IT Drug delivery systems
(oral; platelet factor 4-related anti-inflammatory peptides)
IT Peritoneum
(peritonitis; platelet factor 4-related anti-inflammatory peptides)
IT Anti-inflammatory agents
Antirheumatic agents
Autoimmune disease
Drug delivery systems
Lymphocyte
Macrophage
Neutrophil
Protein sequences
(platelet factor 4-related anti-inflammatory peptides)
IT Peptides, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(platelet factor 4-related anti-inflammatory peptides)

IT Connective tissue
(scleroderma; platelet factor 4-related anti-inflammatory peptides)
IT Drug delivery systems
(solns., i.p.; platelet factor 4-related anti-inflammatory peptides)
IT Lupus erythematosus
(systemic; platelet factor 4-related anti-inflammatory peptides)
IT Intestine, disease
(ulcerative colitis; platelet factor 4-related anti-inflammatory peptides)
IT 63940-02-3, Blood platelet factor 4 (human reduced)
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)
(amino acid sequence; platelet factor 4-related anti-inflammatory peptides)
IT 9003-99-0, Myeloperoxidase
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(platelet factor 4-related anti-inflammatory peptides)
IT 144207-60-3 144207-61-4 144207-62-5 144207-63-6 144207-64-7
144207-65-8 144207-66-9 144207-67-0 162040-22-4 162040-22-4D, derivs. and analogs 162040-23-5 162040-23-5D, derivs. and analogs
162040-24-6 162040-24-6D, derivs. and analogs 162051-59-4
162051-59-4D, derivs. and analogs 162051-60-7 162051-60-7D, derivs. and analogs 162051-61-8 162051-61-8D, derivs. and analogs
162051-62-9 162051-62-9D, derivs. and analogs 162051-64-1
162051-64-1D, derivs. and analogs 162051-68-5 162051-68-5D, derivs. and analogs 162051-69-6 162051-69-6D, derivs. and analogs
162051-70-9 162051-70-9D, derivs. and analogs 162051-74-3
162051-74-3D, derivs. and analogs 162051-76-5 162051-76-5D, derivs. and analogs 162051-78-7 162051-78-7D, derivs. and analogs
162051-79-8 162051-79-8D, derivs. and analogs 162051-80-1
162051-80-1D, derivs. and analogs 162051-81-2 162051-81-2D, derivs. and analogs 162051-83-4 162051-83-4D, derivs. and analogs
162051-85-6 162051-85-6D, derivs. and analogs 162051-89-0
162051-89-0D, derivs. and analogs 162051-90-3 162051-90-3D, derivs. and analogs 162051-91-4 162051-91-4D, derivs. and analogs
162051-92-5 162051-92-5D, derivs. and analogs 162051-93-6
162051-93-6D, derivs. and analogs 162051-94-7 162051-94-7D, derivs. and analogs 162051-95-8 162051-95-8D, derivs. and analogs
162051-96-9 162051-97-0 162051-97-0D, derivs. and analogs
162051-98-1 162051-98-1D, derivs. and analogs 162051-99-2
162051-99-2D, derivs. and analogs 162052-00-8 162052-00-8D, derivs. and analogs 162052-02-0 162052-02-0D, derivs. and analogs
162052-03-1 162052-03-1D, derivs. and analogs 162052-04-2
162052-04-2D, derivs. and analogs 162071-40-1 162071-40-1D, derivs. and analogs 162071-41-2 **162071-42-3 162071-80-9**
210092-69-6 210092-69-6D, derivs. and analogs 210092-70-9
210092-70-9D, derivs. and analogs 210092-71-0 210092-71-0D, derivs. and analogs 210092-72-1 210092-72-1D, derivs. and analogs
210092-73-2 210092-73-2D, derivs. and analogs 210092-74-3
210092-74-3D, derivs. and analogs 210092-75-4 210092-75-4D, derivs. and analogs 210092-76-5 210092-76-5D, derivs. and analogs
210092-77-6 210092-77-6D, derivs. and analogs 210092-78-7
210092-78-7D, derivs. and analogs 210092-79-8 210092-79-8D, derivs. and analogs 210092-80-1 210092-80-1D, derivs. and analogs
210092-81-2 210092-82-3 210092-83-4 210092-84-5 210092-86-7
210092-87-8 210092-88-9 210092-89-0 210092-90-3 210092-91-4
210092-92-5 210092-93-6 210092-94-7 210092-95-8 210092-96-9
210092-97-0 210092-98-1 210092-99-2 210093-00-8 210093-01-9
210093-02-0 210093-03-1 210093-04-2 210093-05-3 210093-06-4
210093-07-5 210093-08-6 210093-09-7 210093-10-0 210093-11-1
210093-12-2 210093-13-3 210093-14-4 210093-15-5 210093-16-6
210093-17-7
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)
(platelet factor 4-related anti-inflammatory peptides)
IT 363-24-6, PGE2 71160-24-2, LTB4
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(platelet factor 4-related anti-inflammatory peptides)
RE.CNT 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Anon; EP 0378364 1990 HCAPLUS
(2) Anon; WO 9211021 1992 HCAPLUS
(3) Banda; Proc Natl Acad Sci USA 1982, V79, P7773 HCAPLUS
(4) Barone; J Neurosci Res 1991, V29, P336 MEDLINE
(5) Bebawy; J Leukocyte Biol 1986, V39, P423 HCAPLUS
(6) Bernstein; J Cell Sci 1982, V56, P71 HCAPLUS
(7) Blackwell; Nature 1980, V287, P147 HCAPLUS
(8) Borovsky; US 5358934 1994 HCAPLUS
(9) Brown; US 5141851 1992 HCAPLUS
(10) Browne; Surg Gynecol Obstet 1976, V143, P738 MEDLINE
(11) Broxmeyer; J Immunol 1993, V150, P3448 HCAPLUS
(12) Cella; Folia Haematol 1986, V113, P646 MEDLINE
(13) Ciaglowski; Arch Biochem and Biophys 1986, V250, P249 HCAPLUS
(14) Cortellaro; Thromb Res 1990, V58, P571 MEDLINE
(15) Diezel; J Invest Dermatol 1989, V93, P322 HCAPLUS
(16) Doherty; J Invest Derm 1988, V91, P298 HCAPLUS
(17) Edgington; Bio/Technol 1993, V11, P676 HCAPLUS
(18) Eisman; Blood 1990, V76, P336 HCAPLUS
(19) Filipp; Allergy 1984, V39, P499 HCAPLUS
(20) Freidinger; US 4703034 1987 HCAPLUS
(21) Fuhrer; US 4719288 1988 HCAPLUS
(22) Gimbrone; J Nat'l Cancer Inst 1974, V52, P413
(23) Griswold; Biochem Pharmacol 1991, V42, P825 HCAPLUS
(24) Guastamacchia; Boll Soc It Biol 1985, V61, P499 MEDLINE
(25) Hahn; US 4816449 1989 HCAPLUS
(26) Hanna; Drugs Exptl Clin Res 1990, V16, P137 HCAPLUS
(27) Johansson; Acta Derm Venereol (Stockh) 1993, V73, P401 MEDLINE
(28) Johansson; Acta Derm Venereol (Stockh) 1994, V74, P106 MEDLINE
(29) Konishi; US 4461724 1984 HCAPLUS
(30) Kragballe; Curr Probl Derm 1985, V13, P1 MEDLINE
(31) Kuna; US 5436222 1995 HCAPLUS
(32) Maione; US 5086164 1992 HCAPLUS
(33) Medici; Thromb Res 1989, V54, P277 HCAPLUS
(34) Morgan; US 4585755 1986 HCAPLUS
(35) Obal; Am J Physiol 1990, V259, PR439 HCAPLUS
(36) Rybak; Blood 1989, V73, P1534 HCAPLUS
(37) Schmitz-Huebner; Thromb Res 1984, V34, P277 MEDLINE
(38) Twardzik; US 4645828 1987 HCAPLUS
(39) Verdini; US 4816560 1989 HCAPLUS
(40) Weerasinghe; Thromb Res 1984, V33, P625 HCAPLUS
(41) Wei; Annu Rev Pharmacol Toxicol 1993, V33, P91 HCAPLUS
(42) Whitman; US 5470831 1995 HCAPLUS
(43) Widmer; US 5411942 1995 HCAPLUS
(44) Wiedeman; US 5386011 1995 HCAPLUS
(45) Wooley; Meth Enzym 1988, V162, P361 HCAPLUS
(46) Young; J Invest Derm 1984, V82, P367 HCAPLUS
(47) Zucker; Proc Natl Acad Sci USA 1989, V86, P7571 HCAPLUS
IT **162071-42-3 162071-80-9**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(platelet factor 4-related anti-inflammatory peptides)

L52 ANSWER 19 OF 33 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1998:430094 HCAPLUS
DN 129:90879
ED Entered STN: 13 Jul 1998
TI Peptide ligands for the erythropoietin receptor that act as erythropoietin

agonists
IN Wrighton, Nicholas C.; Dower, William J.; Chang, Ray S.; Kashyap, Arun K.; Jolliffe, Linda K.; Johnson, Dana; Mulcahy, Linda
PA Affymax Technologies N.V., UK
SO U.S., 103 pp., Cont.-in-part of U. S. Ser. No. 155,940, abandoned.
CODEN: USXXAM
DT Patent
LA English
IC ICM C07K007-00
ICS C12N015-09
INCL 530300000
CC 2-10 (Mammalian Hormones)
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 5773569	A	19980630	US 1995-484635	19950607	<--
	CA 2223833	AA	19961219	CA 1996-2223833	19960607	<--
	WO 9640749	A1	19961219	WO 1996-US9810	19960607	<--
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG					
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA					
	AU 9661667	A1	19961230	AU 1996-61667	19960607	<--
	AU 712713	B2	19991111			
	CN 1192748	A	19980909	CN 1996-196094	19960607	<--
	EP 886648	A1	19981230	EP 1996-919296	19960607	<--
	EP 886648	B1	20031112			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
	JP 11507367	T2	19990629	JP 1996-502023	19960607	<--
	BR 9609006	A	19991214	BR 1996-9006	19960607	<--
	TR 9701557	T2	20020621	TR 1997-9701557	19960607	<--
	PL 185040	B1	20030228	PL 1996-323858	19960607	<--
	AT 254138	E	20031115	AT 1996-919296	19960607	<--
	ES 2210374	T3	20040701	ES 1996-919296	19960607	<--
	EP 1510524	A2	20050302	EP 2003-25811	19960607	<--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
	US 5986047	A	19991116	US 1997-827570	19970328	<--
	NO 9705729	A	19980205	NO 1997-5729	19971205	<--
PRAI	US 1993-155940	B2	19931119	<--		
	US 1995-484631	A	19950607	<--		
	US 1995-484635	A	19950607	<--		
	EP 1996-919296	A3	19960607	<--		
	WO 1996-US9810	W	19960607	<--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES	
US 5773569	ICM	C07K007-00	
	ICS	C12N015-09	
	INCL	530300000	
US 5773569	NCL	530/300.000; 435/069.100; 530/324.000; 530/325.000; 530/326.000; 530/327.000; 530/328.000	
	ECLA	C07K014/505	<--
WO 9640749	ECLA	C07K014/505	<--
US 5986047	NCL	530/300.000; 530/323.000; 530/324.000; 530/325.000; 530/326.000; 530/327.000; 530/328.000	
	ECLA	C07K014/505	<--

OS MARPAT 129:90879
AB Peptides of 10 to 40 or more amino acids that bind and activate the erythropoietin receptor (EPO-R) or otherwise act as an EPO agonist for therapeutic uses are described. Peptides were identified by screening of libraries prepared using degenerate oligonucleotides to construct a phage display library that was screened by panning with the receptor. Candidate

peptides were synthesized as C-terminal amide derivs by standard Fmoc on PAL resins and tested for biol. activity. Many peptides showed greater affinity for the receptor than did erythropoietin.

ST erythropoietin receptor ligand peptide

IT Peptides, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(as erythropoietin agonists; peptide ligands for erythropoietin receptor that act as erythropoietin agonists)

IT Structure-activity relationship
(erythropoietin-binding; peptide ligands for erythropoietin receptor that act as erythropoietin agonists)

IT Drug screening
(for erythropoietin analogs; peptide ligands for erythropoietin receptor that act as erythropoietin agonists)

IT Erythropoietin receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(peptide ligands for erythropoietin receptor that act as erythropoietin agonists)

IT 11096-26-7, Erythropoietin
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(agonists of; peptide ligands for erythropoietin receptor that act as erythropoietin agonists)

IT 209593-78-2 209593-79-3 209593-81-7 209593-83-9 209593-85-1
209593-87-3 209593-89-5 209593-91-9 209593-93-1 209593-94-2
209593-95-3 209593-96-4 209593-97-5 209593-98-6 209594-00-3
209594-01-4 209594-02-5 209594-03-6 209594-04-7 209594-05-8
209594-06-9 209594-07-0 209594-08-1 209594-09-2 209594-10-5
209594-11-6 209594-12-7 209594-13-8 209594-14-9 209594-15-0
209594-16-1 209594-17-2 209594-18-3 209594-19-4 209594-20-7
209594-21-8 209594-22-9 209594-23-0 209594-24-1 209594-25-2
209594-26-3 209594-27-4 209594-28-5 209594-29-6 209594-30-9
209594-31-0 209594-32-1 209594-33-2 209594-34-3 209594-35-4
209594-36-5 209594-37-6 209594-38-7 209594-39-8 209594-40-1
209594-41-2 209594-42-3 209594-43-4 209594-44-5 209594-45-6
209594-46-7 209594-47-8 209594-48-9 209594-49-0 209594-50-3
209594-51-4 209594-52-5 209594-53-6 209594-54-7 209594-55-8
209594-56-9 209594-57-0 209594-58-1 209594-59-2 209594-60-5
209594-61-6 209594-62-7 209594-63-8 209594-64-9 209594-65-0
209594-66-1 209594-67-2 209594-68-3 209594-69-4 209594-70-7
209594-71-8 209594-72-9 209594-73-0 209594-74-1 209594-75-2
209594-76-3 209594-77-4 209594-78-5 209594-79-6 209594-80-9
209594-81-0 209594-82-1 209594-83-2 209594-84-3 209594-85-4
209594-86-5 209594-87-6 209594-88-7 209594-89-8 209594-90-1
209594-91-2 209594-92-3 209594-93-4 209594-94-5 209594-95-6
209594-96-7 209594-97-8 209594-98-9 209594-99-0 209595-00-6
209595-01-7 209595-02-8 209595-03-9 209595-04-0 209595-05-1
209595-06-2 209595-07-3 209595-08-4 209595-09-5 **209595-10-8**
209595-11-9 209595-12-0 209595-13-1 209595-14-2 209595-15-3
209595-16-4 209595-17-5 **209595-18-6** 209595-19-7
209595-20-0 209595-21-1 209595-22-2 209595-23-3 209595-24-4
209595-25-5 209595-26-6 209595-27-7 209595-28-8 209595-29-9
209595-30-2 **209595-31-3** 209595-32-4 209595-33-5
209595-34-6 209595-35-7 209595-36-8 209595-37-9 209595-38-0
209595-39-1 209595-40-4 209595-41-5 209595-42-6 209595-43-7
209595-44-8 209595-45-9 209595-46-0 209595-47-1 209595-48-2
209595-49-3 209595-50-6 209595-51-7 209595-52-8 209595-53-9
209595-54-0 209595-55-1 209595-56-2 209595-57-3 209595-58-4
209595-59-5 209595-60-8 209595-61-9 209595-62-0 209595-63-1
209595-64-2 209595-65-3 209595-66-4 209595-67-5 209595-68-6
209595-69-7 209595-70-0 209595-71-1 209595-72-2 209595-73-3
209595-74-4 209595-75-5 209595-76-6 209595-77-7 209595-78-8
209595-79-9 209595-80-2 209595-81-3 209595-82-4 209595-83-5
209595-84-6 209595-85-7 209595-86-8 209595-87-9 209595-88-0
209595-89-1 209595-90-4 209595-91-5 209595-92-6 209595-93-7
209595-94-8 209595-95-9 209595-96-0 209595-98-2 209595-99-3

209596-00-9 209596-01-0 209596-02-1 209596-03-2 209596-04-3
209596-05-4 209596-06-5 209596-07-6 209596-08-7 209596-09-8
209596-11-2 209596-13-4 209596-15-6 209596-17-8 209596-19-0
209596-21-4 209596-22-5 209596-23-6 209596-24-7 209596-25-8
209596-26-9 209596-27-0 209596-28-1
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; peptide ligands for erythropoietin receptor that act as erythropoietin agonists)

IT 209596-50-9 209597-09-1 209728-59-6 209728-60-9 209728-68-7
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; peptide ligands for erythropoietin receptor that act as erythropoietin agonists)

RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Anon; WO 9008822 1990 HCAPLUS
(2) Anon; EP 0427189 1991 HCAPLUS
(3) Anon; EP 0428267 1991 HCAPLUS
(4) Anon; CA 2021528 1991 HCAPLUS
(5) Anon; WO 9105867 1991 HCAPLUS
(6) Anon; WO 9325221 1993 HCAPLUS
(7) Anon; WO 9402611 1994 HCAPLUS
(8) Anon; WO 9640749 1996 HCAPLUS
(9) Anon; WO 9640772 1996 HCAPLUS
(10) Barker, P; J Med, Chem 1992, V35, P2040 HCAPLUS
(11) Bowie, J; Science 1990, V247, P1306 HCAPLUS
(12) Brugnara; US 5369014 1994 HCAPLUS
(13) Cwirla, S; Proc Natl Acad Sci USA 1990, V87, P6378 HCAPLUS
(14) D'Andrea; US 5278065 1994 HCAPLUS
(15) Fibi; US 5106954 1992 HCAPLUS
(16) Hewick; US 4677195 1987 HCAPLUS
(17) Hewick; US 5322837 1994 HCAPLUS
(18) Ise; US 5399551 1995 HCAPLUS
(19) Kitamura, T; Blood 1989, V73(2), P375 HCAPLUS
(20) Krystal, G; Exp Hematol 1983, V11(7), P649 HCAPLUS
(21) Landschulz, K; Blood 1989, V73(6), P1476 HCAPLUS
(22) Lin; US 4703008 1987 HCAPLUS
(23) Or, Y; J Org Chem 1991, V56, P3146 HCAPLUS
(24) Royet; US 5482924 1996 HCAPLUS
(25) Sasaki, H; The Journal of Biological Chemistry 1987, V262(25), P12059 HCAPLUS
(26) Sawyer, S; Proc Natl Acad Sci USA 1987, V84, P3690 HCAPLUS
(27) Sawyer, S; The Journal of Biological Chemistry 1987, V262(12), P5554 HCAPLUS

IT **209595-10-8 209595-18-6 209595-31-3**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; peptide ligands for erythropoietin receptor that act as erythropoietin agonists)

L52 ANSWER 20 OF 33 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1997:761604 HCAPLUS
DN 128:30398
ED Entered STN: 06 Dec 1997
TI Agonist peptides of thrombin receptor and stimulation of platelet aggregation
IN Coughlin, Shaun R.; Scarborough, Robert M.
PA COR Therapeutics, Inc., USA
SO U.S., 89 pp., Cont.-in-part of U.S. 5,256,766.
CODEN: USXXAM
DT Patent
LA English
IC ICM A61K036-00
ICS C07K007-06; C07K007-08; C07K007-10
INCL 514015000

```
CC   1-8 (Pharmacology)
     Section cross-reference(s): 3, 6, 13
FAN.CNT 2
     PATENT NO.            KIND   DATE        APPLICATION NO.          DATE
     ---------------       ----   --------    --------------------     --------
PI   US 5688768             A     19971118    US 1991-789184           19911107 <--
     US 5256766             A     19931026    US 1991-657769           19910219 <--
     CA 2104394             AA    19920820    CA 1992-2104394          19920219 <--
     WO 9214750             A1    19920903    WO 1992-US1312           19920219 <--
         W:  AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP,
             KR, LK, LU, MG, MN, MW, NL, NO, PL, RO, RU, SD, SE
        RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GN,
             GR, IT, LU, MC, ML, MR, NL, SE, SN, TD, TG
     AU 9214568             A1    19920915    AU 1992-14568            19920219 <--
     AU 665752              B2    19960118
     EP 572553              A1    19931208    EP 1992-907700           19920219 <--
     EP 572553              B1    20030813
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE
     JP 06508742            T2    19941006    JP 1992-507331           19920219 <--
     JP 3556215             B2    20040818
     JP 2003159088          A2    20030603    JP 2002-259364           19920219 <--
     AT 247165              E     20030815    AT 1992-907700           19920219 <--
     EP 1378524             A2    20040107    EP 2003-16689            19920219 <--
     EP 1378524             A3    20040609
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC
     US 6197541             B1    20010306    US 1993-18760            19930217 <--
     US 5759994             A     19980602    US 1995-475263           19950607 <--
     US 5798248             A     19980825    US 1995-485886           19950607 <--
     US 5849507             A     19981215    US 1995-477362           19950607 <--
     US 5856448             A     19990105    US 1995-477134           19950607 <--
     US 6024936             A     20000215    US 1995-473489           19950607 <--
PRAI US 1991-657769         A2    19910219  <--
     US 1991-789184         A     19911107  <--
     EP 1992-907700         A3    19920219  <--
     JP 1992-507331         A3    19920219  <--
     WO 1992-US1312         A     19920219  <--
CLASS
 PATENT NO.        CLASS  PATENT FAMILY CLASSIFICATION CODES
 --------------    -----  ----------------------------------------------
 US 5688768        ICM    A61K036-00
                   ICS    C07K007-06; C07K007-08; C07K007-10
                   INCL   514015000
 US 5688768        NCL    514/015.000; 514/014.000; 514/016.000; 514/017.000;
                          514/018.000; 530/327.000; 530/328.000; 530/329.000;
                          530/330.000; 530/331.000
                   ECLA   C07K014/705; C07K016/28; C12N009/74                 <--
 US 5256766        NCL    530/327.000; 530/328.000; 530/329.000; 530/330.000  <--
 EP 1378524        ECLA   C07K016/28                                          <--
 US 6197541        NCL    435/069.100; 435/006.000; 435/007.100; 435/007.210;
                          435/024.000; 435/252.300; 435/254.200; 435/320.100;
                          435/325.000; 435/348.000; 435/353.000; 435/354.000;
                          435/358.000; 435/364.000; 536/023.500
                   ECLA   C07K014/705; C07K016/28; C12N009/74                 <--
 US 5759994        NCL    514/009.000; 514/012.000; 514/013.000; 514/014.000;
                          514/015.000; 514/016.000; 514/017.000; 530/317.000;
                          530/324.000; 530/325.000; 530/326.000; 530/327.000;
                          530/328.000; 530/329.000; 530/330.000
                   ECLA   C07K016/28                                          <--
 US 5798248        NCL    435/214.000; 435/252.300; 435/320.100; 536/023.200
                   ECLA   C07K014/705; C07K016/28; C12N009/74                 <--
 US 5849507        NCL    435/007.210; 435/007.100; 435/007.900; 435/013.000;
                          530/387.100; 530/387.900; 530/388.200; 530/388.250;
                          530/389.300; 530/391.100; 530/391.300
                   ECLA   C07K014/705; C07K016/28; C12N009/74                 <--
 US 5856448        NCL    530/388.220; 424/139.100; 424/143.100; 530/381.000;
                          530/387.900; 530/388.250; 530/389.100; 530/389.300;
```

530/837.000
ECLA C07K014/705; C07K016/28; C12N009/74 <--
US 6024936 NCL 424/001.490; 424/009.100; 424/130.100; 424/137.100; 424/139.100; 424/152.100; 424/172.100; 424/178.100; 435/007.210; 530/387.900; 530/388.200; 530/388.220; 530/389.100; 530/391.300
ECLA C07K014/705; C07K016/28; C12N009/74 <--

OS MARPAT 128:30398

AB Peptide agonists of the thrombin receptor which are useful for platelet aggregation are claimed. CDNA encoding the human cell surface receptor for thrombin was cloned and sequenced. Peptides based on the N-terminus of the activated human thrombin receptor were prepared and tested for agonist activity in platelet aggregation assays. Peptides with EC50's as low as 1.1 μM were produced. Addnl., antagonist peptides, thrombin mutant antagonists, and anti-receptor antibody antagonists were prepared and tested.

ST thrombin receptor agonist peptide platelet aggregation

IT Platelet (blood)
(aggregation; agonist peptides of thrombin receptor and stimulation of platelet aggregation)

IT Peptides, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(agonist peptides of thrombin receptor and stimulation of platelet aggregation)

IT Thrombin receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)
(agonist peptides of thrombin receptor and stimulation of platelet aggregation)

IT Thrombin receptors
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(agonists; agonist peptides of thrombin receptor and stimulation of platelet aggregation)

IT Structure-activity relationship
(blood platelet aggregation-affecting; agonist peptides of thrombin receptor and stimulation of platelet aggregation)

IT cDNA sequences
(for human thrombin receptor)

IT Antibodies
RL: BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(monoclonal, receptor antagonists; agonist peptides of thrombin receptor and stimulation of platelet aggregation)

IT Protein sequences
(of human thrombin receptor)

IT Cell aggregation
(platelet; agonist peptides of thrombin receptor and stimulation of platelet aggregation)

IT Antibodies
RL: BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(receptor antagonists; agonist peptides of thrombin receptor and stimulation of platelet aggregation)

IT 137339-65-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(agonist peptides of thrombin receptor and stimulation of platelet aggregation)

IT 140436-67-5P 141685-52-1P 141923-39-9P 141923-40-2P 141923-41-3P
141923-42-4P 143188-71-0P 143188-72-1P 143188-74-3P 143188-75-4P
143188-76-5P 143188-80-1P 143188-81-2P 145229-78-3P 145229-79-4P

145229-80-7P 145229-81-8P 145229-82-9P 145229-84-1P 145229-85-2P
145229-86-3P 145229-87-4P 145229-90-9P 145229-91-0P 145229-92-1P
145229-93-2P 145229-95-4P 145229-96-5P 145229-97-6P 145229-99-8P
145230-00-8P 145230-01-9P 145230-22-4P 145230-24-6P 145230-25-7P
145230-26-8P 145230-27-9P 145230-28-0P 145230-29-1P 145230-30-4P
145230-31-5P 145230-32-6P 145230-33-7P 145230-34-8P 145230-35-9P
145230-36-0P 145230-37-1P 145230-38-2P 145230-39-3P 145230-40-6P
145230-41-7P 145230-42-8P 145230-43-9P 145230-44-0P 145230-45-1P
145230-46-2P 145230-47-3P 145230-49-5P 145230-50-8P 145230-51-9P
145230-52-0P 145230-53-1P 145230-54-2P 145230-55-3P 145230-56-4P
145230-57-5P 145230-58-6P 145230-59-7P 145230-60-0P 145230-61-1P
145230-62-2P 145230-63-3P 145230-64-4P 145230-65-5P 145230-67-7P
145230-68-8P 145230-69-9P 145230-70-2P 145230-71-3P
145230-72-4P 145230-73-5P 145230-75-7P 145230-76-8P 145230-77-9P
145230-78-0P 145248-03-9P 145248-04-0P 145248-05-1P 145248-08-4P
145248-09-5P 145248-11-9P 145306-97-4P 146362-82-5P 161574-39-6P
179004-06-9P 199658-70-3P 199658-71-4P 199658-72-5P 199658-75-8P
199658-76-9P 199658-77-0P 199658-78-1P 199658-80-5P 199658-81-6P
199658-82-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(agonist peptides of thrombin receptor and stimulation of platelet aggregation)

IT 9002-04-4DP, Thrombin, enzymically inactive mutants
RL: BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(agonist peptides of thrombin receptor and stimulation of platelet aggregation)

IT 136252-38-5
RL: PRP (Properties)
(amino acid sequence; agonist peptides of thrombin receptor and stimulation of platelet aggregation)

IT 145230-80-4P 145230-81-5P 145230-82-6P 145230-83-7P 145230-84-8P
145230-85-9P 145230-86-0P 145230-87-1P 145230-88-2P 145230-89-3P
145230-90-6P 145230-91-7P 145230-92-8P 145230-93-9P 145230-94-0P
145230-95-1P 145230-96-2P 145230-97-3P 145230-98-4P 145230-99-5P
145231-00-1P 145231-01-2P 145231-02-3P 145231-04-5P 145231-05-6P
145231-06-7P 145248-12-0P 145248-13-1P 199658-83-8P 199658-84-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(antagonist; agonist peptides of thrombin receptor and stimulation of platelet aggregation)

IT 136252-72-7, DNA (human thrombin receptor cDNA plus flanks)
RL: PRP (Properties)
(nucleotide sequence; agonist peptides of thrombin receptor and stimulation of platelet aggregation)

IT **145230-68-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(agonist peptides of thrombin receptor and stimulation of platelet aggregation)

L52 ANSWER 21 OF 33 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1997:475133 HCAPLUS
DN 127:162123
ED Entered STN: 30 Jul 1997
TI Peptides having bradykinin antagonist action
IN Henke, Stephan; Anagnostopulos, Hiristo; Breipohl, Gerhard; Knolle, Jochen; Stechl, Jens; Scholkens, Bernward; et al.
PA Hoechst A.-G., Germany
SO U.S., 26 pp., Cont. of U.S. Ser. No. 236,018.
CODEN: USXXAM
DT Patent

LA English
IC ICM C07K007-18
ICS A61K038-17
INCL 514002000
CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 5648333	A	19970715	US 1995-487442	19950607	<--
	DD 284030	A5	19901031	DD 1989-331416	19890802	<--
	ZA 8906068	A	19910130	ZA 1989-6068	19890809	<--
	DE 3926822	A1	19910221	DE 1989-3926822	19890814	<--
	DE 4013270	A1	19911031	DE 1990-4013270	19900426	<--
	RU 2083586	C1	19970710	RU 1992-5052703	19921012	<--
	LT 3375	B	19950825	LT 1993-717	19930625	<--
PRAI	DE 1988-3839581	A	19881124	<--		
	DE 1989-3916291	A	19890519	<--		
	DE 1989-3926225	A	19890603	<--		
	US 1989-374162	B2	19890630	<--		
	DE 1989-3926822	A	19890814	<--		
	DE 1990-4013270	A	19900426	<--		
	US 1990-565270	B2	19900810	<--		
	US 1991-690297	B1	19910424	<--		
	US 1991-746149	B1	19910814	<--		
	US 1992-837090	B2	19920218	<--		
	US 1992-841766	B1	19920302	<--		
	US 1992-969523	B2	19921030	<--		
	US 1992-982052	B2	19921125	<--		
	US 1993-12849	B1	19930203	<--		
	US 1994-236018	A1	19940502	<--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 5648333	ICM	C07K007-18
	ICS	A61K038-17
	INCL	514002000
US 5648333	NCL	514/002.000; 514/010.000; 514/015.000; 514/803.000; 530/314.000; 530/328.000
	ECLA	C07K007/18 <--

OS MARPAT 127:162123
AB Peptides A-B-C-E-F-K-P-G-M-F [A = H, alkyl, alkanoyl, cycloalkyl, aryl, etc.; B = basic amino acid which may be substituted in side chain; C = G'-G'-Gly or G'-NH(CH2)nCO, where G' = heterocyclylcarbonyl and n = 2-8; E = aromatic amino acid radical; F, M = bond or amino acid which may be substituted in side chain; K = bond or NH(CH2)xCO, where x = 1-4; P = D-Tic (Tic = 1,2,3,4-tetrahydroisoquinolin-3-ylcarbonyl); G = bond or G'] were prepared as bradykinin antagonists. Thus, H-D-Arg-Arg-Hyp-Pro-Gly-Phe-Ser-D-Tic-Phe-Arg-OH was prepared by the solid phase method and assayed for bradykinin antagonist activity (IC50 = 4.6 x 10-6 M).
ST peptide prepn bradykinin antagonist
IT Peptides, preparation
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(peptides having bradykinin antagonist action)

IT	130308-03-1P	130308-05-3P	130308-06-4P	130308-08-6P	130308-10-0P
	130308-11-1P	130308-15-5P	130308-21-3P	130308-25-7P	130308-28-0P
	130308-30-4P	130308-33-7P	130308-37-1P	130308-38-2P	130308-39-3P
	130308-44-0P	130308-46-2P	130308-47-3P	130308-48-4P	130308-49-5P
	130308-54-2P	130308-58-6P	130308-59-7P	130308-60-0P	130308-61-1P
	130308-62-2P	130308-63-3P	130308-64-4P	130309-27-2P	
	130309-30-7P	130334-55-3P	130404-60-3P	130404-96-5P	
	133162-75-1P	138680-92-9P	140695-51-8P	153986-61-9P	179486-09-0P
	193618-41-6P	193618-42-7P	193618-50-7P	193618-51-8P	193618-53-0P
	193618-54-1P	193618-55-2P	193618-56-3P	193618-57-4P	193618-58-5P

193618-59-6P 193618-60-9P 193618-61-0P 193618-62-1P 193618-63-2P
193618-64-3P 193618-65-4P 193618-66-5P 193618-67-6P 193618-68-7P
193618-69-8P 193740-37-3P 193740-38-4P 193740-39-5P 193740-58-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(peptides having bradykinin antagonist action)

IT 58-82-2, Bradykinin
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(peptides having bradykinin antagonist action)

IT 130308-04-2P 130308-12-2P 130308-13-3P 130308-14-4P 130308-16-6P
130308-17-7P 130308-18-8P 130308-19-9P 130308-20-2P 130308-22-4P
130308-23-5P 130308-24-6P 130308-26-8P 130308-27-9P 130308-29-1P
130308-31-5P 130308-32-6P 130308-34-8P 130308-35-9P 130308-36-0P
130308-40-6P 130308-41-7P 130308-42-8P 130308-43-9P 130308-45-1P
130308-50-8P 130308-51-9P 130308-52-0P 130308-53-1P 130308-55-3P
130308-56-4P 130308-65-5P 130308-66-6P 130308-67-7P 130308-68-8P
130308-69-9P 130308-70-2P 130308-71-3P 130308-72-4P 130308-73-5P
130308-74-6P 130308-75-7P 130308-76-8P 130308-77-9P 130308-78-0P
130308-79-1P 130308-80-4P 130308-81-5P 130308-82-6P 130308-83-7P
130308-84-8P 130308-85-9P 130308-86-0P 130308-88-2P 130308-89-3P
130308-90-6P 130308-91-7P 130308-92-8P 130308-93-9P 130308-94-0P
130308-95-1P 130308-96-2P 130308-97-3P 130308-98-4P 130308-99-5P
130309-00-1P 130309-01-2P 130309-02-3P 130309-03-4P 130309-04-5P
130309-05-6P 130309-06-7P 130309-07-8P 130309-08-9P 130309-09-0P
130309-10-3P 130309-11-4P 130309-12-5P 130309-13-6P 130309-14-7P
130309-15-8P 130309-16-9P 130309-17-0P 130309-18-1P 130309-19-2P
130309-20-5P 130309-21-6P 130309-22-7P 130309-23-8P 130309-24-9P
130309-25-0P 130309-26-1P 130309-28-3P 130309-29-4P
130309-31-8P 130309-32-9P 130334-54-2P 130334-56-4P
130334-57-5P 130334-58-6P 130334-59-7P 130334-60-0P 130334-61-1P
130334-62-2P 130334-63-3P 130334-64-4P 130334-65-5P 130334-66-6P
130334-67-7P 130334-68-8P 130334-69-9P 130334-70-2P 130334-71-3P
130334-72-4P 130334-73-5P 130389-49-0P 130389-50-3P 130404-61-4P
130425-34-2P 134439-23-9P 144006-47-3P 147820-70-0P 147836-85-9P
193618-43-8P 193618-44-9P 193618-45-0P 193618-46-1P 193618-48-3P
193618-70-1P 193618-71-2P 193618-72-3P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(peptides having bradykinin antagonist action)

IT **130309-30-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(peptides having bradykinin antagonist action)

IT **130309-31-8P 130309-32-9P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(peptides having bradykinin antagonist action)

L52 ANSWER 22 OF 33 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1997:425990 HCAPLUS
DN 127:91019
ED Entered STN: 10 Jul 1997
TI μ-Opioid receptor ligands: agonists and antagonists
IN Dooley, Colette T.; Houghten, Richard A.
PA Torrey Pines Institute for Molecular Studies, USA
SO U.S., 92 pp.
CODEN: USXXAM
DT Patent
LA English
IC ICM A61K038-08
ICS A61K038-04
INCL 530329000
CC 2-5 (Mammalian Hormones)

Section cross-reference(s): 1

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5641861	A	19970624	US 1995-487006	19950607 <--
PRAI	US 1995-487006		19950607 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 5641861	ICM	A61K038-08
	ICS	A61K038-04
	INCL	530329000
US 5641861	NCL	530/329.000
	ECLA	C07K005/08A2; C07K005/10A2; C07K005/10H; C07K007/06A; C07K014/665 <--

OS MARPAT 127:91019

AB The present invention provides novel opioid peptides. Disclosed are opioid peptides having the general structures Ac-Phe-Arg-Trp-Trp-Tyr-Xaa--NH2 ; Ac-Arg-Trp-Ile-Gly-Trp-Xaa--NH2 ; Trp-Trp-Pro-Lys-His-Xaa--NH2 ; and shorter versions of the latter, namely, Trp-Trp-Pro-Xaa--NH2 ; Tyr-Pro-Phe-Gly-Phe-Xaa--NH2 ; (D)Ile-(D)Met-(D)Ser-(D)Trp-(D)Trp-Glyn -Xaa--NH2 ; and (D)Ile-(D)Met-(D)Thr-(D)Trp-Gly-Xaa--NH2. Within each genus, Xaa is substituted by a specific amino acid. The invention also relates to an opioid peptide having the general structure Tyr-A1-B2-C3--NH2 , wherein A is D-Nve or D-Nle, B is Gly, Phe, or Trp, and C is Trp or Nap. Also included within the invention are opioid peptides of the general structure Pm and red {MexHyN-Tyr-(NMe)z -Tyr-Xaaz--NH2}, wherein Xaa is substituted by a specific amino acid and x and y are independently 0, 1, or 2 and z is 0 or 1.

ST mu opioid agonist antagonist; peptide opioid

IT Opioid antagonists
Opioids
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(μ-; novel μ-opioid peptide agonists and antagonists)

IT 186656-06-4
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(nonovel μ-opioid peptide agonists and antagonists)

IT 58822-25-6, 1-5-β-Neoendorphin (human) 164117-54-8 164117-55-9
164117-56-0 164117-57-1 164117-58-2 164117-59-3 164117-60-6
164117-61-7 164117-62-8 164117-63-9 164117-64-0 164117-65-1
164117-66-2 164117-67-3 164117-68-4 164117-69-5 164117-70-8
164117-71-9 164117-72-0 164117-73-1 164117-74-2 164117-75-3
164117-76-4 164117-77-5 164117-78-6 164117-79-7 164117-80-0
164117-81-1 164117-82-2 164117-83-3 164117-84-4 164117-85-5
164117-86-6 164117-87-7 164117-88-8 164117-89-9 164117-90-2
164117-91-3 164117-92-4 164117-93-5 171807-45-7 171807-46-8
171807-49-1 171807-50-4 186654-16-0 186654-17-1 186654-18-2
186654-19-3 186654-20-6 186654-21-7 186654-22-8 186654-23-9
186654-24-0 186654-25-1 186654-26-2 186654-28-4 186654-30-8
186654-32-0 186654-34-2 186654-36-4 186654-38-6 186654-40-0
186654-42-2 186654-44-4 **186654-69-3 186654-70-6**
186654-71-7 186654-72-8 186654-73-9 186654-74-0 186654-75-1
186654-76-2 186654-77-3 186654-78-4 186654-79-5 186654-80-8
186654-81-9 186654-82-0 186654-83-1 186654-84-2 186654-85-3
186654-86-4 186654-87-5 186654-88-6 186654-89-7 186654-90-0
186654-91-1 186654-92-2 186654-93-3 186654-94-4 186654-95-5
186654-96-6 186654-97-7 186654-98-8 186654-99-9 186655-00-5
186655-01-6 186655-02-7 186655-03-8 186655-04-9 186655-05-0
186655-06-1 186655-07-2 186655-08-3 186655-09-4 186655-10-7
186655-11-8 186655-12-9 186655-13-0 186655-14-1 186655-15-2
186655-16-3 186655-17-4 186655-18-5 186655-19-6 186655-20-9
186655-21-0 186655-22-1 186655-23-2 186655-24-3 186655-25-4
186655-26-5 186655-27-6 186655-28-7 186655-29-8 186655-30-1
186655-31-2 186655-32-3 186655-33-4 186655-34-5 186655-35-6

186655-36-7 186655-37-8 186655-38-9 186655-39-0 186655-40-3
186655-41-4 186655-42-5 186655-43-6 186655-44-7 186655-45-8
186655-46-9 186655-47-0 186655-48-1 186655-49-2 186655-50-5
186655-51-6 186655-52-7 186655-53-8 186655-54-9 186655-55-0
186655-56-1 186655-57-2 186655-58-3 186655-59-4 186655-60-7
186655-61-8 186655-68-5 186655-70-9 186655-72-1 186655-74-3
186655-76-5 186655-78-7 186655-79-8 186655-80-1 186655-81-2
186655-82-3 186655-83-4 186655-84-5 186655-85-6 186655-86-7
186655-87-8 186655-92-5 186655-94-7 186655-95-8 186656-05-3
186656-07-5 186656-08-6 186656-09-7 186656-10-0 186656-11-1
186656-12-2 186656-13-3 186656-14-4 186656-15-5 186656-16-6
186656-17-7 186656-18-8 186656-19-9 186656-20-2 192126-30-0
192126-34-4 192126-36-6 192126-37-7 192126-38-8 192126-39-9
192126-40-2 192126-41-3 192126-42-4 192126-43-5 192126-44-6
192126-45-7 192126-46-8 192126-47-9 192126-48-0 192126-49-1
192126-50-4
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(novel μ-opioid peptide agonists and antagonists)

IT **186654-69-3 186654-70-6**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(novel μ-opioid peptide agonists and antagonists)

L52 ANSWER 23 OF 33 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1996:702041 HCAPLUS
DN 126:37059
ED Entered STN: 27 Nov 1996
TI Compositions and methods for the treatment of male-pattern baldness
IN Tien, Henry C.
PA USA
SO U.S., 23 pp.
CODEN: USXXAM
DT Patent
LA English
IC ICM A61K037-24
INCL 514014000
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 2, 62
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 5574011	A	19961112	US 1995-416190	19950404	<--
	WO 9802133	A1	19980122	WO 1996-US11709	19960715	<--
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
	AU 9664933	A1	19980209	AU 1996-64933	19960715	<--
PRAI	US 1995-416190		19950404	<--		
	WO 1996-US11709	W	19960715	<--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES	
US 5574011	ICM	A61K037-24	
	INCL	514014000	
US 5574011	NCL	514/014.000; 514/015.000	
	ECLA	A61K009/00L4; A61K038/09	<--
WO 9802133	ECLA	A61K009/00L4; A61K038/09	<--

AB The present invention provides methods and compns. of LH-RH analogs for the treatment of male-pattern baldness. Male-pattern baldness is treated by the administration of compns. containing LH-RH analogs capable of

suppressing testosterone formation. The LH-RH analogs include LH-RH agonists, e.g. nafarelin and leuprolide, and antagonists, e.g. ganirelix, ramorelix, anitide, and cetrorelix. The compns. may be administered by any of a variety of routes, including parenteral, topical, transdermal, or trans-mucosal routes. For example, a tablet contained anitide 5, corn starch 90, cellulose 1, colloidal silica 1, Na citrate 1, Na starch glycolate 1, and stearic acid 1 %.

ST LHRH analog male pattern baldness

IT Drug delivery systems
(capsules; LH-RH analogs for treatment of male-pattern baldness)

IT Drug delivery systems
(implants; LH-RH analogs for treatment of male-pattern baldness)

IT Drug delivery systems
(inhalants; LH-RH analogs for treatment of male-pattern baldness)

IT Alopecia
(male pattern; LH-RH analogs for treatment of male-pattern baldness)

IT Drug delivery systems
Drug delivery systems
(nasal sprays; LH-RH analogs for treatment of male-pattern baldness)

IT Drug delivery systems
(solns., topical; LH-RH analogs for treatment of male-pattern baldness)

IT Drug delivery systems
(suppositories; LH-RH analogs for treatment of male-pattern baldness)

IT Drug delivery systems
(tablets; LH-RH analogs for treatment of male-pattern baldness)

IT Drug delivery systems
(transdermal; LH-RH analogs for treatment of male-pattern baldness)

IT 9034-40-6D, LH-RH, analogs 33515-09-2, Gonadorelin 53422-04-1 53714-56-0 57292-41-8 57521-78-5 57773-63-4 57773-65-6 57982-77-1 60143-35-3 61012-18-8 65807-02-5 68630-75-1, Buserelin acetate 74381-53-6, Leuprolide acetate 75851-13-7 76712-82-8, Histrelin 76932-56-4, Nafarelin 76932-59-7 76932-60-0, Nafarelin acetate 78115-75-0 78708-43-7 81608-49-3 82163-19-7 86855-16-5 89662-20-4 89662-21-5 89662-27-1 89662-28-2 89662-29-3 89662-30-6, Detirelix 89662-32-8 89662-33-9 89680-24-0 90761-05-0 91991-07-0 98501-05-4 110798-13-5D, D-Homoarginine, derivs. 112568-12-4, Antide 120287-85-6, Cetrorelix 121362-84-3 124904-93-4, Ganirelix 127932-90-5 134457-26-4, Azaline 134457-28-6, Azaline B 184686-51-9 184686-52-0 184686-53-1 184686-54-2 **184686-55-3** **184686-56-4**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(LH-RH analogs for treatment of male-pattern baldness)

IT 58-22-0, Testosterone, 9002-67-9, LH 9002-68-0, FSH
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(LH-RH analogs for treatment of male-pattern baldness)

IT **184686-55-3** **184686-56-4**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(LH-RH analogs for treatment of male-pattern baldness)

L52 ANSWER 24 OF 33 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1989:173765 HCAPLUS
DN 110:173765
ED Entered STN: 12 May 1989
TI Preparation and testing of 1,6-dicarba-vasopressin compounds as drugs
IN Callahan, James F.; Huffman, William F.; Newlander, Kenneth A.; Yim, Nelson C. F.
PA SmithKline Beckman Corp., USA
SO U.S., 13 pp. Cont.-in-part of U.S. Ser. No. 819,336, abandoned.
CODEN: USXXAM
DT Patent
LA English

IC ICM A61K037-34
ICS C07K007-16
INCL 514011000
CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1, 63
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 4760052	A	19880726	US 1987-43658	19870428	<--
	DK 8700206	A	19870717	DK 1987-206	19870115	<--
	FI 8700156	A	19870717	FI 1987-156	19870115	<--
	NO 8700175	A	19870717	NO 1987-175	19870115	<--
	ZA 8700275	A	19880831	ZA 1987-275	19870115	<--
	HU 46342	A2	19881028	HU 1987-115	19870115	<--
	HU 199882	B	19900328			
	HU 50457	A2	19900228	HU 1988-4124	19870115	<--
	AU 8767624	A1	19870723	AU 1987-67624	19870116	<--
	JP 62181297	A2	19870808	JP 1987-8865	19870116	<--
	CN 87100308	A	19870916	CN 1987-100308	19870116	<--
	US 4810778	A	19890307	US 1988-191673	19880509	<--
	US 4908475	A	19900313	US 1988-192736	19880509	<--
PRAI	US 1986-819336	A2	19860116	<--		
	US 1987-43658	A3	19870428	<--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES	
US 4760052	ICM	A61K037-34	
	ICS	C07K007-16	
	INCL	514011000	
US 4760052	NCL	514/011.000; 514/807.000; 530/315.000; 930/020.000; 930/021.000; 930/150.000; 930/DIG.566; 930/DIG.567	<--
US 4810778	NCL	530/328.000; 530/332.000; 930/020.000; 930/021.000; 930/150.000; 930/DIG.567	<--
US 4908475	NCL	560/115.000; 560/012.000; 560/017.000; 560/121.000; 560/125.000; 562/430.000; 562/431.000; 562/503.000; 562/507.000	<--

OS CASREACT 110:173765; MARPAT 110:173765
GI



I



II

AB The title compds. [I; P = bond, D- or L-Pro, Ala, MeAl, Arg, Lys, MeArg, MeLys, MeHArg, etc., A = bond, Gly, D- or L- Arg, Lys, Orn, HArg, MeLys, MeOrn, MeHArg, Gln; D = bond, Gly, D- or L-Arg, Lys, HArg, MeArg, MeLys, MeHArg, Gln, Orn; B = OH, amino; Z = Phe, Phe (4'-Alk), Tyr(Alk), Ile, Tyr; X = D- or L- Phe,Phe(4'-alk), Val, Nva, Leu, Ile, Pba, Me, Cha, Abu, Met, Chg, Tyr, Trp, Tyr(Alk); Y = Val, Ile, Abu, Ala, Chg, Gln, Lys, Cha, Nle, Thr, Phe, Leu, Gly; n = 0, 1; MeHArg = N-methylhomoarginyl; HArg = homoarginyl, Pba = α-aminophenylbutyryl; Cha = cyclohexylalanyl, Abu = α-aminobutyl; Chg = cyclohexylglycyl; Alk = C1-4 alkyl] useful as vasopressin antagonists, were prepared H-D-Tyr(Et)-Phe-Val-Asn-DL-Pas-Pro-Arg-NH2 (Pas = 6,6-cyclopentamethylene-2-aminosuberyl) (prepared by the solid phase method on benzhydrylamine resin) in DMF was treated with Et3N and (PhO)2P(O)N3 to give cyclic peptide II as the racemate. I stimulated adenylate cyclase activity in hog medullary kidney tissue with Ki's of 4.3-4.5 + 10-9 M.

ST vasopressin antagonist peptide prepn; antihypertensive vasopressin antagonist prepn

IT Diuretics
(dicarbavasopressin analogs)

IT Peptides, preparation
RL: SPN (Synthetic preparation); PREP (Preparation)
(dicarbavasopressin analogs, preparation of, as vasopressin antagonists)

IT 11000-17-2, Vasopressin
RL: RCT (Reactant); RACT (Reactant or reagent)
(antagonists, dicarbavasopressin derivs. as)

IT 7766-48-5, 5-Iodopent-1-ene
RL: RCT (Reactant); RACT (Reactant or reagent)
(condensation of, with Me cyclohexanecarboxylate)

IT 4630-82-4, Methyl cyclohexanecarboxylate
RL: RCT (Reactant); RACT (Reactant or reagent)
(condensation of, with iodopentene)

IT 13836-37-8 15761-39-4 51644-96-3 113009-18-0 113084-43-8
114359-37-4 114420-16-5 119834-08-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(peptide coupling of, in preparation of vasopressin antagonist)

IT 7536-55-2 13734-34-4 13734-41-3 76757-92-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(peptide coupling of, in preparation of vasopressin antagonists)

IT **114359-25-0P** 119834-06-9P 119834-11-6P 119834-14-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and cyclization of, in preparation of vasopressin antagonist)

IT 119834-13-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and salification of, in preparation of vasopressin antagonist)

IT **114359-16-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

IT 113009-17-9P 113009-18-0P 113009-19-1P 113009-21-5P 113009-23-7P
113009-24-8P 113009-26-0P 113009-27-1P 114359-24-9P 114359-32-9P
114359-33-0P 114359-34-1DP, benzhydrylamine resin bound 114359-36-3DP, benzhydrylamine resin bound 114387-68-7DP, benzhydrylamine resin bound
119833-97-5P 119833-98-6P 119834-01-4P **119834-02-5P**
119834-04-7P 119834-05-8DP, resin bound 119834-12-7DP, benzhydrylamine resin bound 119834-15-0DP, benzhydrylamine resin bound
119834-16-1DP, benzhydrylamine resin bound 119834-17-2DP, benzhydrylamine resin bound 119834-18-3P 119834-19-4P 119834-20-7P
119834-21-8P 119834-22-9P 119906-36-4P 119943-27-0DP, benzhydrylamine resin bound
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for vasopressin antagonist)

IT 114359-31-8P 119834-23-0DP, benzhydrylamine resin bound
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate of vasopressin antagonist)

IT **114359-15-8P** 114359-17-0P **114359-18-1P** 114820-55-2P
114923-99-8P 119833-94-2P 119834-03-6P 119834-09-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as vasopressin antagonist)

IT 119834-07-0P 119834-10-5DP, benzhydrylamine resin bound
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as vasopressin antagonist intermediate)

IT 114359-19-2P 114387-65-4P 114387-66-5P 114387-67-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, vasopressin antagonist)

IT **114359-25-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and cyclization of, in preparation of vasopressin antagonist)

IT **114359-16-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

IT **119834-02-5P 119834-04-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for vasopressin antagonist)
IT **114359-15-8P 114359-18-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as vasopressin antagonist)

L52 ANSWER 25 OF 33 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1989:135741 HCAPLUS
DN 110:135741
ED Entered STN: 15 Apr 1989
TI Preparation of vasopressin V2 antagonists as cardiovascular agents
IN Huffman, William F.; Moore, Michael L.; Yim, Nelson C.
PA SmithKline Beckman Corp., USA
SO U.S., 8 pp. Cont.-in-part of U.S. Ser. No. 782,671, abandoned.
CODEN: USXXAM
DT Patent
LA English
IC ICM A61K037-02
INCL 530328000
CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1, 63
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 4749782	A	19880607	US 1987-27769	19870319 <--
EP 219275	A2	19870422	EP 1986-307580	19861001 <--
EP 219275	A3	19890503		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
PRAI US 1985-782671	A2	19851002 <--		
EP 1986-307580	A	19861001 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 4749782	ICM	A61K037-02
	INCL	530328000
US 4749782	NCL	530/328.000; 530/329.000; 930/020.000; 930/021.000; 930/150.000; 930/DIG.566; 930/DIG.567; 930/DIG.803 <--

OS MARPAT 110:135741
GI



I



II

AB The title compds. [I; A = bond, D- or L-Pro, MeArg, HArg, Arg; B = D- or L-MeArg, HArg, Arg, Lys, Orn, etc; C = Gly-OH, Gly-NH2, OH, NH2, null; W = D- orL-Phe(4'-alk), Phe, Ile, Cha, D-Tyr, D-Tyr(Oalk); alk = C1-4 alkyl; X = Phe, Phe(4'-alk), Tyr(Oalk), Ile, Tyr; Y = Val, Ile, Abu, Chg, Gln, Lys, Cha, Nle, Leu, Ala, Gly; Z = D- or L-Cys; HArg = homoarginyl; Cha = cyclohexylalanyl] and salts and esters prodrugs were prepared as vasopressin U2 antagonists. BOC-D-Tyr(Et)-Phe-Val-Asn-Cys(SBzl)-Pro-Arg(Tos)-Gly-Benzhydrylamine resin (Bzl = CH2Ph) was coupled with β-(S-benzylmercapto)-β,β-diethylpropionic acid and the product was resin cleaved/deprotected with Na/MeOH and then Na/NH3 and oxidatively cyclized with K3Fe(CN)6 to give vasopressin analog II [Mpr(Et) = β-mercapto-β,β-diethylpropionyl]. The latter had an ED300 of 27.0 μg/kg in hydropenic rats. an ampoule containing II 0.5 and mannitol

20mg was prepared
ST vasopressin antagonist prepn cardiovascular agent; peptide amide prepn antihypertensive diuretic
IT Antihypertensives
Cardiotonics
(vasopressin analogs)
IT Peptides, preparation
RL: SPN (Synthetic preparation); PREP (Preparation)
(vasopressin analogs, preparation of, as cardiovascular agents)
IT 867-13-0, Triethyl phosphonoacetate
RL: RCT (Reactant); RACT (Reactant or reagent)
(Wittig reaction of, with pentanone)
IT 96-22-0, 3-Pentanone
RL: RCT (Reactant); RACT (Reactant or reagent)
(Wittig reaction of, with tri-Et phosphonoacetate)
IT 100-53-8, Benzylmercaptan 4498-99-1, p-Methylbenzylmercaptan
RL: RCT (Reactant); RACT (Reactant or reagent)
(condensation of, with diethylacrylic acid Et ester)
IT 51644-96-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(coupling of, with heptaopeptide derivative, in preparation of vasopressin antagonist)
IT 76757-91-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(peptide coupling of, in preparation of vasopressin V2 antagonist)
IT 13734-34-4 76757-92-1 104054-99-1D, resin bound
RL: RCT (Reactant); RACT (Reactant or reagent)
(peptide coupling of, in preparation of vasopressin antagonist)
IT 109212-85-3DP, benzhydrylamine resin bound
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and coupling of, with mercapto di-Et propionic acid derivative)
IT **119624-06-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and cyclization of, in preparation of V2 antagonist)
IT 109212-87-5P **119624-04-3P** 119624-07-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and oxidative cyclization of, in preparation of vasopressin V2 antagonist)
IT 119624-09-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and oxidative cyclization of, in preparation of vasopressin antagonist)
IT 119624-01-0DP, resin bound
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and resin cleavage of, in preparation of vasopressin antagonist)
IT 119624-03-2DP, benzyhydrylamine resin bound 119624-05-4DP, benzhydrylamine resin bound 119624-08-7DP, benzhydrylamine resin bound
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and resin cleavage reaction of, in preparation of vasopressin V2 antagonist)
IT 109212-86-4DP, benzhydrylamine resin bound 119642-07-8DP, benzhydrylamine resin bound
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and resin cleavage reaction of, in preparation of vasopressin antagonist)
IT 15249-93-1P 36038-80-9P 104532-41-4P 109212-79-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for vasopressin antagonist)
IT 104532-37-8P **104532-38-9P** **104532-39-0P** 109212-76-2P
109212-77-3P 109212-83-1DP, benzhydrylamine resin bound 109230-47-9P

119623-99-3P 119624-00-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as vasopressin V2 antagonist)
IT 11000-17-2DP, Vasopressin, analogs
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as vasopressin V2 antagonists)
IT 109212-80-8DP, resin-bound 109212-84-2DP, benzhydrylamine resin bound
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as vasopressin antagonist intermediate)
IT 119624-02-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, deprotection, and oxidative cyclization of, in preparation of vasopressin antagonist)
IT 109212-88-6DP, resin bound
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, resin cleavage reaction, and oxidative cyclization of, in preparation of vasopressin antagonist)
IT **119624-06-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and cyclization of, in preparation of V2 antagonist)
IT **119624-04-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and oxidative cyclization of, in preparation of vasopressin V2 antagonist)
IT **104532-38-9P 104532-39-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as vasopressin V2 antagonist)

L52 ANSWER 26 OF 33 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1988:406978 HCAPLUS
DN 109:6978
ED Entered STN: 09 Jul 1988
TI Preparation of (7-arginine-8-arginine-9-arginine)-vasopressin analogs as vasopressin antagonists and antihypertensives
IN Ali, Fadia E.
PA SmithKline Beckman Corp., USA
SO U.S., 7 pp.
CODEN: USXXAM
DT Patent
LA English
IC ICM C07K007-16
ICS A61K037-34
INCL 514011000
CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 2, 63
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4724229	A	19880209	US 1986-913439	19860930 <--
	AU 8778887	A1	19880414	AU 1987-78887	19870923 <--
	DK 8705105	A	19880331	DK 1987-5105	19870928 <--
	EP 270214	A2	19880608	EP 1987-308532	19870928 <--
	EP 270214	A3	19900509		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	JP 63096199	A2	19880427	JP 1987-245728	19870929 <--
	ZA 8707305	A	19880928	ZA 1987-7305	19870929 <--
PRAI	US 1986-913439	A	19860930 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 4724229	ICM	C07K007-16
	ICS	A61K037-34
	INCL	514011000
US 4724229	NCL	514/011.000; 514/807.000; 530/315.000; 930/020.000;

930/021.000; 930/150.000; 930/DIG.567 <--

OS MARPAT 109:6978

GI



I

AB The title peptides [I; P,A,E = D or L - Arg, Lys, Orn, HArg, Me-Lys, or Me-HArg; B = OH, NH2, alkylamino; Z = Phe, 4'-alkyl Ppe, O-alkylTyr, Ile, or Tyr; X = D or L-Phe, 4'-alkyl Phe, Val, Nva, Leu, Ile, Pba, Nle, Cha, Abu, Met, Chg, Tyr, O-alkyl Tyr; Y = Val, Ile, Abn, Ala, Chg, Gln, Lys, Cha, Me, Thr, Phe, Leu, Gly; R1, R2 = H, Me, Et; CR1R2 = 4-6 membered cycloalkylene ring; HArg = homoarginine; Pba = α-aminophenylbutyric acid; Cha = cyclohexylalanine; Abu = α-amino-n-butyric acid; Chg = cyclohexylglycine] were prepared as vasopressin antagonists and antihypertensives. I [CR1R2CH2CO = β-mercapto-β,β-(cyclopentamethylene)propionic acid residue (Pmp) P-A-E-B=Arg-Arg-Arg-NH2, X = D-Tyr(Et), Z = Phe,Y = Val] (II) was synthesized using the solid-phase method on an automated synthesizer. II exhibited a ED300 (the dose of the compound μg/kg required to lower urine osmolality to 300 mOsm/kg H2O) of 22.1 ± 4.6 μg/mL i.p. in rats. Parenteral dosage unit compns. containing 0.10 I and 20 mg mannitol were prepared

ST vasopressin analog prepn vasopressin antagonist antihypertensive

IT Edema
(treatment of, vasopressin analogs for)

IT Antihypertensives
Diuretics
(vasopressin analogs)

IT Peptides, preparation
RL: SPN (Synthetic preparation); PREP (Preparation)
(vasopressin analogs, preparation of, as vasopressin antagonists and antihypertensives)

IT Heart, disease or disorder
(failure, treatment of, vasopressin analogs for)

IT 76757-91-0 76757-92-1 87242-91-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(peptide coupling of, in preparation of vasopressin antagonist)

IT 114736-06-0DP, benzhydrylamine resin-bound 114736-07-1DP, benzhydrylamine resin-bound 114736-08-2DP, benzhydrylamine resin-bound 114736-09-3DP, benzhydrylamine resin-bound
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and resin cleavage of, in preparation of vasopressin antagonist)

IT **90332-82-4P** 94497-37-7P 110500-75-9P 114735-93-2P
114735-94-3P 114735-95-4P 114735-96-5P 114735-97-6P 114735-98-7P
114735-99-8P 114736-00-4P 114736-01-5P 114736-02-6P 114736-03-7P
114736-04-8P 114736-05-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as vasopressin antagonist and antihypertensive)

IT 11000-17-2DP, Vasopressin, analogs
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as vasopressin antagonists and antihypertensives)

IT **90332-82-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as vasopressin antagonist and antihypertensive)

L52 ANSWER 27 OF 33 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1987:637298 HCAPLUS
DN 107:237298
ED Entered STN: 25 Dec 1987
TI Copper(II) oxidation of 1,6-dimercapto-containing peptides
IN Kalbag, Suresh M.; Voelker, Paul J.

PA SmithKline Beckman Corp., USA
SO U.S., 3 pp.
CODEN: USXXAM
DT Patent
LA English
IC ICM C07K007-16
INCL 530315000
CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 2
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 4656248	A	19870407	US 1985-726433	19850423 <--
PRAI US 1985-726433		19850423 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 4656248	ICM	C07K007-16
	INCL	530315000
US 4656248	NCL	530/315.000; 530/345.000; 930/020.000; 930/021.000; 930/150.000; 930/DIG.567 <--

OS CASREACT 107:237298
GI For diagram(s), see printed CA Issue.
AB Cyclic peptide amide I is obtained by oxidation of linear peptide II with a Cu (II) salt. II.HOAc in MeOH was treated with one equivalent of CuSO4.5H2O and the resulting mixture was stirred at room temperature for 5 min to give 38% I.
ST dimercapto peptide prepn vasopressin antagonist; oxidn dimercapto peptide cupric sulfate
IT Oxidation
(of linear dimercapto peptide, cyclic disulfide by)
IT 7758-98-7, Cupric sulfate, reactions
RL: RCT (Reactant); RACT (Reactant or reagent)
(oxidation by, of linear dimercapto peptide)
IT **111450-99-8 111451-00-4**
RL: RCT (Reactant); RACT (Reactant or reagent)
(oxidation of, by cupric sulfate, cyclic disulfide from)
IT **90332-82-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, via oxidation of linear dimercapto peptide by cupric sulfate)
IT **111450-99-8 111451-00-4**
RL: RCT (Reactant); RACT (Reactant or reagent)
(oxidation of, by cupric sulfate, cyclic disulfide from)
IT **90332-82-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, via oxidation of linear dimercapto peptide by cupric sulfate)

L52 ANSWER 28 OF 33 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1986:515414 HCAPLUS
DN 105:115414
ED Entered STN: 03 Oct 1986
TI Vasopeptides as vasopressin antagonists
IN Yim, Nelson C.
PA SmithKline Beckman Corp., USA
SO U.S., 9 pp.
CODEN: USXXAM
DT Patent
LA English
IC ICM C07K007-16
INCL 530328000
CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 4597901	A	19860701	US 1984-681461	19841214 <--
US 4684716	A	19870804	US 1986-852696	19860416 <--

```
     US 4719199           A     19880112    US 1986-852697         19860416 <--
PRAI US 1984-681461       A3    19841214  <--
CLASS
 PATENT NO.       CLASS  PATENT FAMILY CLASSIFICATION CODES
 --------------   -----  ----------------------------------------------
 US 4597901       ICM    C07K007-16
                  INCL   530328000
 US 4597901       NCL    530/328.000; 930/020.000; 930/021.000; 930/150.000;
                         930/DIG.565; 930/DIG.803                          <--
 US 4684716       NCL    530/328.000; 530/329.000; 930/020.000; 930/021.000;
                         930/150.000; 930/260.000; 930/DIG.802             <--
 US 4719199       NCL    514/009.000; 514/010.000; 930/020.000; 930/021.000;
                         930/150.000; 930/260.000; 930/DIG.565; 930/DIG.803  <--
GI
```



I

```
AB   Peptides I [n = 0, 1, 2; X1 = Trp, D-Phe, D-Tyr, Tyr, etc.; X2 = Phe,
     Phe(4-alkyl), Trp; X3 = Val, Ile, Abn, Ala, Gly, etc.; X4 = D-Pro, Pro; X5
     = D-Arg, Arg, D-Lys, Lys, Harg; R1 = NH2, alkylamino, OH, Gly-OH, etc.],
     which exhibited diuretic activity, were prepared  Among the polypeptides
     prepared was I (n = 1, X1 = D-Trp, X2 = Phe, X3 = Val, X4 = Pro, X5 = Gly,
     R1 = NH2).
ST   peptide prepn diuretic; vasopressin antagonist peptide prepn
IT   Diuretics
        (polypeptides)
IT   11000-17-2
     RL: RCT (Reactant); RACT (Reactant or reagent)
        (antagonists of, polypeptides as)
IT   4530-20-5D, resin-bound
     RL: RCT (Reactant); RACT (Reactant or reagent)
        (peptide synthesis with)
IT   77446-72-1DP, resin-bound   104054-89-9P   104054-90-2DP,
     p-methylbenzhydrylamine resin-bound   104054-93-5P   104054-95-7DP,
     resin-bound   104054-97-9DP, p-methylbenzhydrylamine resin-bound
     104055-00-7DP, resin-bound   104055-04-1P   104075-53-8DP,
     p-methylbenzhydrylamine resin-bound   104075-54-9DP, p-
     methylbenzhydrylamine resin-bound   104075-56-1P
     RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
     (Reactant or reagent)
        (preparation and reaction of)
IT   6747-15-5P
     RL: SPN (Synthetic preparation); PREP (Preparation)
        (preparation of)
IT   102992-26-7P   103065-80-1P   104054-91-3P   104054-92-4P   104054-94-6P
     104054-96-8P 104054-98-0P   104055-01-8P   104055-02-9P
     104055-03-0P   104055-06-3P 104075-57-2P
     RL: SPN (Synthetic preparation); PREP (Preparation)
        (preparation of, as diuretic)
IT   5241-64-5   13139-14-5   55154-80-8   58237-94-8   64905-10-8   87242-91-9
     93449-74-2D, p-methylbenzhydrylamine resin-bound   104054-99-1D,
     resin-bound   104075-55-0D, p-methylbenzhydrylamine resin-bound
     RL: RCT (Reactant); RACT (Reactant or reagent)
        (reaction of)
IT   104054-96-8P 104054-98-0P 104075-57-2P
     RL: SPN (Synthetic preparation); PREP (Preparation)
        (preparation of, as diuretic)

L52  ANSWER 29 OF 33  HCAPLUS  COPYRIGHT 2005 ACS on STN
AN   1986:443335  HCAPLUS
```

DN 105:43335
ED Entered STN: 09 Aug 1986
TI Octapeptide vasopressin antagonists
IN Huffman, William F.; Moore, Michael L.
PA SmithKline Beckman Corp., USA
SO U.S., 13 pp. Cont.-in-part of U.S. 4,469,679.
CODEN: USXXAM
DT Patent
LA English
IC A61K037-00; C07C103-52
INCL 514011000
CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 4542124	A	19850917	US 1984-624542	19840626	<--
	US 4469679	A	19840904	US 1983-467117	19830216	<--
	EP 119705	A2	19840926	EP 1984-300692	19840203	<--
	EP 119705	A3	19870422			
	EP 119705	B1	19890906			
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE					
	US 4587045	A	19860506	US 1985-734522	19850516	<--
PRAI	US 1983-467117	A2	19830216	<--		
	EP 1984-300692	A	19840203	<--		
	US 1984-624542	A3	19840626	<--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES	
US 4542124	IC	A61K037-00IC C07C103-52	
	INCL	514011000	
US 4542124	NCL	514/011.000; 514/807.000; 530/328.000; 930/020.000; 930/021.000; 930/150.000; 930/DIG.567	<--
US 4469679	NCL	514/011.000; 514/807.000; 530/315.000; 530/328.000; 930/020.000; 930/021.000; 930/150.000; 930/DIG.567	<--
US 4587045	NCL	530/328.000; 930/020.000; 930/021.000; 930/150.000	<--

GI



I

AB The title compds. I [P = (substituted) Phe; X = D-Phe, -Val, -Nva, -Leu, -Ile, -aIle, -Pba, -Nle, -Cha, -Abu, -Met, -Chg, D- or L-Tyr, D- or L-(alkyl)Tyr; Y = OH, substituted amino; W = D-Pro, L-Pro, dehydro-Pro; A = Val, Ile, Abu, Ala, Gly, Lys, Cha, Nle, Phe, Leu, Chg, Nva; Z = D-Arg, L-Arg, D-Lys, L-Lys; n = 0, 1, or 2], useful as antihypertensives (anti-vasopressin activity measured in hydropenic rats) were prepared I [X = D-Tyr(Et), P=Phe, A=Abu, W=Pro, Z=Arg, Y=NHz] was among the prepared
ST octapeptide prepn antihypertensive; vasopressin antagonist octapeptide
IT Antihypertensives
(octapeptides)
IT Peptides, preparation
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of octapeptides as vasopressin antagonist)
IT 107-10-8, reactions
RL: RCT (Reactant); RACT (Reactant or reagent)
(amidation by, of vasopressin analog)

IT 13836-37-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(amidation of, by benzhydrylamine resin)
IT 93449-76-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(amidation of, by propylamine)
IT 11000-17-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(antagonist, octapeptides as)
IT 15761-39-4 61925-77-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(esterification of, by (chloromethyl)phenyl resin)
IT 2788-83-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(peptide coupling of, with heptapeptide)
IT 102995-63-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(peptide coupling of, with pentapeptide)
IT 102995-68-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and deblocking of)
IT 102995-64-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and esterification of, by diazomethane)
IT 93449-72-0P 93449-73-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and oxidative cyclization of)
IT 98612-58-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and peptide coupling of, with dipeptide derivative)
IT 93957-04-1DP, resin-bound
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and resin cleavage-deblocking of)
IT 93449-75-3DP, benzhydrylamine resin-bound 99753-62-5DP, resin-bound 102995-56-2DP, benzhydrylamine resin-bound 102995-58-4DP, benzhydrylamine resin-bound 102995-59-5DP, p-methylbenzhydrylamine resin-bound 102995-61-9DP, p-methylbenzhydrylamine resin-bound 103022-87-3DP, benzhydrylamine resin-bound 103062-54-0DP, benzhydrylamine resin-bound
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and sequential resin cleavage-deblocking and oxidative cyclization of)
IT 102995-55-1DP, benzhydrylamine resin-bound
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and solid-phase peptide coupling of)
IT 15761-39-4DP, resin-bound
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and solid-phase peptide synthesis with)
IT 102995-65-3P 102995-66-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
IT 90332-82-4P 93449-69-5P 93449-70-8P 93472-64-1P 102995-54-0P 102995-57-3P 102995-60-8P 102995-62-0P 102995-67-5P 103022-88-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as vasopressin antagonist)
IT 98612-55-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, esterification and peptide coupling of)
IT 33294-54-1 33294-55-2 33294-56-3 64817-62-5 68059-30-3

93449-74-2D, p-methylbenzhydrylamine resin-bound 102995-52-8
102995-53-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(solid-phase peptide coupling of)
IT 13836-37-8D, resin-bound
RL: RCT (Reactant); RACT (Reactant or reagent)
(solid-phase peptide synthesis with)
IT **93449-72-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and oxidative cyclization of)
IT **90332-82-4P 93449-69-5P 93449-70-8P**
102995-54-0P 102995-57-3P 102995-60-8P
102995-62-0P 102995-67-5P 103022-88-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as vasopressin antagonist)

L52 ANSWER 30 OF 33 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1985:25046 HCAPLUS
DN 102:25046
ED Entered STN: 26 Jan 1985
TI Iodinated vasopressin antagonists
IN Huffman, William F.; Moore, Michael L.
PA SmithKline Beckman Corp., USA
SO U.S., 5 pp.
CODEN: USXXAM
DT Patent
LA English
IC A61K037-00; A61K043-00; G01N033-00; C07C103-52
INCL 424177000
CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 2
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 4469680	A	19840904	US 1983-511120,	19830706 <--
PRAI US 1983-511120		19830706 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 4469680	IC	A61K037-00IC A61K043-00IC G01N033-00IC C07C103-52
	INCL	424177000
US 4469680	NCL	424/001.690; 514/011.000; 514/807.000; 530/315.000; 530/328.000; 530/334.000; 530/345.000; 930/021.000; 930/023.000; 930/150.000; 930/DIG.565; 930/DIG.662 <--

GI For diagram(s), see printed CA Issue.
AB Iodinated vasopressin analogs I (R = OH, C1-2 alkoxy; R1 = H, iodo; X = D- or L-Arg; R2 = NH2, OH, Gly-OH, or Gly-NH2) were prepared as vasopressin antagonists. Thus, Pmp(CH2Ph)-D-Tyr(CO2CH2C6H4Br-p)-Phe-Val-Asn-Cys(CH2C6H4OMe-p)-Pro-Arg(Tos)-resin (Pmp = β-mercapto-β,β-cyclopentamethyleneproprionic acid, Tos = tosyl) was prepared by the solid-phase method and then it was cleaved by NH3/MeOH and deblocked by Na/NH3 to give Pmp-D-Tyr-Phe-Val-Asn-Cys-Pro-Arg-NH2, which was oxidized by K3[Fe(CN)6] to give [Pmp1, D-Tyr2, Val4, desGly9]AVP (II, AVP = arginine-vasopressin). II was iodinated to give [Pmp1, D-Tyr(I)2, Val4, desGly9]AVP. [Pmp1, D-Tyr(I)2, Val4]AVP exhibited in vivo anti-antidiuretic hormone activity in rats with an ED300 of 92.6 μg/kg.
ST iodinated vasopressin analog prepn antagonist
IT Peptides, preparation
RL: SPN (Synthetic preparation); PREP (Preparation)
(iodo, vasopressin-related, preparation and vasopressin antagonistic activity of)
IT 11000-17-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(antagonist, iodinated vasopressin analogs as)

IT 91919-89-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(antagonists, for vasopressin)
IT 61543-38-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(esterification of, with chloromethylated resin)
IT 81094-15-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(iodination of)
IT **93449-69-5P** 93472-64-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and iodination of)
IT **93449-72-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and oxidative cyclization of)
IT 93957-04-1DP, resin-bound
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and resin cleavage and deblocking of)
IT 13836-37-8DP, resin-bound
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and solid-phase peptide synthesis with)
IT 11000-17-2DP, iodinated analogs 91919-86-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and vasopressin antagonistic activity of)
IT **93957-06-3P** 93957-07-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
IT **93449-69-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and iodination of)
IT **93449-72-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and oxidative cyclization of)
IT **93957-06-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

L52 ANSWER 31 OF 33 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1985:7098 HCAPLUS
DN 102:7098
ED Entered STN: 12 Jan 1985
TI Octapeptide vasopressin antagonists
IN Huffman, William F.; Moore, Michael L.
PA SmithKline Beckman Corp., USA
SO U.S., 8 pp.
CODEN: USXXAM
DT Patent
LA English
IC A61K037-00; C07C103-52
INCL 424177000
CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 2
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4469679	A	19840904	US 1983-467117	19830216 <--
	EP 119705	A2	19840926	EP 1984-300692	19840203 <--
	EP 119705	A3	19870422		
	EP 119705	B1	19890906		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	AT 46174	E	19890915	AT 1984-300692	19840203 <--
	AU 8424534	A1	19840823	AU 1984-24534	19840213 <--

AU 577778	B2	19881006			
IL 70944	A1	19901129	IL 1984-70944	19840213	<--
IL 83945	A1	19901129	IL 1984-83945	19840213	<--
DK 8400652	A	19840817	DK 1984-652	19840214	<--
FI 8400577	A	19840817	FI 1984-577	19840214	<--
NO 8400563	A	19840817	NO 1984-563	19840215	<--
JP 59155348	A2	19840904	JP 1984-27986	19840215	<--
HU 34042	O	19850128	HU 1984-597	19840215	<--
HU 196227	B	19881028			
ZA 8401104	A	19850424	ZA 1984-1104	19840215	<--
ES 529738	A1	19860401	ES 1984-529738	19840215	<--
US 4542124	A	19850917	US 1984-624542	19840626	<--
ES 535842	A1	19851001	ES 1984-535842	19840912	<--
US 4587045	A	19860506	US 1985-734522	19850516	<--
PRAI US 1983-467117	A	19830216	<--		
EP 1984-300692	A	19840203	<--		
IL 1984-70944	A	19840213	<--		
US 1984-624542	A3	19840626	<--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 4469679	IC	A61K037-00IC C07C103-52
	INCL	424177000
US 4469679	NCL	514/011.000; 514/807.000; 530/315.000; 530/328.000; 930/020.000; 930/021.000; 930/150.000; 930/DIG.567 <--
US 4542124	NCL	514/011.000; 514/807.000; 530/328.000; 930/020.000; 930/021.000; 930/150.000; 930/DIG.567 <--
US 4587045	NCL	530/328.000; 930/020.000; 930/021.000; 930/150.000 <--

GI For diagram(s), see printed CA Issue.

AB Vasopressin analogs I [X = D-Phe, D-Val, D-Leu, D-Ile, D-Nva, D-Nle, D-NHCHEtCO, D-Met, D-Tyr, D-Tyr(R1) (R1 = C1-4 alkyl); X1 = Pro, dehydroproline residue; X2 = D-Arg, Arg, D-Lys, Lys; R = NHR2 (R2 = H, C1-4 alkyl, CH2Ph), OH] were prepared as vasopressin antagonists. Thus, Pmp(CH2Ph)-D-Tyr(CO2CH2C6H4Br-2)-Phe-Val-Asn-Cys(CH2C6H4OMe-4)-Pro-Arg(Tos)-R3 (II; Pmp = β-mercapto-β,β-cyclopentamethylenepropionic acid residue, Tos = tosyl, R3 = resin) was prepared by the solid-phase method and was cleaved by ammonolysis to give II (R3 = NH2). The latter was deblocked by Na/NH3 to give Pmp-D-Tyr-Phe-Val-Asn-Cys-Pro-Arg-NH2, which was oxidized by K3Fe(CN)6 to give vasopressin analog III. III at 63 μg/kg lowered urine osmalality in rats to 300 m-Osmoles/kg.

ST mercaptocyclopentamethylenepropionic vasopressin analog

IT Peptides, preparation
RL: SPN (Synthetic preparation); PREP (Preparation)
(vasopressin-related, preparation and vasopressin antagonistic activity of)

IT 13836-37-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(amidation of, with benzhydrylamine resin)

IT 93449-76-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(amidation of, with propylamine)

IT 11000-17-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(antagonist, mercaptocyclopentamethylenepropionic acid-containing vasopressin analog as)

IT 87242-92-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(coupling of, with peptidyl resin)

IT **93449-77-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and deblocking of)

IT 93449-75-3DP, benzhydrylamine resin-bound
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and deblocking-oxidative cyclization of)

IT **93449-72-0P** **93449-73-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and oxidative cyclization of)
IT 93449-71-9DP, resin bound
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and resin cleavage of, by ammonolysis)
IT 93449-74-2DP, benzhydrylamine resin-bound
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and solid-phase peptide synthesis with)
IT **90332-82-4P** **93449-69-5P** 93472-64-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and vasopressin antagonistic activity of)
IT **93449-70-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
IT 7536-55-2 76757-92-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(solid-phase peptide coupling of)
IT 13836-37-8D, resin-bound
RL: RCT (Reactant); RACT (Reactant or reagent)
(solid-phase peptide synthesis with)
IT 80148-24-9 81094-15-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(vasopressin antagonistic activity of)
IT **93449-77-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and deblocking of)
IT **93449-72-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and oxidative cyclization of)
IT **90332-82-4P** **93449-69-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and vasopressin antagonistic activity of)
IT **93449-70-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

L52 ANSWER 32 OF 33 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1980:94693 HCAPLUS
DN 92:94693
ED Entered STN: 12 May 1984
TI Polypeptide agents for blocking the human allergic response
IN Hamburger, Robert N.
PA University of California, Berkeley, USA
SO U.S., 10 pp.
CODEN: USXXAM
DT Patent
LA English
IC C07C103-52
INCL 260112500R
CC 34-3 (Synthesis of Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 15, 63
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4171299	A	19791016	US 1976-652868	19760127 <--
	JP 51118702	A2	19761018	JP 1976-7400	19760126 <--
	JP 60002318	B4	19850121		
	BE 840193	A1	19760930	BE 1976-165690	19760330 <--
	US 4161522	A	19790717	US 1978-940323	19780907 <--
	AU 8065181	A1	19810416	AU 1980-65181	19801208 <--
	AU 531075	B2	19830811		
PRAI	US 1975-565425	A2	19750404 <--		

```
     US 1976-652868        A2    19760127  <--
     AU 1976-12303         A     19760324  <--
CLASS
 PATENT NO.       CLASS  PATENT FAMILY CLASSIFICATION CODES
 --------------   -----  ----------------------------------------------
 US 4171299       IC     C07C103-52
                  INCL   260112500R
 US 4171299       NCL    530/329.000; 530/328.000; 530/330.000; 530/331.000;
                         930/010.000                                      <--
 US 4161522       NCL    514/015.000; 514/016.000; 514/017.000; 514/018.000;
                         530/328.000; 530/329.000; 530/330.000; 530/331.000;
                         930/010.000                                      <--
AB   Tri- to decapeptides related to the epsilon chain of Ig E were prepared as
     agents for the blocking of the allergic response.  Thus,
     BOC-Arg(NO2)-O-resin (BOC = Me3CO2C) was extended by stepwise solid-phase
     couplings to BOC-Asp(OCH2Ph)-Pro-Arg(NO2)-O-resin, which was cleaved and
     deblocked by HBr/CF3CO2H to give H-Asp-Pro-Arg(NO2)-OH, which was
     hydrogenated to give H-Asp-Pro-Arg-OH (I).  H-Ser-Asp-Pro-Arg-OH,
     H-Asp-Ser-Asp-Pro-Arg-OH, and H-Ala-Asp-Ser-Asp-Pro-Arg-OH were prepared
     similarly.  I had an average 15% allergic response-blocking activity according
     to the Prausnitz-Kustner reaction.
ST   Ig tripeptide decapeptide allergy blocking
IT   Peptides, preparation
     RL: SPN (Synthetic preparation); PREP (Preparation)
        (Ig E epsilon chain-related, preparation and allergic response-blocking
        activity of)
IT   Allergy
        (inhibitors, tri- to decapeptides related to Ig E epsilon chain)
IT   Immunoglobulins
     RL: SPN (Synthetic preparation); PREP (Preparation)
        (E, tri- to decapeptides related to epsilon chain of, preparation and
        allergic response-blocking activity of)
IT   62087-80-3
     RL: RCT (Reactant); RACT (Reactant or reagent)
        (allergic response-blocking activity of)
IT   31948-52-4
     RL: PROC (Process)
        (conversion of, to cesium salt)
IT   62087-70-1P   62087-72-3P   62087-73-4P   71658-92-9DP, resin-bound
     RL: SPN (Synthetic preparation); PREP (Preparation)
        (preparation and allergic response-blocking activity of)
IT   62087-75-6P
     RL: SPN (Synthetic preparation); PREP (Preparation)
        (preparation and conversion of, to azide)
IT   62087-75-6P   71659-00-2P
     RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
     (Reactant or reagent)
        (preparation and deblocking of)
IT   72504-07-5P
     RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
     (Reactant or reagent)
        (preparation and esterification of, with methanol)
IT   62087-81-4P
     RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
     (Reactant or reagent)
        (preparation and hydrogenolysis of)
IT   71658-93-0P
     RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
     (Reactant or reagent)
        (preparation and reaction of, with chloromethylated resins)
IT   62087-75-6DP, resin-bound
     RL: SPN (Synthetic preparation); PREP (Preparation)
        (preparation and resin cleavage of)
IT   71658-90-7DP, resin-bound   71658-91-8DP, resin-bound   71658-94-1DP,
     resin-bound
     RL: SPN (Synthetic preparation); PREP (Preparation)
```

(preparation and resin cleavage-deblocking of)
IT 2188-18-3DP, resin-bound 31948-52-4DP, resin-bound 62087-77-8DP, resin-bound 71658-97-4DP, resin-bound
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and solid-phase peptide synthesis with)
IT 62087-78-9DP, resin-bound
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and O-acylation of, with hexanoic acid)
IT 62087-76-7P 71658-95-2P 71658-96-3P **71659-01-3P**
72504-05-3P 72504-06-4P 72510-60-2P 72529-34-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
IT 25692-95-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with carboxy hydrazide resin)
IT 2188-18-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with chloromethylated resin)
IT 7536-58-5 15761-38-3 15761-39-4 23680-31-1 26048-69-1 39747-65-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(solid-phase peptide coupling of)
IT 142-62-1, reactions
RL: RCT (Reactant); RACT (Reactant or reagent)
(O-acylation by, of serine-containing peptide resins)
IT **71659-01-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

L52 ANSWER 33 OF 33 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1979:558110 HCAPLUS
DN 91:158110
ED Entered STN: 12 May 1984
TI Blocking allergic responses
IN Hamburger, Robert N.
PA University of California, Berkeley, USA
SO U.S., 12 pp.
CODEN: USXXAM
DT Patent
LA English
IC A61K037-00; C07C103-52
INCL 424177000
CC 34-3 (Synthesis of Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 63
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 4161522	A	19790717	US 1978-940323	19780907	<--
	US 4171299	A	19791016	US 1976-652868	19760127	<--
	AU 8065181	A1	19810416	AU 1980-65181	19801208	<--
	AU 531075	B2	19830811			
PRAI	US 1975-565425	A2	19750404	<--		
	US 1976-652868	A2	19760127	<--		
	AU 1976-12303	A	19760324	<--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES	
US 4161522	IC	A61K037-00IC C07C103-52	
	INCL	424177000	
US 4161522	NCL	514/015.000; 514/016.000; 514/017.000; 514/018.000; 530/328.000; 530/329.000; 530/330.000; 530/331.000; 930/010.000	<--
US 4171299	NCL	530/329.000; 530/328.000; 530/330.000; 530/331.000; 930/010.000	<--

AB Tripeptides to decapeptides from the 265-537 sequence of the Fc region of Ig E, useful as agents for blocking the mammalian allergic response, were

prepared by solid-phase methods. Thus, BOC-Asp-(OCH2Ph)-Pro-Arg(NO2)-O-resin (I, BOC = Me3CO2C) was prepared by stepwise solid-phase couplings and then was resin-cleaved and deblocked by HBr/CF3CO2H to give H-Asp-Pro-Arg(NO2)-OH, which was hydrogenated to give H-Asp-Pro-Arg-OH. I was used in the solid-phase preparation of BOC-Ser(CH2Ph)-Asp(OCH2Ph)-Pro-Arg(NO2)-O-resin (II), which was cleaved and deblocked to give H-Ser-Asp-Pro-Arg-OH, and II was used in the solid-phase preparation of H-Asp-Ser-Asp-Pro-OH (III). H-Ala-Asp-Ser-Asp-Pro-Arg-OH was also prepared III exhibited an average allergic inhibition of 72% in an assay of the Prausnitz-Kustner reaction.

ST peptide Ig prepn allergy blocking

IT Allergy
(inhibitors, tri- to decapeptides from sequence 265-537 of Fc region of Ig E)

IT Peptides, preparation
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and antiallergic activity of, from sequence 265-537 of Fc region of Ig E)

IT Immunoglobulins
RL: SPN (Synthetic preparation); PREP (Preparation)
(E, tri- to decapeptides from sequence 265-537 of Fc region of, preparation and antiallergic activity of)

IT 62087-80-3
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antiallergic activity of)

IT 31948-52-4
RL: PROC (Process)
(conversion of, to cesium salt)

IT 62087-70-1P 62087-71-2P 62087-72-3P 62087-73-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and antiallergic activity of)

IT 62087-75-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and conversion of, to azide)

IT 71658-99-6P 71659-00-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and deblocking of)

IT 71658-98-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and esterification of, with methanol)

IT 62087-81-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrogenolysis of)

IT 71658-93-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, with chloromethylated resin)

IT 71658-90-7DP, resin-bound 71658-91-8DP, resin-bound 71658-92-9DP, resin-bound 71658-94-1DP, resin-bound
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and resin cleavage and deblocking of)

IT 62087-75-6DP, resin-bound
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and resin cleavage of)

IT 2188-18-3DP, resin-bound 31948-52-4DP, resin-bound 62087-77-8DP, resin-bound 70689-04-2DP, resin-bound 71658-97-4DP, resin-bound
RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation and solid-phase peptide synthesis with)
IT 62087-71-2P 62087-76-7P 62087-78-9DP, resin-bound 62087-79-0P
71658-95-2P 71658-96-3P **71659-01-3P** 71659-02-4P
71659-03-5P 71659-04-6P 71659-05-7P 71659-06-8P 71659-07-9P
71659-08-0P 71659-09-1P 71659-10-4P 71659-11-5P 71659-12-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
IT 25692-95-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with solid-phase resin)
IT 7536-58-5 15761-38-3 15761-39-4 23680-31-1 39747-65-4 62087-78-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(solid-phase peptide coupling of)
IT **71659-01-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

```
=> b reg
FILE 'REGISTRY' ENTERED AT 12:42:05 ON 15 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   14 JUN 2005  HIGHEST RN 852282-01-0
DICTIONARY FILE UPDATES:  14 JUN 2005  HIGHEST RN 852282-01-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,    *
* effective March 20, 2005.  A new display format, IDERL, is now     *
* available and contains the CA role and document type information.  *
*                                                                    *
**********************************************************************

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data a
information enter HELP PROP at an arrow pro
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.ht

=> d sqide l53 tot

L53  ANSWER 1 OF 63  REGISTRY  COPYRIGHT 200
RN   636593-90-3  REGISTRY
CN   L-Argininamide, N-acetyl-L-leucyl-L-arg
     tyrosyl-L-arginyl-L-alanyl-L-isoleucyl-
     prolyl- (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   776: PN: US20040058881 PAGE: 84 claimed
FS   PROTEIN SEQUENCE; STEREOSEARCH
SQL  14
NTE  modified
-----------------------------------------
 type            ------ location ------
-----------------------------------------
terminal mod.    Leu-1          -         N-
terminal mod.    Arg-14         -         C-terminal amide
-----------------------------------------

PATENT ANNOTATIONS (PNTE):
Sequence |Patent
Source   |Reference
=========+============
Not Given|US2004058881
         |claimed PAGE
         |84


SEQ      1 LRMKAYRAIR HIPR
MF   C81 H140 N30 O16 S
SR   CA
```

L53: hit registry numbers from set l52

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PRP (Properties); USES (Uses)
RL.NP Roles from non-patents: BIOL (Biological study); PRP (Properties)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L53 ANSWER 2 OF 63 REGISTRY COPYRIGHT 2005 ACS on STN
RN 636593-89-0 REGISTRY
CN L-Argininamide, N-acetyl-L-leucyl-L-arginyl-L-methionyl-L-lysyl-5-aminopentanoyl-L-tyrosyl-L-arginyl-L-alanyl-L-isoleucyl-L-arginyl-L-histidyl-L-isoleucyl-L-prolyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 775: PN: US20040058881 PAGE: 84 claimed protein
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 14
NTE modified

type	------ location ------		description
terminal mod.	Leu-1	-	N-acetyl
terminal mod.	Arg-14	-	C-terminal amide
uncommon	Oaa-5	-	-

PATENT ANNOTATIONS (PNTE):

Sequence Source	Patent Reference
Not Given	US2004058881 claimed PAGE 84

SEQ 1 LRMKXYRAIR HIPR
MF C83 H144 N30 O16 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PRP (Properties); USES (Uses)

RL.NP Roles from non-patents: BIOL (Biological study); PRP (Properties)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B

NHAc

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L53 ANSWER 3 OF 63 REGISTRY COPYRIGHT 2005 ACS on STN
RN 636593-88-9 REGISTRY
CN L-Argininamide, N-acetyl-L-leucyl-L-arginyl-L-methionyl-L-lysyl-5-aminopentanoyl-L-alanyl-L-tyrosyl-L-arginyl-L-alanyl-L-isoleucyl-L-arginyl-L-histidyl-L-isoleucyl-L-prolyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 774: PN: US20040058881 PAGE: 84 claimed protein
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 15
NTE modified

type	------ location ------		description
terminal mod.	Leu-1	-	N-acetyl
terminal mod.	Arg-15	-	C-terminal amide
uncommon	Oaa-5	-	-

PATENT ANNOTATIONS (PNTE):

Sequence Source	Patent Reference
Not Given	US2004058881 claimed PAGE 84

SEQ 1 LRMKXAYRAI RHIPR
MF C86 H149 N31 O17 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PRP (Properties); USES (Uses)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

Search done by Noble Jarrell

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L53 ANSWER 4 OF 63 REGISTRY COPYRIGHT 2005 ACS on STN
RN 636593-87-8 REGISTRY
CN L-Argininamide, N-acetyl-L-leucyl-L-arginyl-L-methionyl-L-lysyl-5-aminopentanoyl-5-aminopentanoyl-L-alanyl-L-tyrosyl-L-arginyl-L-alanyl-L-isoleucyl-L-arginyl-L-histidyl-L-isoleucyl-L-prolyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 773: PN: US20040058881 PAGE: 84 claimed protein
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 16
NTE modified

type	------ location ------		description
terminal mod.	Leu-1	-	N-acetyl
terminal mod.	Arg-16	-	C-terminal amide
uncommon	Oaa-5	-	-
uncommon	Oaa-6	-	-

PATENT ANNOTATIONS (PNTE):

Sequence Source	Patent Reference
Not Given	US2004058881 claimed PAGE 84

SEQ 1 LRMKXXAYRA IRHIPR
MF C91 H158 N32 O18 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PRP (Properties); USES (Uses)
RL.NP Roles from non-patents: BIOL (Biological study); PRP (Properties)

Absolute stereochemistry.

PAGE 1-A





PAGE 1-B



PAGE 1-C



PAGE 2-A



PAGE 2-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L53 ANSWER 5 OF 63 REGISTRY COPYRIGHT 2005 ACS on STN
RN **586954-22-5** REGISTRY
CN Peptide nucleic acid, ([(9H-fluoren-9-ylmethoxy)carbonyl]-[(4R)-1-(2-aminoethyl)-4-(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)-D-Pro]10)-Lys-NH2 (9CI) (CA INDEX NAME)
FS NUCLEIC ACID SEQUENCE; STEREOSEARCH
SQL 10
NA 10 t
NTE modified

type	------ location ------	description
modified base	t-1	modified thymidine
modified base	t-1	5'-substituted

Search done by Noble Jarrell

modified base	t-2	modified thymidine
modified base	t-3	modified thymidine
modified base	t-4	modified thymidine
modified base	t-5	modified thymidine
modified base	t-6	modified thymidine
modified base	t-7	modified thymidine
modified base	t-8	modified thymidine
modified base	t-9	modified thymidine
modified base	t-10	modified thymidine
modified base	t-10	3'-deoxy
modified base	t-10	3'-nh2

SEQ 1 ttttttttt

RELATED SEQUENCES AVAILABLE WITH SEQLINK
MF C141 H185 N43 O33
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

PAGE 2-A



PAGE 2-B



PAGE 2-C



PAGE 3-B



PAGE 3-C



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L53 ANSWER 6 OF 63 REGISTRY COPYRIGHT 2005 ACS on STN
RN 586954-19-0 REGISTRY
CN Peptide nucleic acid, (H-[(4R)-1-(2-aminoethyl)-4-(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)-D-Pro]10)-Lys-NH2 (9CI) (CA INDEX NAME)
FS NUCLEIC ACID SEQUENCE; STEREOSEARCH
SQL 10
NA 10 t
NTE modified

type	------ location ------	description
modified base	t-1	modified thymidine
modified base	t-2	modified thymidine
modified base	t-3	modified thymidine
modified base	t-4	modified thymidine
modified base	t-5	modified thymidine
modified base	t-6	modified thymidine
modified base	t-7	modified thymidine
modified base	t-8	modified thymidine
modified base	t-9	modified thymidine
modified base	t-10	modified thymidine
modified base	t-10	3'-deoxy
modified base	t-10	3'-nh2

SEQ 1 ttttttttt

RELATED SEQUENCES AVAILABLE WITH SEQLINK
MF C126 H175 N43 O31
CI COM
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)

Absolute stereochemistry.

PAGE 1-A

Me

PAGE 1-B





PAGE 1-C



PAGE 2-A



PAGE 2-B



PAGE 2-C



PAGE 3-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L53 ANSWER 7 OF 63 REGISTRY COPYRIGHT 2005 ACS on STN
RN **544448-59-1** REGISTRY
CN L-Lysinamide, N-acetyl-L-valyl-D-isoleucyl-L-threonyl-L-norvalyl-L-isoleucyl-L-arginyl-L-prolyl-N6-acetyl-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

Search done by Noble Jarrell

FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 8
NTE modified

type	location		description
terminal mod.	Val-1	-	N-acetyl
terminal mod.	Lys-8	-	C-terminal amide
uncommon	Nva-4	-	-
modification	-	-	undetermined modification
modification	Lys-8	-	acetyl<Ac>

SEQ 1 VITXIRPK

RELATED SEQUENCES AVAILABLE WITH SEQLINK
MF C47 H85 N13 O11 . C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: PREP (Preparation)

CM 1

CRN 544448-58-0
CMF C47 H85 N13 O11

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L53 ANSWER 8 OF 63 REGISTRY COPYRIGHT 2005 ACS on STN
RN 544448-58-0 REGISTRY
CN L-Lysinamide, N-acetyl-L-valyl-D-isoleucyl-L-threonyl-L-norvalyl-L-isoleucyl-L-arginyl-L-prolyl-N6-acetyl- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 8
NTE modified

type	------ location ------		description
terminal mod.	Val-1	-	N-acetyl
terminal mod.	Lys-8	-	C-terminal amide
uncommon	Nva-4	-	-
modification	Lys-8	-	acetyl<Ac>

SEQ 1 VITXIRPK

RELATED SEQUENCES AVAILABLE WITH SEQLINK
MF C47 H85 N13 O11
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L53 ANSWER 9 OF 63 REGISTRY COPYRIGHT 2005 ACS on STN
RN 540737-98-2 REGISTRY
CN L-Argininamide, N2-acetyl-L-glutaminyl-L-valyl-D-isoleucyl-L-threonyl-L-norvalyl-L-prolyl-N-ethyl-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 7
NTE modified

type	------ location ------		description
terminal mod.	Gln-1	-	N-acetyl
uncommon	Nva-5	-	-
modification	-	-	undetermined modification

SEQ 1 QVITXPR

RELATED SEQUENCES AVAILABLE WITH SEQLINK
MF C40 H72 N12 O10 . C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

CM 1

CRN 521943-71-5
CMF C40 H72 N12 O10

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L53 ANSWER 10 OF 63 REGISTRY COPYRIGHT 2005 ACS on STN
RN 539853-66-2 REGISTRY
CN L-Argininamide, N-acetyl-L-tryptophyl-L-prolyl-N-ethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 75: PN: US20030109456 SEQID: 75 claimed sequence
FS STEREOSEARCH
MF C26 H38 N8 O4 . C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

CM 1

CRN 521292-36-4
CMF C26 H38 N8 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L53 ANSWER 11 OF 63 REGISTRY COPYRIGHT 2005 ACS on STN
RN 522609-87-6 REGISTRY
CN D-Lysinamide, N-acetyl-D-isoleucyl-L-threonyl-L-norvalyl-L-isoleucyl-L-arginyl-L-prolyl-N6-acetyl-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 7
NTE modified

type	------ location ------		description
terminal mod.	Ile-1	-	N-acetyl
terminal mod.	Lys-7	-	C-terminal amide
uncommon	Nva-3	-	-
modification	-	-	undetermined modification
modification	Lys-7	-	acetyl<Ac>

SEQ 1 ITXIRPK

RELATED SEQUENCES AVAILABLE WITH SEQLINK
MF C42 H76 N12 O10 . C2 H F3 O2

SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

CM 1

CRN 522609-86-5
CMF C42 H76 N12 O10

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L53 ANSWER 12 OF 63 REGISTRY COPYRIGHT 2005 ACS on STN
RN 522609-86-5 REGISTRY
CN D-Lysinamide, N-acetyl-D-isoleucyl-L-threonyl-L-norvalyl-L-isoleucyl-L-arginyl-L-prolyl-N6-acetyl- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 7
NTE modified

type	------ location ------		description
terminal mod.	Ile-1	-	N-acetyl
terminal mod.	Lys-7	-	C-terminal amide
uncommon	Nva-3	-	-

modification Lys-7 - acetyl<Ac>

SEQ 1 ITXIRPK

RELATED SEQUENCES AVAILABLE WITH SEQLINK
MF C42 H76 N12 O10
CI COM
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L53 ANSWER 13 OF 63 REGISTRY COPYRIGHT 2005 ACS on STN
RN 521943-71-5 REGISTRY
CN L-Argininamide, N2-acetyl-L-glutaminyl-L-valyl-D-isoleucyl-L-threonyl-L-norvalyl-L-prolyl-N-ethyl- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 7
NTE modified

type	location		description
terminal mod.	Gln-1	-	N-acetyl
uncommon	Nva-5	-	-

SEQ 1 QVITXPR

RELATED SEQUENCES AVAILABLE WITH SEQLINK
MF C40 H72 N12 O10
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA CAplus document type: Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L53 ANSWER 14 OF 63 REGISTRY COPYRIGHT 2005 ACS on STN
RN **521292-36-4** REGISTRY
CN L-Argininamide, N-acetyl-L-tryptophyl-L-prolyl-N-ethyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 38: PN: US20030109456 SEQID: 38 claimed sequence
FS STEREOSEARCH
MF C26 H38 N8 O4
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L53 ANSWER 15 OF 63 REGISTRY COPYRIGHT 2005 ACS on STN
RN 502620-59-9 REGISTRY
CN L-Lysinamide, glycyl-L-prolyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 13: PN: US20030060599 PAGE: 15 claimed sequence
FS STEREOSEARCH
MF C13 H25 N5 O3
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PRP (Properties); USES (Uses)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L53 ANSWER 16 OF 63 REGISTRY COPYRIGHT 2005 ACS on STN
RN 282096-82-6 REGISTRY
CN L-Lysinamide, N-acetyl-L-threonyl-L-threonyl-L-serylglycyl-L-isoleucyl-L-histidyl-L-prolyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2: PN: WO0042069 SEQID: 18 claimed protein
CN Ac-Thr-Thr-Ser-Gly-Ile-His-Pro-Lys-NH2
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 8
NTE modified

type	------ location ------	description

terminal mod.	Thr-1	-	N-acetyl
terminal mod.	Lys-8	-	C-terminal amide

PATENT ANNOTATIONS (PNTE):

Sequence Source	Patent Reference
Not Given	WO2000042069 claimed SEQID 18

SEQ 1 TTSGIHPK

RELATED SEQUENCES AVAILABLE WITH SEQLINK
MF C38 H64 N12 O12
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

Absolute stereochemistry.



2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L53 ANSWER 17 OF 63 REGISTRY COPYRIGHT 2005 ACS on STN
RN 226714-20-1 REGISTRY
CN L-Argininamide, L-α-aspartyl-L-seryl-L-asparaginyl-L-prolyl- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 5
NTE modified

type	location	description
terminal mod.	Arg-5 -	C-terminal amide

SEQ 1 DSNPR

RELATED SEQUENCES AVAILABLE WITH SEQLINK
MF C22 H38 N10 O9
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PRP (Properties); USES

(Uses)

Absolute stereochemistry.





1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L53 ANSWER 18 OF 63 REGISTRY COPYRIGHT 2005 ACS on STN
RN **226714-12-1** REGISTRY
CN L-Argininamide, L-α-aspartyl-L-seryl-L-α-aspartyl-L-prolyl- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 5
NTE modified

type	------ location ------		description
terminal mod.	Arg-5	-	C-terminal amide

SEQ 1 DSDPR

RELATED SEQUENCES AVAILABLE WITH SEQLINK
MF C22 H37 N9 O10
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PRP (Properties); USES (Uses)

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L53 ANSWER 19 OF 63 REGISTRY COPYRIGHT 2005 ACS on STN
RN 217433-25-5 REGISTRY
CN D-Argininamide, N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-histidyl-D-arginyl-D-tryptophyl-L-lysyl-L-prolyl- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 10
NTE modified

type	location		description
terminal mod.	Ala-1	-	N-acetyl
terminal mod.	Arg-10	-	C-terminal amide
modification	Ala-1	-	2-naphthalenyl<2-Naph>
modification	Phe-2	-	chloro<Cl>
modification	Ala-3	-	3-pyridinyl<3Py>

SEQ 1 AFASHRWKPR
MF C75 H97 Cl N22 O12
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); USES (Uses)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L53 ANSWER 20 OF 63 REGISTRY COPYRIGHT 2005 ACS on STN
RN 212955-65-2 REGISTRY
CN L-Argininamide, N-acetyl-L-phenylalanyl-L-tyrosyl-L-arginyl-L-alanyl-L-α-aspartyl-L-glutaminyl-L-prolyl- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 8
NTE modified

---

type ------ location ------ description

Search done by Noble Jarrell

terminal mod.	Phe-1	-	N-acetyl
terminal mod.	Arg-8	-	C-terminal amide

SEQ 1 FYRADQPR

RELATED SEQUENCES AVAILABLE WITH SEQLINK
MF C49 H72 N16 O13
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: ANST (Analytical study); PRP (Properties); USES (Uses)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L53 ANSWER 21 OF 63 REGISTRY COPYRIGHT 2005 ACS on STN
RN **209595-31-3** REGISTRY
CN L-Argininamide, L-threonyl-L-arginylglycyl-L-methionyl-L-tyrosyl-L-alanyl-L-cysteinyl-L-histidyl-L-methionylglycyl-L-prolyl-L-glutaminyl-L-threonyl-L-tryptophyl-L-valyl-L-cysteinyl-L-arginyl-L-prolyl-L-threonyl-L-

glutaminyl-L-prolyl- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 22
NTE modified

type	------ location ------		description
terminal mod.	Arg-22	-	C-terminal amide

SEQ 1 TRGMYACHMG PQTWVCRPTQ PR
MF C109 H171 N37 O28 S4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PRP (Properties)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-A



PAGE 2-B

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L53 ANSWER 22 OF 63 REGISTRY COPYRIGHT 2005 ACS on STN
RN **209595-18-6** REGISTRY
CN L-Argininamide, L-alanyl-L-arginylglycyl-L-lysyl-L-tyrosyl-L-glutaminyl-L-cysteinyl-L-glutaminyl-L-phenylalanylglycyl-L-prolyl-L-leucyl-L-threonyl-L-tryptophyl-L-α-glutamyl-L-cysteinyl-L-leucyl-L-prolyl-L-isoleucyl-L-arginyl-L-prolyl- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 22
NTE modified

type	------ location ------	description
terminal mod.	Arg-22 -	C-terminal amide

SEQ 1 ARGKYQCQFG PLTWECLPIR PR
MF C118 H184 N36 O28 S2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PRP (Properties)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 1-D

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L53 ANSWER 23 OF 63 REGISTRY COPYRIGHT 2005 ACS on STN
RN **209595-10-8** REGISTRY
CN L-Argininamide, L-leucyl-L-leucyl-L-arginylglycyl-L-tyrosyl-L-α-glutamyl-L-cysteinyl-L-tyrosyl-L-methionylglycyl-L-prolyl-L-leucyl-L-threonyl-L-tryptophyl-L-valyl-L-cysteinyl-L-arginyl-L-seryl-L-seryl-L-lysyl-L-prolyl- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 22
NTE modified

type	------ location ------	description

Search done by Noble Jarrell

---

terminal mod. Arg-22 - C-terminal amide

SEQ 1 LLRGYECYMG PLTWVCRSSK PR
MF C116 H184 N34 O29 S3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PRP (Properties)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 1-D



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L53 ANSWER 24 OF 63 REGISTRY COPYRIGHT 2005 ACS on STN
RN 186654-70-6 REGISTRY
CN L-Argininamide, L-tryptophyl-L-tryptophyl-L-prolyl- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 4
NTE modified

type	------ location ------	description

Search done by Noble Jarrell

terminal mod. Arg-4 - C-terminal amide

SEQ 1 WWPR
MF C33 H42 N10 O4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PROC (Process); PRP (Properties); USES (Uses)

Absolute stereochemistry.



3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L53 ANSWER 25 OF 63 REGISTRY COPYRIGHT 2005 ACS on STN
RN 186654-69-3 REGISTRY
CN L-Lysinamide, L-tryptophyl-L-tryptophyl-L-prolyl- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 4
NTE modified

type	location		description
terminal mod.	Lys-4	-	C-terminal amide

SEQ 1 WWPK
MF C33 H42 N8 O4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PROC (Process); PRP (Properties); USES (Uses)

Absolute stereochemistry.



3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L53 ANSWER 26 OF 63 REGISTRY COPYRIGHT 2005 ACS on STN
RN **184686-56-4** REGISTRY
CN D-Argininamide, N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-D-tryptophyl-L-seryl-L-tyrosyl-N5-[bis(ethylamino)methylene]-D-ornithyl-L-leucyl-L-arginyl-L-prolyl- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 10
NTE modified

type	------ location ------		description
terminal mod.	Ala-1	-	N-acetyl
terminal mod.	Arg-10	-	C-terminal amide
modification	Ala-1	-	2-naphthalenyl<2-Naph>
modification	Phe-2	-	chloro<Cl>
modification	Arg-6	-	ethyl<2; Et>

SEQ 1 AFWSYRLRPR
MF C80 H110 Cl N21 O13
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); USES (Uses)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L53 ANSWER 27 OF 63 REGISTRY COPYRIGHT 2005 ACS on STN
RN **184686-55-3** REGISTRY
CN D-Argininamide, N-acetyl-4-chloro-D-phenylalanyl-4-chloro-D-phenylalanyl-D-tryptophyl-L-seryl-L-tyrosyl-D-arginyl-L-leucyl-L-arginyl-L-prolyl- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 10
NTE modified

type	------ location ------		description
terminal mod.	Phe-1	-	N-acetyl

Search done by Noble Jarrell

terminal mod. Arg-10 - C-terminal amide
modification Phe-1 - chloro<Cl>
modification Phe-2 - chloro<Cl>

SEQ 1 FFWSYRLRPR
MF C72 H99 Cl2 N21 O13
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); USES (Uses)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L53 ANSWER 28 OF 63 REGISTRY COPYRIGHT 2005 ACS on STN
RN 179555-43-2 REGISTRY
CN L-Argininamide, glycylglycylglycyl-D-phenylalanyl-L-prolyl- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 6
NTE modified

---

type	------ location ------		description
terminal mod.	Arg-6	-	C-terminal amide

SEQ 1 GGGFPR

RELATED SEQUENCES AVAILABLE WITH SEQLINK
MF C26 H40 N10 O6
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent)
RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
RLD.NP Roles for non-specific derivatives from non-patents: BIOL (Biological study); PREP (Preparation)

Absolute stereochemistry.



4 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L53 ANSWER 29 OF 63 REGISTRY COPYRIGHT 2005 ACS on STN
RN 162071-80-9 REGISTRY
CN L-Argininamide, N-acetyl-L-threonyl-L-threonyl-L-seryl-L-glutaminyl-L-valyl-L-arginyl-L-prolyl- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 8
NTE modified

type	------ location ------		description
terminal mod.	Thr-1	-	N-acetyl
terminal mod.	Arg-8	-	C-terminal amide

SEQ 1 TTSQVRPR

RELATED SEQUENCES AVAILABLE WITH SEQLINK
MF C40 H72 N16 O13
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PRP (Properties); USES (Uses)

Absolute stereochemistry.



2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L53 ANSWER 30 OF 63 REGISTRY COPYRIGHT 2005 ACS on STN
RN **162071-42-3** REGISTRY
CN L-Argininamide, L-threonyl-L-threonyl-L-seryl-L-glutaminyl-L-valyl-L-arginyl-L-prolyl- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 8
NTE modified

type	------ location ------	description
terminal mod.	Arg-8 -	C-terminal amide

SEQ 1 TTSQVRPR

RELATED SEQUENCES AVAILABLE WITH SEQLINK
MF C38 H70 N16 O12
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PRP (Properties); USES (Uses)

Absolute stereochemistry.



2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L53 ANSWER 31 OF 63 REGISTRY COPYRIGHT 2005 ACS on STN
RN 145230-68-8 REGISTRY
CN L-Argininamide, L-seryl-L-phenylalanyl-L-leucyl-L-prolyl- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 5
NTE modified

type	------ location ------	description
terminal mod.	Arg-5 -	C-terminal amide

SEQ 1 SFLPR
MF C29 H47 N9 O6
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
RL.NP Roles from non-patents: BIOL (Biological study); PROC (Process); PRP (Properties)

Absolute stereochemistry.



3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L53 ANSWER 32 OF 63 REGISTRY COPYRIGHT 2005 ACS on STN
RN **142689-18-7** REGISTRY
CN Dermorphin, 7-L-lysinamide- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 7
NTE modified

type	------ location ------	description
terminal mod.	Lys-7 -	C-terminal amide

SEQ 1 YAFGYPK

RELATED SEQUENCES AVAILABLE WITH SEQLINK
MF C43 H57 N9 O9
SR CA
LC STN Files: CA, CAPLUS, CHEMCATS, USPATFULL
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: RACT (Reactant or reagent)
RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation)
RLD.NP Roles for non-specific derivatives from non-patents: BIOL (Biological study); PROC (Process)

Absolute stereochemistry.

PAGE 1-A



Search done by Noble Jarrell

PAGE 1-B



6 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
6 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L53 ANSWER 33 OF 63 REGISTRY COPYRIGHT 2005 ACS on STN
RN 130309-32-9 REGISTRY
CN Bradykinin, N2-D-arginyl-7-(D-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid)-8-[L-(2α,3aβ,6aβ)-octahydrocyclopenta[b]pyrrole-2-carboxylic acid]-9-L-argininamide- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Cyclopenta[b]pyrrole, bradykinin deriv.
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 10
NTE modified

type	------ location ------		description
terminal mod.	Arg-10	-	C-terminal amide
uncommon	Tic-8	-	-
uncommon	Aaa-9	-	-
stereo	Arg-1	-	D
stereo	Tic-8	-	D

SEQ 1 RRPPGFSXXR

RELATED SEQUENCES AVAILABLE WITH SEQLINK
MF C60 H90 N20 O11
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L53 ANSWER 34 OF 63 REGISTRY COPYRIGHT 2005 ACS on STN
RN **130309-31-8** REGISTRY
CN L-Argininamide, D-arginyl-L-arginyl-(4R)-4-hydroxy-L-prolyl-L-prolylglycyl-L-phenylalanyl-L-seryl-(3R)-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-(2S,3aS,6aS)-octahydrocyclopenta[b]pyrrole-2-carbonyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Cyclopenta[b]pyrrole, L-argininamide deriv.
CN L-Argininamide, D-arginyl-L-arginyl-trans-4-hydroxy-L-prolyl-L-prolylglycyl-L-phenylalanyl-L-seryl-D-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-L-(2α,3aβ,6aβ)-octahydrocyclopenta[b]pyrrole-2-carbonyl-
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 10
NTE modified

type	------ location ------	description

terminal mod.	Arg-10	-	C-terminal amide
uncommon	Hyp-3	-	-
uncommon	Tic-8	-	-
uncommon	Aaa-9	-	-
stereo	Arg-1	-	D
stereo	Tic-8	-	D

SEQ 1 RRXPGFSXXR

RELATED SEQUENCES AVAILABLE WITH SEQLINK
MF C60 H90 N20 O12
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L53 ANSWER 35 OF 63 REGISTRY COPYRIGHT 2005 ACS on STN
RN 130309-30-7 REGISTRY
CN L-Argininamide, D-arginyl-L-arginyl-L-prolyl-(4R)-4-hydroxy-L-prolylglycyl-L-phenylalanyl-L-seryl-(3R)-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-(2S,3aS,6aS)-octahydrocyclopenta[b]pyrrole-2-carbonyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Cyclopenta[b]pyrrole, L-argininamide deriv.
CN L-Argininamide, D-arginyl-L-arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-L-phenylalanyl-L-seryl-D-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-L-(2α,3aβ,6aβ)-octahydrocyclopenta[b]pyrrole-2-carbonyl-
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 10
NTE modified

type	------ location ------		description
terminal mod.	Arg-10	-	C-terminal amide
uncommon	Hyp-4	-	-
uncommon	Tic-8	-	-
uncommon	Aaa-9	-	-
stereo	Arg-1	-	D
stereo	Tic-8	-	D

SEQ 1 RRPXGFSXXR

RELATED SEQUENCES AVAILABLE WITH SEQLINK
MF C60 H90 N20 O12
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L53 ANSWER 36 OF 63 REGISTRY COPYRIGHT 2005 ACS on STN
RN **119834-04-7** REGISTRY
CN L-Argininamide, O-ethyl-D-tyrosyl-L-phenylalanyl-L-valyl-L-asparaginyl-5-[1-(carboxymethyl)cyclohexyl]norvalyl-L-prolyl-, acetate (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN L-Argininamide, O-ethyl-D-tyrosyl-L-phenylalanyl-L-valyl-L-asparaginyl-5-[1-(carboxymethyl)cyclohexyl]-DL-norvalyl-L-prolyl-, acetate
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 7
NTE modified

type	------ location ------		description
terminal mod.	Arg-7	-	C-terminal amide
uncommon	Nva-5	-	-
modification	-	-	undetermined modification
modification	Tyr-1	-	ethyl<Et>

Search done by Noble Jarrell

modification	Nva-5	-	carboxymethyl<Cm>
modification	Nva-5	-	1-(carboxymethyl) cyclohexyl

SEQ 1 YFVNXPR

RELATED SEQUENCES AVAILABLE WITH SEQLINK
MF C53 H80 N12 O11 . x C2 H4 O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: PREP (Preparation)

CM 1

CRN 119834-02-5
CMF C53 H80 N12 O11

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



CM 2

CRN 64-19-7
CMF C2 H4 O2



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L53 ANSWER 37 OF 63 REGISTRY COPYRIGHT 2005 ACS on STN
RN 119834-02-5 REGISTRY
CN L-Argininamide, O-ethyl-D-tyrosyl-L-phenylalanyl-L-valyl-L-asparaginyl-5-[1-(carboxymethyl)cyclohexyl]norvalyl-L-prolyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN L-Argininamide, O-ethyl-D-tyrosyl-L-phenylalanyl-L-valyl-L-asparaginyl-5-[1-(carboxymethyl)cyclohexyl]-DL-norvalyl-L-prolyl-
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 7
NTE modified

type	------ location ------		description
terminal mod.	Arg-7	-	C-terminal amide
uncommon	Nva-5	-	-
modification	Tyr-1	-	ethyl<Et>
modification	Nva-5	-	carboxymethyl<Cm>
modification	Nva-5	-	1-(carboxymethyl) cyclohexyl

SEQ 1 YFVNXPR

RELATED SEQUENCES AVAILABLE WITH SEQLINK
MF C53 H80 N12 O11
CI COM
SR CA
LC STN Files: CA, CAPLUS, CASREACT, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: PREP (Preparation)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L53 ANSWER 38 OF 63 REGISTRY COPYRIGHT 2005 ACS on STN
RN 119624-06-5 REGISTRY
CN L-Argininamide, O-ethyl-N-(3-ethyl-3-mercapto-1-oxopentyl)-L-tyrosyl-L-phenylalanyl-L-valyl-L-asparaginyl-L-cysteinyl-L-prolyl- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 7
NTE modified

type	------ location ------		description
terminal mod.	Arg-7	-	C-terminal amide
modification	Tyr-1	-	ethyl<Et>
modification	Tyr-1	-	undetermined modification

SEQ 1 YFVNCPR

RELATED SEQUENCES AVAILABLE WITH SEQLINK
MF C50 H76 N12 O10 S2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L53 ANSWER 39 OF 63 REGISTRY COPYRIGHT 2005 ACS on STN
RN **119624-04-3** REGISTRY
CN L-Argininamide, O-ethyl-N-(3-ethyl-3-mercapto-1-oxopentyl)-D-tyrosyl-L-phenylalanyl-L-valyl-L-asparaginyl-L-cysteinyl-L-prolyl- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 7
NTE modified

type	location		description
terminal mod.	Arg-7	-	C-terminal amide
modification	Tyr-1	-	ethyl<Et>
modification	Tyr-1	-	undetermined modification

SEQ 1 YFVNCPR

RELATED SEQUENCES AVAILABLE WITH SEQLINK
MF C50 H76 N12 O10 S2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L53 ANSWER 40 OF 63 REGISTRY COPYRIGHT 2005 ACS on STN
RN 114359-25-0 REGISTRY
CN L-Argininamide, O-ethyl-D-tyrosyl-L-phenylalanyl-L-valyl-L-asparaginyl-5-[1-(carboxymethyl)cyclohexyl]-L-norvalyl-L-prolyl- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 7
NTE modified

type	------ location ------		description
terminal mod.	Arg-7	-	C-terminal amide
uncommon	Nva-5	-	-
modification	Tyr-1	-	ethyl<Et>
modification	Nva-5	-	carboxymethyl<Cm>
modification	Nva-5	-	1-(carboxymethyl) cyclohexyl

SEQ 1 YFVNXPR

RELATED SEQUENCES AVAILABLE WITH SEQLINK
MF C53 H80 N12 O11
CI COM
SR CA
LC STN Files: CA, CAPLUS, CASREACT, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)

Absolute stereochemistry.

PAGE 1-A



Search done by Noble Jarrell

PAGE 1-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L53 ANSWER 41 OF 63 REGISTRY COPYRIGHT 2005 ACS on STN
RN **114359-18-1** REGISTRY
CN L-Argininamide, O-ethyl-D-tyrosyl-L-phenylalanyl-L-valyl-L-asparaginyl-5-[1-(carboxymethyl)cyclohexyl]-D-norvalyl-D-prolyl-, cyclic (5→1)-peptide (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 9,12,15,18,21-Pentaazaspiro[5.19]pentacosane, cyclic peptide deriv.
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 7
NTE modified (modifications unspecified)

type	------ location ------		description
bridge	Tyr-1	- Asu-5	lactam
uncommon	Asu-5	-	-
stereo	Tyr-1	-	D
stereo	Pro-6	-	D

SEQ 1 YFVNXPR

RELATED SEQUENCES AVAILABLE WITH SEQLINK
MF C53 H78 N12 O10
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L53 ANSWER 42 OF 63 REGISTRY COPYRIGHT 2005 ACS on STN
RN **114359-16-9** REGISTRY
CN L-Argininamide, O-ethyl-D-tyrosyl-L-phenylalanyl-L-valyl-L-asparaginyl-5-[1-(carboxymethyl)cyclohexyl]-L-norvalyl-L-prolyl-, cyclic (5→1)-peptide (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 9,12,15,18,21-Pentaazaspiro[5.19]pentacosane, cyclic peptide deriv.
OTHER NAMES:
CN SKF 104222
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 7
NTE modified (modifications unspecified)

type	------ location ------		description
bridge	Tyr-1	- Asu-5	lactam
uncommon	Asu-5	-	-
stereo	Tyr-1	-	D

SEQ 1 YFVNXPR

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF C53 H78 N12 O10
SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT, PROUSDDR, USPATFULL
(*File contains numerically searchable property data)
DT.CA CAplus document type: Conference; Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation)
RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

7 REFERENCES IN FILE CA (1907 TO DATE)
7 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L53 ANSWER 43 OF 63 REGISTRY COPYRIGHT 2005 ACS on STN
RN **114359-15-8** REGISTRY
CN L-Argininamide, O-ethyl-D-tyrosyl-L-phenylalanyl-L-valyl-L-asparaginyl-5-[1-(carboxymethyl)cyclohexyl]-D-norvalyl-L-prolyl-, cyclic (5→1)-peptide (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 9,12,15,18,21-Pentaazaspiro[5.19]pentacosane, cyclic peptide deriv.
OTHER NAMES:
CN SKF 104223
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 7

NTE modified (modifications unspecified)

type	location		description
bridge	Tyr-1	- Asu-5	lactam
uncommon	Asu-5	-	-
stereo	Tyr-1	-	D

SEQ 1 YFVNXPR

RELATED SEQUENCES AVAILABLE WITH SEQLINK
MF C53 H78 N12 O10
SR CA
LC STN Files: CA, CAPLUS, CASREACT, DDFU, DRUGU, USPATFULL
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation)
RL.NP Roles from non-patents: BIOL (Biological study)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

Search done by Noble Jarrell

L53 ANSWER 44 OF 63 REGISTRY COPYRIGHT 2005 ACS on STN
RN 111451-00-4 REGISTRY
CN L-Argininamide, O-ethyl-N-[(1-mercaptocyclohexyl)acetyl]-D-tyrosyl-L-phenylalanyl-L-valyl-L-asparaginyl-L-cysteinyl-L-prolyl-, monoacetate (salt) (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 7
NTE modified

type	location		description
terminal mod.	Arg-7	-	C-terminal amide
modification	-	-	undetermined modification
modification	Tyr-1	-	(1-mercaptocyclohexyl) acetyl
modification	Tyr-1	-	ethyl<Et>

SEQ 1 YFVNCPR

RELATED SEQUENCES AVAILABLE WITH SEQLINK
MF C51 H76 N12 O10 S2 . C2 H4 O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: RACT (Reactant or reagent)

CM 1

CRN 111450-99-8
CMF C51 H76 N12 O10 S2

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



CM 2

CRN 64-19-7
CMF C2 H4 O2



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L53 ANSWER 45 OF 63 REGISTRY COPYRIGHT 2005 ACS on STN
RN **111450-99-8** REGISTRY
CN L-Argininamide, O-ethyl-N-[(1-mercaptocyclohexyl)acetyl]-D-tyrosyl-L-phenylalanyl-L-valyl-L-asparaginyl-L-cysteinyl-L-prolyl- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 7
NTE modified

type	------ location ------		description
terminal mod.	Arg-7	-	C-terminal amide
modification	Tyr-1	-	(1-mercaptocyclohexyl) acetyl
modification	Tyr-1	-	ethyl<Et>

SEQ 1 YFVNCPR

RELATED SEQUENCES AVAILABLE WITH SEQLINK
MF C51 H76 N12 O10 S2
CI COM
SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT, USPATFULL
(*File contains numerically searchable property data)
DT.CA CAplus document type: Patent
RL.P Roles from patents: RACT (Reactant or reagent)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L53 ANSWER 46 OF 63 REGISTRY COPYRIGHT 2005 ACS on STN
RN 104532-39-0 REGISTRY
CN L-Argininamide, O-ethyl-N-(3-ethyl-3-mercapto-1-oxopentyl)-L-tyrosyl-L-phenylalanyl-L-valyl-L-asparaginyl-L-cysteinyl-L-prolyl-, cyclic (1→5)-disulfide (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1,2-Dithia-5,8,11,14,17-pentaazacycloeicosane, cyclic peptide deriv.
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 8
NTE modified

type	------ location ------		description
terminal mod.	Arg-8	-	C-terminal amide
bridge	Mpa-1	- Cys-6	disulfide bridge
uncommon	Mpa-1	-	-
modification	Mpa-1	-	undetermined modification
modification	Tyr-2	-	ethyl<Et>

SEQ 1 XYFVNCPR

RELATED SEQUENCES AVAILABLE WITH SEQLINK
MF C50 H74 N12 O10 S2
SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS, USPATFULL
(*File contains numerically searchable property data)

Search done by Noble Jarrell

DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: PREP (Preparation)
RL.NP Roles from non-patents: PREP (Preparation)

PAGE 1-A



PAGE 1-B



3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L53 ANSWER 47 OF 63 REGISTRY COPYRIGHT 2005 ACS on STN
RN **104532-38-9** REGISTRY
CN L-Argininamide, O-ethyl-N-(3-ethyl-3-mercapto-1-oxopentyl)-D-tyrosyl-L-phenylalanyl-L-valyl-L-asparaginyl-L-cysteinyl-L-prolyl-, cyclic (1→5)-disulfide (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1,2-Dithia-5,8,11,14,17-pentaazacycloeicosane, cyclic peptide deriv.
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 8
NTE modified

type	------ location ------		description
terminal mod.	Arg-8	-	C-terminal amide
bridge	Mpa-1	- Cys-6	disulfide bridge
uncommon	Mpa-1	-	-
modification	Mpa-1	-	undetermined modification
modification	Tyr-2	-	ethyl<Et>

SEQ 1 XYFVNCPR

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF C50 H74 N12 O10 S2
SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS, USPATFULL
(*File contains numerically searchable property data)
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: PREP (Preparation)
RL.NP Roles from non-patents: PREP (Preparation)

PAGE 1-A



PAGE 1-B



3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L53 ANSWER 48 OF 63 REGISTRY COPYRIGHT 2005 ACS on STN
RN 104075-57-2 REGISTRY
CN L-Argininamide, N-[(1-mercaptocyclohexyl)acetyl]-D-tryptophyl-L-phenylalanyl-L-valyl-L-asparaginyl-L-cysteinyl-L-prolyl-, cyclic (1→5)-disulfide (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 7,8-Dithia-11,14,17,20,23-pentaazaspiro[5.19]pentacosane, cyclic peptide deriv.
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 8
NTE modified

type	------ location ------		description
terminal mod.	Arg-8	-	C-terminal amide
bridge	Mpa-1	- Cys-6	disulfide bridge
uncommon modification	Mpa-1	-	-
	Mpa-1	-	undetermined modification

SEQ 1 XWFVNCPR

RELATED SEQUENCES AVAILABLE WITH SEQLINK
MF C51 H71 N13 O9 S2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: PREP (Preparation)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



Search done by Noble Jarrell

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L53 ANSWER 49 OF 63 REGISTRY COPYRIGHT 2005 ACS on STN
RN 104054-98-0 REGISTRY
CN L-Argininamide, N-[(1-mercaptocyclohexyl)acetyl]-D-tryptophyl-4-ethyl-L-phenylalanyl-L-valyl-L-asparaginyl-L-cysteinyl-L-prolyl-, cyclic (1→5)-disulfide (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 7,8-Dithia-11,14,17,20,23-pentaazaspiro[5.19]pentacosane, cyclic peptide deriv.
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 8
NTE modified

type	------ location ------	description
terminal mod.	Arg-8 -	C-terminal amide
bridge	Mpa-1 - Cys-6	disulfide bridge
uncommon	Mpa-1 -	-
modification	Mpa-1 -	undetermined modification
modification	Phe-3 -	ethyl<Et>

SEQ 1 XWFVNCPR

RELATED SEQUENCES AVAILABLE WITH SEQLINK
MF C53 H75 N13 O9 S2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: PREP (Preparation)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L53 ANSWER 50 OF 63 REGISTRY COPYRIGHT 2005 ACS on STN
RN **104054-96-8** REGISTRY
CN L-Argininamide, D-2-(1H-indol-3-yl)-N-[(1-mercaptocyclohexyl)acetyl]glycyl-L-phenylalanyl-L-valyl-L-asparaginyl-L-cysteinyl-L-prolyl-, cyclic (1→5)-disulfide (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 7,8-Dithia-11,14,17,20,23-pentaazaspiro[5.19]pentacosane, cyclic peptide deriv.
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 8
NTE modified

type	------ location ------		description
bridge	Maa-1	- Cys-6	disulfide bridge
uncommon	Maa-1	-	-
uncommon	Aaa-2	-	-

SEQ 1 XXFVNCPR
MF C50 H69 N13 O9 S2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: PREP (Preparation)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L53 ANSWER 51 OF 63 REGISTRY COPYRIGHT 2005 ACS on STN
RN **103022-88-4** REGISTRY
CN L-Argininamide, O-ethyl-N-[(1-mercaptocyclohexyl)acetyl]-D-tyrosyl-4-ethyl-L-phenylalanyl-L-valyl-L-asparaginyl-L-cysteinyl-L-prolyl-, cyclic (1→5)-disulfide (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 7,8-Dithia-11,14,17,20,23-pentaazaspiro[5.19]pentacosane, cyclic peptide

Search done by Noble Jarrell

deriv.
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 8
NTE modified

type	location		description
terminal mod.	Arg-8	-	C-terminal amide
bridge	Mpa-1	- Cys-6	disulfide bridge
uncommon	Mpa-1	-	-
modification	Mpa-1	-	undetermined modification
modification	Tyr-2	-	ethyl<Et>
modification	Phe-3	-	ethyl<Et>

SEQ 1 XYFVNCPR

RELATED SEQUENCES AVAILABLE WITH SEQLINK
MF C53 H78 N12 O10 S2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: PREP (Preparation)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



Search done by Noble Jarrell

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L53 ANSWER 52 OF 63 REGISTRY COPYRIGHT 2005 ACS on STN
RN 102995-67-5 REGISTRY
CN D-Argininamide, O-ethyl-N-[(1-mercaptocyclohexyl)acetyl]-D-tyrosyl-L-phenylalanyl-L-valyl-L-asparaginyl-L-cysteinyl-L-prolyl-, cyclic (1→5)-disulfide (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 7,8-Dithia-11,14,17,20,23-pentaazaspiro[5.19]pentacosane, cyclic peptide deriv.
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 8
NTE modified

type	------ location ------		description
terminal mod.	Arg-8	-	C-terminal amide
bridge	Mpa-1	- Cys-6	disulfide bridge
uncommon	Mpa-1	-	-
modification	Mpa-1	-	undetermined modification
modification	Tyr-2	-	ethyl<Et>

SEQ 1 XYFVNCPR

RELATED SEQUENCES AVAILABLE WITH SEQLINK
MF C51 H74 N12 O10 S2
SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS, USPATFULL
(*File contains numerically searchable property data)
DT.CA CAplus document type: Patent
RL.P Roles from patents: PREP (Preparation)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L53 ANSWER 53 OF 63 REGISTRY COPYRIGHT 2005 ACS on STN
RN 102995-62-0 REGISTRY
CN L-Argininamide, O-ethyl-N-[(1-mercaptocyclohexyl)acetyl]-D-tyrosyl-L-phenylalanyl-L-2-cyclohexylglycyl-L-asparaginyl-L-cysteinyl-L-prolyl-, cyclic (1→5)-disulfide (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 7,8-Dithia-11,14,17,20,23-pentaazaspiro[5.19]pentacosane, cyclic peptide deriv.
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 8
NTE modified

type	------ location ------		description
terminal mod.	Arg-8	-	C-terminal amide
bridge	Mpa-1	- Cys-6	disulfide bridge
uncommon	Mpa-1	-	-
uncommon	Aaa-4	-	-
modification	Mpa-1	-	undetermined modification
modification	Tyr-2	-	ethyl<Et>

SEQ 1 XYFXNCPR
MF C54 H78 N12 O10 S2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: PREP (Preparation)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L53 ANSWER 54 OF 63 REGISTRY COPYRIGHT 2005 ACS on STN
RN **102995-60-8** REGISTRY
CN L-Argininamide, O-ethyl-N-[(1-mercaptocyclohexyl)acetyl]-D-tyrosyl-L-phenylalanylglycyl-L-asparaginyl-L-cysteinyl-L-prolyl-, cyclic (1→5)-disulfide (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 7,8-Dithia-11,14,17,20,23-pentaazaspiro[5.19]pentacosane, cyclic peptide deriv.
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 8
NTE modified

type	------ location ------		description
terminal mod.	Arg-8	-	C-terminal amide
bridge	Mpa-1	- Cys-6	disulfide bridge
uncommon	Mpa-1	-	-
modification	Mpa-1	-	undetermined modification
modification	Tyr-2	-	ethyl<Et>

SEQ 1 XYFGNCPR
MF C48 H68 N12 O10 S2

Search done by Noble Jarrell

SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: PREP (Preparation)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L53 ANSWER 55 OF 63 REGISTRY COPYRIGHT 2005 ACS on STN
RN **102995-57-3** REGISTRY
CN L-Argininamide, O-ethyl-N-[(1-mercaptocyclohexyl)acetyl]-D-tyrosyl-L-phenylalanyl-L-alanyl-L-asparaginyl-L-cysteinyl-L-prolyl-, cyclic (1→5)-disulfide (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 7,8-Dithia-11,14,17,20,23-pentaazaspiro[5.19]pentacosane, cyclic peptide deriv.
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 8
NTE modified

type	------ location ------		description
terminal mod.	Arg-8	-	C-terminal amide
bridge	Mpa-1	- Cys-6	disulfide bridge
uncommon	Mpa-1	-	-

modification Mpa-1 - undetermined modification
modification Tyr-2 - ethyl<Et>

SEQ 1 XYFANCPR
MF C49 H70 N12 O10 S2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: PREP (Preparation)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L53 ANSWER 56 OF 63 REGISTRY COPYRIGHT 2005 ACS on STN
RN 102995-54-0 REGISTRY
CN L-Argininamide, O-ethyl-N-[(1-mercaptocyclohexyl)acetyl]-D-tyrosyl-L-phenylalanyl-L-2-aminobutanoyl-L-asparaginyl-L-cysteinyl-L-prolyl-, cyclic (1→5)-disulfide (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 7,8-Dithia-11,14,17,20,23-pentaazaspiro[5.19]pentacosane, cyclic peptide deriv.
CN L-Argininamide, O-ethyl-N-[(1-mercaptocyclohexyl)acetyl]-D-tyrosyl-L-phenylalanyl-L-α-aminobutyryl-L-asparaginyl-L-cysteinyl-L-prolyl-, cyclic (1→5)-disulfide

FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 8
NTE modified

type	location		description
terminal mod.	Arg-8	-	C-terminal amide
bridge	Mpa-1	- Cys-6	disulfide bridge
uncommon	Mpa-1	-	-
uncommon	Abu-4	-	-
modification	Mpa-1	-	undetermined modification
modification	Tyr-2	-	ethyl<Et>

SEQ 1 XYFXNCPR

RELATED SEQUENCES AVAILABLE WITH SEQLINK
MF C50 H72 N12 O10 S2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: PREP (Preparation)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

Search done by Noble Jarrell

L53 ANSWER 57 OF 63 REGISTRY COPYRIGHT 2005 ACS on STN
RN 93957-06-3 REGISTRY
CN L-Argininamide, 3-iodo-N-[(1-mercaptocyclohexyl)acetyl]-D-tyrosyl-L-phenylalanyl-L-valyl-L-asparaginyl-L-cysteinyl-L-prolyl-, cyclic (1→5)-disulfide (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 7,8-Dithia-11,14,17,20,23-pentaazaspiro[5.19]pentacosane, cyclic peptide deriv.
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 8
NTE modified

type	------ location ------		description
terminal mod.	Arg-8	-	C-terminal amide
bridge	Mpa-1	- Cys-6	disulfide bridge
uncommon	Mpa-1	-	-
modification	Mpa-1	-	undetermined modification
modification	Tyr-2	-	iodo<I>

SEQ 1 XYFVNCPR

RELATED SEQUENCES AVAILABLE WITH SEQLINK
MF C49 H69 I N12 O10 S2
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: PREP (Preparation)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L53 ANSWER 58 OF 63 REGISTRY COPYRIGHT 2005 ACS on STN
RN **93449-77-5** REGISTRY
CN L-Argininamide, O-[[(2-bromophenyl)methoxy]carbonyl]-N-[[1-[(phenylmethyl)thio]cyclohexyl]acetyl]-D-tyrosyl-L-phenylalanyl-L-valyl-L-asparaginyl-S-[(4-methoxyphenyl)methyl]-L-cysteinyl-L-prolyl- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 7
NTE modified

type	location		description
terminal mod.	Arg-7	-	C-terminal amide
modification	Tyr-1	-	undetermined modification
modification	Tyr-1	-	[(2-bromophenyl)methoxy] carbonyl<2BZ>
modification	Cys-5	-	(4-methoxyphenyl)methyl<MOB>

SEQ 1 YFVNCPR

RELATED SEQUENCES AVAILABLE WITH SEQLINK
MF C72 H91 Br N12 O13 S2
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L53 ANSWER 59 OF 63 REGISTRY COPYRIGHT 2005 ACS on STN
RN 93449-72-0 REGISTRY
CN L-Argininamide, N-[(1-mercaptocyclohexyl)acetyl]-D-tyrosyl-L-phenylalanyl-L-valyl-L-asparaginyl-L-cysteinyl-L-prolyl- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 7
NTE modified

type	------ location ------		description
terminal mod.	Arg-7	-	C-terminal amide
modification	Tyr-1	-	(1-mercaptocyclohexyl) acetyl

SEQ 1 YFVNCPR

RELATED SEQUENCES AVAILABLE WITH SEQLINK
MF C49 H72 N12 O10 S2
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)

Search done by Noble Jarrell

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L53 ANSWER 60 OF 63 REGISTRY COPYRIGHT 2005 ACS on STN
RN **93449-70-8** REGISTRY
CN L-Argininamide, N-[(1-mercaptocyclohexyl)acetyl]-D-leucyl-L-phenylalanyl-L-valyl-L-asparaginyl-L-cysteinyl-L-prolyl-N-propyl-, cyclic (1→5)-disulfide (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 7,8-Dithia-11,14,17,20,23-pentaazaspiro[5.19]pentacosane, cyclic peptide deriv.
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 8
NTE modified (modifications unspecified)

type	------ location ------		description
bridge	Mpa-1	- Cys-6	disulfide bridge
uncommon	Mpa-1	-	-
modification	Mpa-1	-	undetermined modification

SEQ 1 XLFVNCPR

RELATED SEQUENCES AVAILABLE WITH SEQLINK
MF C49 H78 N12 O9 S2
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent

Search done by Noble Jarrell

RL.P Roles from patents: PREP (Preparation)

Absolute stereochemistry.



2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L53 ANSWER 61 OF 63 REGISTRY COPYRIGHT 2005 ACS on STN
RN 93449-69-5 REGISTRY
CN L-Argininamide, N-[(1-mercaptocyclohexyl)acetyl]-D-tyrosyl-L-phenylalanyl-L-valyl-L-asparaginyl-L-cysteinyl-L-prolyl-, cyclic (1→5)-disulfide (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 7,8-Dithia-11,14,17,20,23-pentaazaspiro[5.19]pentacosane, cyclic peptide deriv.
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 8
NTE modified

type	------ location ------		description
terminal mod.	Arg-8	-	C-terminal amide
bridge	Mpa-1	- Cys-6	disulfide bridge
uncommon modification	Mpa-1	-	-
	Mpa-1	-	undetermined modification

SEQ 1 XYFVNCPR

RELATED SEQUENCES AVAILABLE WITH SEQLINK
DR 93957-05-2
MF C49 H70 N12 O10 S2
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L53 ANSWER 62 OF 63 REGISTRY COPYRIGHT 2005 ACS on STN
RN **90332-82-4** REGISTRY
CN L-Argininamide, O-ethyl-N-[(1-mercaptocyclohexyl)acetyl]-D-tyrosyl-L-phenylalanyl-L-valyl-L-asparaginyl-L-cysteinyl-L-prolyl-, cyclic (1→5)-disulfide (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 7,8-Dithia-11,14,17,20,23-pentaazaspiro[5.19]pentacosane, cyclic peptide deriv.
OTHER NAMES:
CN SKF 101926
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 8
NTE modified

type	------ location ------	description
terminal mod.	Arg-8 -	C-terminal amide
bridge	Mpa-1 - Cys-6	disulfide bridge
uncommon	Mpa-1 -	-
modification	Mpa-1 -	undetermined modification
modification	Tyr-2 -	ethyl<Et>

SEQ 1 XYFVNCPR

RELATED SEQUENCES AVAILABLE WITH SEQLINK
DR 96827-97-3
MF C51 H74 N12 O10 S2
LC STN Files: ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CHEMCATS, DDFU, DRUGU, EMBASE, MEDLINE, PHAR, PROUSDDR, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)
DT.CA CAplus document type: Conference; Journal; Patent
RL.P Roles from patents: PREP (Preparation)
RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

52 REFERENCES IN FILE CA (1907 TO DATE)
52 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L53 ANSWER 63 OF 63 REGISTRY COPYRIGHT 2005 ACS on STN
RN 71659-01-3 REGISTRY
CN L-Argininamide, L-asparaginyl-L-seryl-L-asparaginyl-L-prolyl- (9CI) (CA INDEX NAME)

Search done by Noble Jarrell

FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 5
NTE modified

type	------ location ------		description
terminal mod.	Arg-5	-	C-terminal amide

SEQ 1 NSNPR

RELATED SEQUENCES AVAILABLE WITH SEQLINK
MF C22 H39 N11 O8
LC STN Files: CA, CAPLUS, IFICDB, IFIPAT, IFIUDB, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: PREP (Preparation)

Absolute stereochemistry.





2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> b home
FILE 'HOME' ENTERED AT 12:42:32 ON 15 JUN 2005

```
=> d all hitstr l12 tot

L12  ANSWER 1 OF 1  HCAPLUS  COPYRIGHT 2005 ACS on STN
AN   2004:467702  HCAPLUS
DN   141:33798
ED   Entered STN:  10 Jun 2004
TI   Peptides which inhibit angiogenesis, cell migration, cell invasion and
     cell proliferation, their preparation, and compositions and therapeutic
     uses thereof
IN   Allan, Amy L.; Donate, Fernando; Hopkins, Stephanie A.; Gladstone,
     Patricia L.; Mazar, Andrew; O'Hare, Sean M.; Parry, Graham; Plunkett,
     Marian L.; Ternansky, Robert J.; Yoon, Won Hyung
PA   Attenuon, LLC, USA
SO   PCT Int. Appl., 88 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
IC   ICM  A61K
CC   1-8 (Pharmacology)
     Section cross-reference(s): 34, 63
FAN.CNT 2
     PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
     ---------------      ----   --------    --------------------     --------
PI   WO 2004047771         A2    20040610    WO 2003-US38175          20031125
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
             PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
             TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
             ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
             TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     US 2004162239          A1    20040819    US 2003-723144           20031125
     US 2005020810          A1    20050127    US 2003-722843           20031125
PRAI US 2002-429174P        P     20021125
     US 2003-475539P        P     20030602
CLASS
 PATENT NO.        CLASS  PATENT FAMILY CLASSIFICATION CODES
 ---------------   -----  ----------------------------------------------
 WO 2004047771     ICM    A61K
 US 2004162239     NCL    514/012.000; 514/013.000; 514/014.000; 514/015.000;
                          514/016.000; 514/017.000; 514/018.000; 530/324.000;
                          530/325.000; 530/326.000
 US 2005020810     NCL    530/324.000; 530/325.000; 530/326.000; 530/327.000;
                          530/328.000; 530/329.000
OS   MARPAT 141:33798
AB   The invention discloses peptides which inhibit angiogenesis, cell
     migration, cell invasion and cell proliferation, as well as methods of
     making the peptides, pharmaceutical compns. containing the peptides, and
     methods of using the peptides and pharmaceutical compns. to treat diseases
     associated with aberrant vascularization, e.g. cancer.
ST   peptide cell invasion migration proliferation inhibition; antitumor
     aberrant vascularization disease peptide prepn
IT   Sarcoma
        (cartilage chondrosarcoma; peptide inhibitors of angiogenesis, cell
        migration, cell invasion and cell proliferation, preparation, and compns.
        and therapeutic uses)
IT   Cartilage, neoplasm
        (chondrosarcoma; peptide inhibitors of angiogenesis, cell migration,
        cell invasion and cell proliferation, preparation, and compns. and
        therapeutic uses)
IT   Intestine, neoplasm
        (colon; peptide inhibitors of angiogenesis, cell migration, cell
        invasion and cell proliferation, preparation, and compns. and therapeutic
```

uses)
IT Blood vessel
(endothelium; peptide inhibitors of angiogenesis, cell migration, cell invasion and cell proliferation, preparation, and compns. and therapeutic uses)
IT Blood vessel, neoplasm
Sarcoma
(hemangiosarcoma; peptide inhibitors of angiogenesis, cell migration, cell invasion and cell proliferation, preparation, and compns. and therapeutic uses)
IT Angiogenesis
Angiogenesis inhibitors
Antitumor agents
Brain, neoplasm
Drug delivery systems
Kidney, neoplasm
Mammary gland, neoplasm
Neoplasm
Prostate gland, neoplasm
(peptide inhibitors of angiogenesis, cell migration, cell invasion and cell proliferation, preparation, and compns. and therapeutic uses)
IT Endothelium
(vascular; peptide inhibitors of angiogenesis, cell migration, cell invasion and cell proliferation, preparation, and compns. and therapeutic uses)
IT 701201-26-5D, biotinylated
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peptide inhibitors of angiogenesis, cell migration, cell invasion and cell proliferation, preparation, and compns. and therapeutic uses)
IT 701200-82-0P 701201-01-6P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(peptide inhibitors of angiogenesis, cell migration, cell invasion and cell proliferation, preparation, and compns. and therapeutic uses)
IT 81658-55-1P 701200-81-9P 701200-83-1P 701200-84-2P 701200-85-3P
701200-86-4P 701200-87-5P 701200-88-6P 701200-89-7P 701200-90-0P
701200-91-1P 701200-92-2P 701200-93-3P 701200-94-4P 701200-95-5P
701200-96-6P 701200-97-7P 701200-98-8P 701200-99-9P 701201-00-5P
701201-02-7P 701201-03-8P 701201-04-9P 701201-05-0P
701201-06-1P 701201-07-2P 701201-08-3P 701201-09-4P 701201-10-7P
701201-11-8P 701201-12-9P 701201-13-0P 701201-14-1P 701201-15-2P
701201-16-3P 701201-17-4P 701201-18-5P 701201-19-6P 701201-20-9P
701201-21-0P 701201-22-1P 701201-23-2P 701201-24-3P 701201-25-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(peptide inhibitors of angiogenesis, cell migration, cell invasion and cell proliferation, preparation, and compns. and therapeutic uses)
IT 701201-28-7
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peptide inhibitors of angiogenesis, cell migration, cell invasion and cell proliferation, preparation, and compns. and therapeutic uses)
IT 98-88-4, Benzoyl chloride 100-39-0, Benzyl bromide 106-95-6, Allyl bromide, reactions 930-69-8 1212-08-4, S-Phenyl benzenethiosulfonate 2719-27-9, Cyclohexanoyl chloride 2937-50-0, Allyl chloroformate 2949-92-0, S-Methyl methanethiosulfonate 3282-30-2, Pivaloyl chloride 5271-67-0, 2-Thiophenecarbonyl chloride 6482-24-2, 2-Bromoethyl methylether 7031-27-8, (Phenylthio)acetyl chloride 10400-19-8, Nicotinoyl chloride 25644-88-6, S-Benzyl-L-cysteine sulfone 82911-69-1 262438-43-7 475150-36-8 701201-27-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(peptide inhibitors of angiogenesis, cell migration, cell invasion and cell proliferation, preparation, and compns. and therapeutic uses)

IT 701201-02-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(peptide inhibitors of angiogenesis, cell migration, cell invasion and cell proliferation, preparation, and compns. and therapeutic uses)
RN 701201-02-7 HCAPLUS
CN L-Aspartamide, 1-acetyl-L-prolyl-L-histidyl-L-seryl-S-benzoyl-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> b home
FILE 'HOME' ENTERED AT 12:45:42 ON 15 JUN 2005

=>